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Abstract 
 
Inductively coupled plasma mass spectrometry (ICP-MS) is a well established and 
versatile technique for the elemental analysis of a wide spectrum of samples.  For a 
majority of the elements that can be analysed by ICP-MS limits of detection in the 
order of sub ng l-1 levels can be attained.  However, a number of these elements have 
problems associated with them that lead to a restriction of the limits of detection that 
can be achieved.  Phosphorus and Sulphur are two such elements that exhibit poorer 
limits of detection, the improvement of which would be highly desirable to the ICP-
MS analyst. 
 
Six methods for the measurement of 31P and 32S isotopes have been developed with 
the aim of avoiding the spectroscopic interferences at the native m/z ratios of 31 and 
32 respectively.  These approaches have utilised a hexapole collision cell, a ‘cold/cool 
plasma’ and an experimental ICP torch bonnet.  Via the collision cell and ‘cold/cool 
plasma’ approaches the isotopes of interest were either converted to different species 
for successful measurement at an alternative m/z ratio or interfering species were 
removed allowing measurement at the native m/z.  Limits of detection achieved by 
these approaches were comparable with those quoted in the literature and by ICP-MS 
instrument manufacturers.  The approach using the torch bonnet was not successful in 
attenuating spectroscopic interferences; however, it did show potential for continuing 
as an area of research.  The development of these six methods is discussed in Chapter 
2. 
 
As an application of the successful methods developed for the measurement of 31P and 
32S isotopes, DNA (and its associated components) was selected for study as this bio-
molecule is comprised of approximately 10 % phosphorus.  DNA in solution was 
successfully quantified by these methods and DNA components, studied during 
polymerase chain reaction processes and in single nucleotide polymorphisms, were 
qualified.  The application of these methods to the study of DNA and its components 
is discussed in Chapter 3. 
 
 
 3
As part of a collaboration between the Loughborough University Atomic 
Spectroscopy Research Group and the Cancer Biomarkers and Prevention Group at 
the University of Leicester, ICP-MS was employed in the investigation of the 
interactions between two Pt based anti-cancer drugs (cisplatin and oxaliplatin) and 
their biological target DNA.  For this collaboration, DNA was the interest common to 
both groups.  The interaction of each of these drugs with known quantities of DNA 
was measured by ICP-MS and binding constant data was calculated for use as the 
basis of a clinical test for drug efficacy in cancer patients.  The binding constant data 
showed that the interaction between drug and target is particularly inefficient.  This 
area of research is discussed in Chapter 4. 
 
The potential for ICP-MS interface modification was also explored.  Two modified 
designs are discussed that may prove to be advantageous for the transport of ions 
between the atmospheric pressure conditions of the ICP ion source and the vacuum 
conditions of the mass spectrometer.  One of these designs was successfully 
manufactured and produced positive data.  Research into this design is being furthered 
by the Thermo Electron Corporation, the discussion of which is in Chapter 5. 
 
A further collaboration was established with both the Biomaterials-related Infection 
Group of the School of Medical and Surgical Sciences and the Polymer Group of the 
School of Mechanical, Materials and Manufacturing Engineering at the University of 
Nottingham.  Here ICP-MS was employed in the measurement of silver leaching from 
a silver nano-particle impregnated polymer material that could be used in the 
production of catheters.  Silver leaching from a catheter is potentially desirable due to 
its anti-microbial properties.  The study of this leaching revealed that significant 
quantities of silver were being transferred from the polymer into surrounding human 
serum media over the period of seven days and beyond.  For the most part this work 
was routine ICP-MS measurement, and did not involve research or development, so 
does not take part in the main body of this thesis.  This work is discussed in Appendix 
5. 
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Abbreviation Word/Title/Term Further Detail 
AAS Atomic Absorption Spectroscopy - 
amu Atomic Mass Unit Unit used within mass spectrometry 
referring to resolution 
ATP Adenosine Triphosphate - 
Bar - Unit of pressure 
°C Degrees Centigrade Unit of temperature described by the 
centigrade scale 
CC Collision Cell - 
CID Collisionally Induced Dissociation - 
cm Centimetre Unit of length dimension (x 10-2 m) 
cps Counts Per Second Unit referring to the ICP-MS signal, the 
number of ion counts measured in a 
second 
CTP Cytosine Triphosphate - 
CVC Central Venous Catheter - 
DC Direct Current - 
DRC Dynamic Reaction Cell - 
DNA Deoxyribose Nucleic Acid - 
dNTP Deoxynucleotidetriphosphate - 
EIE Easily Ionisable Element - 
Ek Kinetic Energy - 
eV Electronvolt A unit of energy equal to the work done 
on an electron in moving it through a 
potential difference of one volt 
FAAS Flame Atomic Absorption 
Spectroscopy 
- 
FDA Food and Drug Administration - 
γ Ratio of Heat Capacity at Constant 
Pressure to Heat Capacity at Constant 
Volume 
- 
g Gram Unit of mass 
GC Gas Chromatography - 
GF-AAS Graphite Furnace Atomic Absorption 
Spectroscopy 
- 
GTP Guanine Triphosphate - 
HPLC High Performance Liquid 
Chromatography 
- 
ΔHr Enthalpy of Reaction A thermodynamic property of a system 
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Abbreviation Word/Title/Term Further Detail 
ICP-MS Inductively Coupled Plasma Mass 
Spectrometry 
- 
ICP-QMS Inductively Coupled Plasma 
Quadrupole Mass Spectrometry 
- 
ICP-OES Inductively Coupled Plasma Optical 
Emission Spectroscopy 
- 
ICP-ToFMS Inductively Coupled Plasma Time of 
Flight Mass Spectrometry 
- 
IKEE Ion Kinetic Energy Effect - 
IP Ionisation Potential Parameter describing the energy required 
to ionise an atom, measured in electron 
volts (eV) 
K Kelvin Unit of temperature described by the 
Kelvin scale 
kcal mol-1 Kilocalories Per Mole Unit describing enthalpy of reaction 
KED Kinetic Energy Discrimination - 
kr Rate Constant The constant in an expression for the rate 
of a chemical reaction in terms of 
concentrations or activities 
LA-ICP-MS Laser Ablation Inductively Coupled 
Plasma Mass Spectrometry 
- 
LC-MS Liquid Chromatography Mass 
Spectrometry 
- 
l min-1 Litres Per Minute Unit of flow rate 
LOD Limit of Detection - 
m Metre Unit of length dimension 
M Mole Unit of the amount of a substance 
M Mach Number - 
M2+ Doubly Charged Ion - 
mBar Millibar Unit of pressure (x 10-3 Bar) 
mg Milligram Unit of mass (x 10-3 g) 
MHz Megahertz Unit for the measurement of frequency (x 
103 Hz) 
mg ml-1 Milligrams Per Millilitre Unit of concentration (same as g l-1) 
ml min-1 Millilitres Per Minute Unit of flow rate (x 10-3 l min-1) 
mm Millimetre Unit of length dimension (x 10-3 m) 
mM Millimole Unit of the amount of a substance (x 10-3 
M) 
 30
Abbreviation Word/Title/Term Further Detail 
MWCO Molecular Weight Cut-Off - 
m/z Mass-To-Charge Ratio - 
NADH  Nicotinamide Adenine Dinucleotide Reduced form 
NADPH Nicotinamide Adenine Dinucleotide 
Phosphate 
Reduced form 
nm Nanometre Unit of length dimension (x 10-9 m) 
NMR Nuclear Magnetic Resonance - 
P0 Pressure Within the ICP Ion Source - 
Pi Pressure Within the Isentropic Core of 
the Expansion 
- 
PCR Polymerase Chain Reaction An artificial nucleic acid 
replication/amplification process 
PCR-SSCP Polymerase Chain Reaction Single 
Strand Conformation Polymorphism 
- 
pmol Picomole Unit of the amount of a substance (x 10-
12 M) 
RAM Relative Atomic Mass - 
RF Radio Frequency - 
RMM Relative Molecular Mass - 
RNA Ribonucleic Acid - 
RPM Revolutions Per Minute - 
RSD Relative Standard Deviation A statistical parameter 
s Second Unit of time dimension 
SD Standard Deviation A statistical parameter 
SFC Supercritical Fluid Chromatography - 
SNP Single Nucleotide Polymorphism - 
T0 Temperature Within the ICP Ion 
Source 
- 
Ti Temperature Within the Isentropic 
Core of the Expansion 
- 
TBE Tris-Borate Buffer - 
TRA Time Resolved Analysis - 
TTP Thymine Triphosphate - 
μg Microgram Unit of mass (10-6 g) 
μg l-1 Micrograms Per Litre Unit of concentration 
μl Microlitre Unit of volume (10-6 l) 
μl min-1 Microlitres Per Minute Unit of flow rate (x 10-6 l min-1) 
μm Micrometre Unit of length dimension (x 10-6 m) 
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Abbreviation Word/Title/Term Further Detail 
μM Micromole Unit of the amount of a substance (x 10-6 
M) 
UV Ultra-Violet Electromagnetic radiation having 
wavelengths between 4 and 400 nm 
V Volt Unit of electromotive force, force 
sufficient to carry one ampere of current 
against one ohm of resistance 
Vh Applied Hexapole Voltage - 
Vp Plasma Potential - 
Vq Applied Quadrupole Voltage - 
   
W Watt Unit of power, used here in the 
description of plasma forward and 
reflected power parameters 
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1.1.  An Introduction to ICP-MS 
 
Inductively coupled plasma mass spectrometry (ICP-MS) is a powerful atomic 
spectroscopy technique employed in the elemental analysis of metals and non-metals 
at ultra-trace levels.  Devised by Gray and Houk in 1980, with the first commercial 
instruments available since 1983,1, 2 ICP-MS is the combination of an inductively 
coupled plasma (ICP) ion source and a mass spectrometer.2 
 
The main attraction of ICP-MS as an atomic spectroscopy technique is its capability 
for low limits of detection (LOD), as low as sub part-per-trillion (ng l-1) levels for 
some elements, and its wide dynamic range, of approximately four to eleven orders of 
magnitude.3-5  The ICP-MS LOD for an element is dependent on a number of factors, 
these include the following: 
 
• The isotopic abundance and ionisation potential of the element under analysis, 
see the periodic table in Figure 1.6 
• The type of gas(es) used to generate the ICP ion source and transport the 
sample through the plasma central channel, see sections 1.1.2.2 and 1.2.1.2. 
• The instrumental conditions, particularly plasma forward power and 
nebulisation flow, see section 1.1.2. 
• The type of mass spectrometer interfaced with the ICP ion source, see section 
1.1.3. 
• The physical state of the sample being introduced (solid, liquid or gaseous) 
and the method and conditions of introduction, see section 1.1.2. 
• Any modifications made to the instrument.  For example the implementation 
of collision or dynamic reaction cell technology and plasma-mass 
spectrometer interface modifications, see sections 1.3 and 1.4 and Chapter 5. 
 
 
As can be seen in Figure 1 ICP-MS can successfully analyse approximately three 
quarters of the elements of the periodic table between concentrations of < 1 ng l-1 and 
10 µg l-1.4, 7  
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Periodic Table of the Elements, Showing Detection Limits and
Ionisation Potentials for useable Elements by ICP-MS Analysis
1 2
1 (99.9%) 4 (100%)
H Detection Limit Ranges He
13.6 24.6
3 4 30 Atomic Number < 1 ng l-1 (ppt) 5 6 7 8 9 10
7 (92.5%) 9 (100%) 64 (48.6%) Most Abundant Isotope (Abundance) 1-10 ng l-1 (ppt) 11 (80.1%) 12 (98.9%) 14 (99.6%) 16 (99.8%) 19 (100%) 20 (90.5%)
Li Be Zn Symbol 10-100 ng l-1 (ppt) B C N O F Ne
5.4 9.3 9.4 Ionisation Potential (eV) 0.1-1 μg l-1 (ppb) 8.3 11.3 14.5 13.6 17.4 21.6
11 12 1-10 μg l-1 (ppb) 13 14 15 16 17 18
23 (100%) 24 (79.0%) 27 (100%) 28 (92.2%) 31 (100%) 32 (95%) 35 (75.8%) 40 (99.6%)
Na Mg Al Si P S Cl Ar
5.1 7.6 6 8.2 10.5 10.4 13 15.8
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
39 (93.3%) 40 (96.9%) 45 (100%) 48 (73.8%) 51 (99.8%) 52 (83.8%) 55 (100%) 56 (91.7%) 59 (100%) 58 (68.3%) 63 (69.2%) 64 (48.6%) 69 (60.1%) 74 (36.5%) 75 (100%) 80 (49.7%) 79 (50.7%) 84 (57%)
K Ca Sc Ti V Cr Mn Fe Co Ni Cu Zn Ga Ge As Se Br Kr
4.3 6.1 6.5 6.8 6.7 6.8 7.4 7.9 7.9 7.6 7.7 9.4 6 7.9 9.8 9.8 11.8 14
37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54
85 (72.2%) 88 (82.6%) 89 (100%) 90 (51.5%) 93 (100%) 98 (24.1%) 99 102 (31.6%) 103 (100%) 106 (27.3%) 107 (51.8%) 114 (28.7%) 115 (95.7%) 120 (32.6%) 121 (57.3%) 130 (33.8%) 127 (100%) 132 (26.9%)
Rb Sr Y Zr Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb Te I Xe
4.2 5.7 6.4 6.8 6.9 7.1 7.3 7.4 7.5 8.3 7.6 9 5.8 7.3 8.6 9 10.5 12.1
55 56 57 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86
133 (100%) 138 (71.7%) 139 (99.9%) 180 (35.1%) 181 (99.9%) 184 (30.7%) 187 (62.6%) 190 (26.4%) 193 (62.7%) 195 (33.8%) 197 (100%) 202 (29.8%) 205 (70.5%) 208 (52.4%) 209 (100%)
Cs Ba La Hf Ta W Re Os Ir Pt Au Hg Tl Pb Bi Po At Rn
3.9 5.2 5.6 7 7.9 8 7.9 8.7 9.1 9 9.2 10.4 6.1 7.4 7.3
87 88 89
Fr Ra Ac
58 59 60 61 62 63 64 65 66 67 68 69 70 71
140 (88.5%) 141 (100%) 142 (27.1%) 152 (26.7%) 153 (52.2%) 158 (24.8%) 159 (100%) 164 (28.2%) 165 (100%) 166 (33.6%) 169 (100%) 174 (31.8%) 175 (97.4%)
Ce Pr Nd Pm Sm Eu Gd Tb Dy Ho Er Tm Yb Lu
5.5 5.4 5.5 5.6 5.7 6.1 5.9 5.9 6 6.1 6.2 6.3 5.4
90 91 92 93 94 95 96 97 98 99 100 101 102 103
232 (100%) 231 238 (99.3%)
Th Pa U Np Pu Am Cm Bk Cf Es Fm Md No Lr
7 - 6.9  
Figure 1.  A Periodic Table of the Elements Showing Detection Limits and Ionisation Potential Data for the Useable Elements by ICP-MS. 
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ICP-MS is a particularly versatile analytical technique as it allows various approaches 
to sample introduction, interfacing with different mass spectrometry techniques and 
simple modification.  Due to this versatility samples can be analysed in solid, liquid or 
gaseous states which in turn allows ICP-MS to be applied to a gamut of samples for 
which the analyst may require elemental composition data.  Alongside other 
techniques, ICP-MS plays a dominant role in the elemental analysis of biological, 
geological, environmental and industrial samples, many of which could also be 
forensic samples.8-38 
 
Although ICP-MS exhibits the analytical benefits already mentioned, limitations are 
observed in the form of analyte interferences in the mass spectrum.  These 
interferences appear for several reasons, see section 1.2.  ICP-MS is also a relatively 
expensive analytical technique; a simple ICP-quadrupole mass analyser instrument 
costs in the range of £90 000 to £150 000.  An instrument incorporating a high 
resolution mass spectrometer is almost double the cost of that of a quadrupole based 
instrument. 
 
 
1.1.1.  The Design and Operation of an ICP-MS Instrument 
 
An inductively coupled plasma is generated in a horizontally-mounted, fused-silica, 
torch consisting of three concentric tubes (outer, middle and injector tubes).1, 4, 39  The 
plasma gas flows tangentially between the outer and middle tubes (≈ 12 to 17 l min-1) 
whilst an auxiliary gas passes between the middle and injector tubes (≈ 1 l min-1).10, 40  
When analysing liquid samples via a nebuliser and spray chamber arrangement a gas, 
typically Ar flowing at ≈ 1 l min-1, carries the sample through the nebuliser and spray 
chamber and into the plasma.4, 10  After generation of the plasma it is this third gas 
flow that is responsible for “punching” a central channel through the plasma 
discharge.10 
 
The last 2-3 cm of a standard ICP-MS torch sits centrally within a water cooled 
induction, or load, coil that provides an alternating current that produces an intense 
electromagnetic field.  The load coil is powered by an RF generator producing 
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between 1.5 W and 2.5 W at 27 or 40 MHz.4, 39  On passage of the plasma gas through 
the torch and load coil, a high voltage spark causes some of the plasma gas atoms to 
ionise; the resulting free electrons are accelerated in the electromagnetic field which 
causes an ionisation cascade effect.  A steady state plasma is formed as a result of this 
ionisation. 
 
Samples are introduced into an ICP ion source positioned end on to a water cooled 
sample cone.4, 41  See Figure 2 for a typical schematic of the ICP-MS ion path.  
Following sample atomisation, excitation and ionisation in the central channel of the 
ICP source,5, 40 a large fraction of positively charged ions are directed from the ion 
source to the mass spectrometer via an interface that allows ions to be extracted whilst 
stepping from atmospheric pressure (1 Bar) to vacuum conditions (≈ 10-7 mBar).5, 40 
 
 
 
2-3 mbar 10-4 mbar 10-7 mbar 
Sampler cone Skimmer cone
Extraction 
lens 
Detector
The ICP-MS Ion Path 
Quadrupole
Barrel Shock 
Zone of Silence 
Collision/Reaction 
Cell (multipole) 
Space Charge Region 
e-
Figure 2.  A Schematic of a Typical ICP-MS Instrument. 
 
 
The fraction of ions sampled, from the ICP source, stream through an aperture 
(approximately 1 to 2 mm in diameter) in the centre of a nickel or platinum sample 
cone into a low pressure expansion chamber that maintains a pressure of 
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approximately 2 to 4 mBar, achieved using a mechanical pump, the remaining analyte 
ions impinge on the cone surrounding the orifice.2, 40, 41  In this chamber the ions are 
accelerated to speeds of approximately ten times the speed of sound due to rapid 
expansion which occurs due to the plunge in pressure.  Due to this expansion a “barrel 
shock” region is formed and within this is an area known as the “zone of silence”.42  
The front wall of this barrel shock region is known as a Mach Disc and it is from just 
behind this Mach Disc, in the zone of silence, that ions are removed (skimmed) for 
analysis, see Figure 3.4, 5, 7, 42  Ions are skimmed from this region via a cone, similar to 
the sample cone, known as the skimmer cone. 
 
 
 
Figure 3.  A Diagram of the Barrel Shock Region Produced in the Interface of an ICP-MS 
Instrument.  
 
 
On the opposite side of the skimmer cone an ion beam is generated consisting of ions 
(originating from the analyte, plasma gas and torch box atmosphere), electrons and 
some surviving neutral species.  This ion beam is then guided into a mass analyser by 
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means of an extraction lens that carries a negative potential (typically -300 V to -700 
V).7, 42, 43  The constituents of the ion beam are then accelerated and focussed towards 
the entrance orifice of the mass analyser by a series of electrostatic lenses (carrying 
varying potentials, see section 1.3.1),2, 7, 43 during this process neutral species are 
removed from the beam and electrons are defocused. 
 
Following filtering in a mass analyser ions are counted by a detector.  For the work 
described in this report a dual mode detector was employed.  Such a detector is 
capable of handling a large range of signals via two detection modes.  For low signals, 
of less than 106 ion counts per second, a pulse counting output is used where ion 
impact onto a surface of high voltage releases primary electrons that impact again and 
continually release further electrons.4, 42  The resultant pulse charge is processed 
generating an analytical signal.  For high signals (those of approximately 106 ion 
counts per second and above) the pulse charge is diverted, integrated and measured as 
a DC current.4, 42 
 
Following ion sampling and skimming it has been calculated that only, 
approximately, 0.7 % of the ions generated from a liquid sample (introduced via a 
nebuliser and spray chamber arrangement) in the plasma are detected by the mass 
analyser.4 
 
 
1.1.2.  Sample Introduction in ICP-MS Analysis 
 
As highlighted previously, with the appropriate sample pre-treatment and introduction 
techniques, it is possible to analyse almost any type of sample (in solid, liquid or 
gaseous states) employing ICP-MS. 
 
The most common approach to the introduction of samples into an ICP ion source is 
by the introduction of analytes in the form of liquids.  With regard to liquid samples 
homogeneity can normally be guaranteed, this is analytically desirable.  Such samples 
are typically introduced using a nebuliser and spray chamber arrangement of which 
there are many designs that may be used to transport a wide range of solutions with 
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differing viscosities or dissolved solid content.1, 4, 7, 44-46  Other methods of introducing 
liquid samples into an ICP source include the formation of volatile hydride species 
from the sample that can be transported into the plasma and direct insertion using 
injector tubes or pyrolytic graphite electrodes.2, 4, 5, 7, 40, 47-52 
 
Due to the ease of introducing liquid samples into the ICP source, the coupling of 
separation techniques such as high performance liquid chromatography (HPLC) with 
ICP-MS has become a routine application.1, 4, 7, 26, 53-57  With some system 
modification, the mobile phase, carrying separated analytes, exiting a liquid 
chromatography column can be introduced into a plasma via the typical 
nebuliser/spray chamber arrangement.  The attraction of such a coupling is the 
potential for analyte pre-concentration and generation of data from both techniques 
that can lead to speciation of analytes within very varied sample types.4, 9, 11, 12, 26, 53-59  
However, the introduction of such organic based mobile phases may be responsible 
for both spectroscopic and non-spectroscopic interferences (due to the presence of 
elevated concentrations of C and N isotopes), see section 1.2.2.  The transport 
efficiency of liquid samples into an ICP ion source is particularly low as 85 to 90 % 
of the liquid aspirated is commonly discarded.42 
 
The introduction of gaseous samples into an ICP source is straight-forward.  Some 
gaseous samples can be injected directly into the ICP or introduced via sampling 
loops or the nebuliser/injector flow of the plasma gas.4, 7  Similar to liquid samples, 
homogeneity can be guaranteed in a gaseous sample.  Hydride species can also be 
evolved from some gaseous samples and transported into the source.2, 4, 5, 7, 42, 49, 50, 60  
Similarly to that discussed previously, instrumental coupling with gas based 
separation techniques, such as gas chromatography (GC) or supercritical fluid 
chromatography (SFC), can free samples from possible interfering species and 
provide speciation information.4, 58  Compared with the introduction of liquids, the 
transport of gaseous samples into an ICP ion source is almost 100 % efficient. 
 
Although more difficult than gaseous or liquid samples the introduction of solid 
samples into an ICP source is possible and such introduction can also be beneficial 
with regard to the evasion of some spectroscopic interferences (see section 1.2.1).  
The most common approach to the analysis of solid samples is to chemically digest or 
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decompose the sample and introduce it into the plasma as a solution.1, 4, 7  A solid 
digest solution also promotes sample homogeneity which can be problematic in other 
solid sampling techniques.  However, such an approach is not appropriate for many 
solid samples so other methods have been developed and employed.  Solid samples 
can be introduced by direct insertion, aerosols and vapours can be evolved and 
introduced from samples after processes such as arc and spark ablation, electrothermal 
vaporisation and laser ablation.2, 4, 21, 29, 30, 34, 47, 61-63  Solid samples can also be ground 
into powders prior to slurry formation and nebulisation.1, 2, 4, 5, 7, 42 
 
The use of laser ablation, as a technique for solid sampling, is rapidly growing in 
popularity.  By firing a laser at a solid surface, small quantities of the solid in 
particulate form can be generated.  This particulate solid sample can then be carried 
via a carrier gas, such as helium, into the ICP for elemental measurement.  This 
sample introduction technique is an incredibly powerful analytical tool; however, it 
presents a number of challenges in the form of elemental fractionation as well as the 
usual solid sampling issues, see below.  These challenges are currently being studied 
by research groups worldwide. 
 
Although solid sample introduction can exhibit advantages in the form of analyte 
transport with a reduced matrix and minimum preparation there are limitations that 
the analyst must have a firm understanding of.  A digested/decomposed solid sample 
may be accompanied by a concentrated or harsh matrix that could lead to 
spectroscopic and non-spectroscopic interferences.  Aerosols and vapours generated 
from solid samples are commonly introduced into the plasma by a carrier gas, e.g. He 
or Ar.4, 64  The presence of this carrier gas is known to affect the mass spectral 
background as such a gaseous introduction is comparable to the employment of a 
mixed-gas plasma (see section 1.2.1).  The greatest limitation for the analysis of solid 
samples is the lack of solid certified standard materials that can be analysed for 
reference data.  This absence means that solid sampling methods do not generally 
reach the same quality of quantification as for a liquid sample introduction. 
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1.1.3.  Mass Spectrometry Employed in ICP-MS Analysis 
 
It is possible to interface an ICP ion source with various mass analysers for the 
elemental analysis of samples.  Following ion formation within an ICP ion source a 
mass spectrometer can be used, either by dispersion or filtering, to determine ions 
according to their mass-to-charge ratio (m/z).  The most important parameters 
concerning a mass spectrometer are upper mass limit, transmission efficiency and 
mass resolution.39, 65  These parameters vary, widely, between the different types of 
mass spectrometer available. 
 
Composed of four parallel hyperbolic or circular rods, a quadrupole mass 
spectrometer separates ions according to their motion.1, 4, 7, 39, 42, 58, 65-67  A voltage 
composed of DC and RF components is applied between adjacent rods of the 
quadrupole and adjustment of these components affects the trajectory stability of the 
ions passing through.  At certain rod voltage conditions some ions will have a stable 
trajectory and pass between the rods from one end of the quadrupole to the other 
whilst some will not and will be rejected.4, 58, 65, 67  In ICP-MS, quadrupoles are the 
most commonly used mass analysers as they are compact and relatively inexpensive.  
However, quadrupole mass analysers are limited as they have a restricted m/z range 
(typically 1 to 4000 amu) and a low resolution of approximately 300 (0.6 amu 
bandpass) is achieved.4, 58, 65, 67 
 
Time-of-flight (ToF) is a particularly simple method of mass spectrometry whereby 
the flight time of ions over a known distance (in a drift tube typically 1 m in length), 
is measured.  Assuming that ions have the same kinetic energy (Ek), which is not 
normally the case (see section 1.3) then their velocity is determined by their mass, i.e. 
heavier ions arrive at the detector after lighter ions.39  Several researchers have 
coupled ToF mass analysers to an ICP ion source obtaining LOD’s in the range of 0.4 
to 2.0 ng ml-1, comparable to the limits obtained with a quadrupole.4  As a result of 
this research, commercial ICP-ToFMS instruments are now available.4, 11  The main 
benefit of employing a ToF mass analyser in ICP-MS is that the problem of Ek spread 
(see section 1.3) can be addressed by taking advantage of electrostatic reflectors, 
otherwise known as reflectrons, which compensate for variations in Ek.39  However, 
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one significant limitation to the coupling of an ICP ion source to a ToF mass analyser 
lies in the transportation of ions between the two.  Pulses, or “bundles”, of ions are 
carried away from the ion beam generated after the ICP and into the ToF analyser.  
The result of such a configuration is a particularly inefficient transport of ions which 
hinders the capability of limit of detection. 
 
A double focussing magnetic sector mass spectrometer employs a combination of 
magnetic and electrical fields in order to focus ions according to their momentum 
which is a function of mass and velocity.4, 39, 42  Such a mass spectrometer allows the 
resolution of ion signals with small differences in m/z and is commonly composed of 
a source slit (allowing ions into the magnetic and electrical fields), a magnetic sector 
analyser, an electrostatic analyser, a collector slit and a detector.39, 42  The 
transmission of ions through a magnetic sector mass analyser is a function of 
resolution and resolution of such an instrument is controlled by the source and 
collector slits. 
 
The main limitation, therefore, of employing such a mass spectrometer in ICP-MS is 
that resolution is gained at the expense of sensitivity.4  However, on comparison to 
quadrupoles, a magnetic sector mass analyser can be more sensitive (an additional 
order of magnitude in terms of sensitivity can be achieved).  For example, in the 
comparison of a quadrupole based instrument with a sector field based instrument for 
the measurement of Pt in urine there was an approximate three fold improvement in 
the limit of detection when employing the sector field instrument (LOD’s of 0.18 ng l-
1 and 0.05 ng l-1 for quadrupole and sector field instruments respectively).68  
Examples of the resolution required to separate interfering signals in a mass spectrum 
can be seen in Table 1.4, 7, 42  Double focussing magnetic sector mass analysers are 
also very expensive and are much more difficult to interface with an ICP ion source. 
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Table 1.  A Table of Resolutions Required to Separate Analyte Ions from Interfering Ions. 
Isotope Isotope Mass Interfering 
Ion 
Interfering 
Ion Mass 
Resolution 
required 
28Si 27.9769 14N2+ 28.0061 960 
31P 30.9738 14N16O1H+ 31.0058 970 
32S 31.9721 16O2+ 31.9898 1800 
39K 38.9637 38Ar1H+ 38.9706 5700 
40Ca 39.9626 40Ar+ 39.9624 193000 
51V 50.9440 35Cl16O+ 50.9638 2600 
52Cr 51.9405 40Ar12C+ 51.9624 2400 
56Fe 55.9349 40Ar16O+ 55.9573 2500 
75As 74.9216 40Ar35Cl+ 74.9312 7800 
80Se 79.9165 40Ar2+ 79.9248 9700 
 
 
High resolution mass spectrometers are widely employed in ICP-MS instruments in 
applications demanding lower LOD’s and the removal of molecular ion 
interferences.9, 12, 38, 69-71 
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1.2.  Limitations of ICP-MS Analysis 
 
Although ICP-MS, employing a low resolution quadrupole mass analyser, can boast 
excellent LOD’s and linear ranges it is hindered, to a certain degree, by various 
sources of interference and transmission problems through the plasma-mass 
spectrometer interface.  Interferences in ICP-MS can be divided into two catagories; 
spectroscopic and non-spectroscopic interferences.1, 5, 7, 70, 72 
 
 
1.2.1.  Spectroscopic Interferences 
 
Spectroscopic interferences are defined as any enhancement of the analyte signal 
caused by atomic or molecular ion species of the same m/z as that of the analyte 
species.1, 5, 7, 36, 73  The major causes of such interference and available remedies are 
described as follows. 
 
In an ICP-MS instrument employing a low resolution mass analyser signals 
originating from different isotopes can be observed at the same m/z, in such a 
situation these signals cannot be separated.  Overlapping isotope signals of this kind 
are described as isobaric interferences.7  The degree of such interference depends on 
the quantity and properties of isotopes present in the plasma.  Isobaric interference is 
therefore dependent on the analyte isotopes of interest, the type of plasma gas(es) 
being used, the sample matrix and entrained atmospheric gases.7, 73, 74  Isobaric 
interference can be assessed in the isotopic abundance table (Figure 90) in Appendix 
1. 
 
Ionic molecular species, otherwise known as polyatomic ions, may also interfere with 
the m/z signal of an analyte isotope.1, 5, 7, 75-80  Polyatomic ions are detected as the 
result of either atomisation survival within the ICP or formation from atomic ions and 
neutral species.  Such formation occurs through combination or ionisation reactions at 
the plasma-mass spectrometer interface.7, 76  The presence of polyatomic ions can 
make elemental analysis by ICP-MS difficult and in some cases even the use of high 
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resolution mass spectrometry is not particularly beneficial.1, 5, 7, 79  Some of the more 
common examples of these polyatomic ions are those based on argon, 40Ar14N+, 
40Ar16O+ and 40Ar2+ ions interfere with the measurement of 54Fe, 56Fe and 80Se 
isotopes respectively.  An extensive list of polyatmic ion interferences can be seen in 
Table 53 (Appendix 1). 
 
Under certain plasma conditions doubly charged ions can be formed from some 
isotopes.  The signal for such an ion in the mass spectrum appears at a m/z at half that 
of the same isotope carrying a single charge.4, 5, 74, 75, 81  Doubly charged ions can 
therefore cause interference in lower regions of the mass spectrum.  Previously, 
however, the presence of doubly charged ions in the mass spectrum has been used to 
the benefit of the analyst.  Jarvis et al.82 used the occurrence of Eu2+ ions to quantify 
151,153Eu at m/z = 75.5 and 76.5 avoiding interfering 135Ba16O+, 134Ba16O1H+, 137Ba16O+ 
and 136Ba16O1H+ ions at the native m/z = 151 and 153.  Further examples of doubly 
charged ions can be seen in Table 53 (Appendix 1). 
 
With basic chemical knowledge most isobaric and doubly charged ion interferences 
can be predicted and avoided by the use of alternative isotopes, in the case of 
polyisotopic analytes, or by the careful selection of sample matrices, plasma gas(es) 
and plasma conditions.  However, in the case of polyatomic ion interferences the 
prediction of their presence and degree of effect can be more difficult.  Various 
methods are available to the analyst that can be used to limit polyatomic ion 
interferences, these include the following: 
 
Although Ar is the most commonly used gas in the generation of an ICP the mass 
spectral background of such a plasma is dominated by Ar based spectroscopic 
interferences particularly between m/z = 50 and 80.83  Employing a plasma generated 
from alternative or mixed gases (such as N2, O2, H2, He, Xe, CH4, CHF3, C2H4 or 
compressed air) will provide a mass spectral background dominated by ions of a 
different m/z.  Some such backgrounds will allow the analysis of certain m/z signals 
that are heavily interfered with when employing an Ar plasma.40, 84-89 
 
The problem of spectroscopic interferences may be tackled by the utilisation of 
collision or dynamic reaction cells.  By bleeding reactive gases into a multipole 
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situated between the plasma-mass spectrometer interface and the mass analyser, 
through which the ion beam generated after the skimmer cone is passing, it is possible 
to react analyte or interfering ions to form product ions at an alternate m/z therefore 
allowing detection and quantification.33, 43, 59, 79, 90-96 
 
Spectroscopic interferences can also be overcome by deliberately altering the 
conditions of the ICP.  Lowering the plasma forward power from the typical 1350 W 
to between 600 W and 900 W (known as the “cold/cool plasma” region) results in a 
plasma with a background spectrum dominated by the 14N16O+ (m/z = 30) ion rather 
than Ar based ions.  Similar to the use of alternate or mixed gas plasmas, a different 
mass spectral background arising from a “cold/cool plasma” will allow the analysis of 
certain m/z’s without interference.  The use of such a plasma is common in the 
determination of K isotopes at m/z = 39 and 41.97-99  Low forward power plasmas 
operate at lower temperatures and have different plasma potentials than those run at 
the normal 1350 W.  It is the variation of these two parameters that result in changes 
in atomisation and ionisation characteristics leading to a different mass spectral 
background. 
 
Some spectroscopic interferences can be avoided by the employment of an alternative 
method of sample introduction.  Although sometimes problematic, introduction 
techniques such as laser ablation, hydride generation and electrothermal vaporisation 
can be employed for this reason as they all involve transport of a sample in a pure 
form.2, 4, 21, 29, 30, 34, 40, 41, 47, 49, 50, 61-63  In many cases interferences arising from the 
presence of polyatomic ions can be resolved by the use of high resolution mass 
spectrometry coupled to the ICP ion source.4, 38, 69-71, 100 
 
 
1.2.2.  Non-Spectroscopic Interferences 
 
Non-Spectroscopic interferences are defined as any degradation in signal that arises as 
a result of physical or chemical parameters of the sample.4, 36  The major causes of 
such interference and approaches to compensate for them are described as follows. 
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Easily Ionisable Elements 
 
Elements with a relatively low ionisation potential (such as Na, K, Ca, Rb and Cs) are 
described as easily ionisable elements (EIE’s).  Theoretically an excess of EIE’s 
present in a sample can create a bias in the ionisation equilibrium of the ICP towards 
elements of a lower ionisation potential (IP).  Such a bias could result in ionisation 
suppression of analyte elements exhibiting a higher ionisation potential.4  For 
example, in the analysis of a sample containing 31P (IP = 10.5 eV) and an excess of 
Na (IP = 5.1 eV) a significant degree of suppression of the ionisation of 31P may be 
expected.  If such suppression is not anticipated, and taken into account through 
matrix matching of standards or internal standardisation, anomalous results might be 
obtained.  In practise, however, the quantity of sample elements passing through the 
ICP in relation to the argon plasma gas will always be low so any non-spectroscopic 
interference effect that would arise due to the presence of EIE’s would be minimal, if 
it occurred at all. 
 
 
Physical Properties of a Sample 
 
The physical properties of the sample being analysed and the method of delivering it 
into an ICP must be understood fully by the analyst so to estimate the degree of non-
spectroscopic interference. 
 
On introduction into an ICP, it would be expected that gaseous samples exhibiting a 
high vapour pressure would vary the width of the plasma central channel and 
therefore affect the local temperature and ionisation capability.  If sample vapour 
pressure is high enough then the plasma may destabilise completely and extinguish.  
This effect must also be considered when employing sample introduction techniques 
that require the use of an alternative carrier gas to transport the sample into the 
plasma.  For example, in laser ablation sample introduction a He carrier gas 
introduced into an Ar plasma is known to vary the properties of the ICP, such as 
temperature and plasma potential, as seen in the employment of a mixed gas plasma.4 
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The efficiency with which a liquid sample can be introduced into an ICP and analysed 
is dependent on an even greater number of physical properties.  Viscosity, surface 
tension, density and vapour pressure all affect the efficiency with which a liquid can 
be nebulised and transported through a spray chamber into the ICP torch.  Once in the 
torch, sample vapour pressure has the same effect on the plasma as that described for 
gaseous samples.4 
 
As mentioned previously, the most common approach to the introduction of solid 
samples is to form a vapour and/or particle cloud from a sample surface.  With regard 
to the introduction of such a vapour or particle cloud there are two main factors that 
can contribute to non-spectroscopic interference that must be considered.  The first 
factor is the use of alternative carrier gases for the transportation of material into the 
ICP, this has already been discussed with regard to gaseous and liquid introduction in 
this section.  The second factor is known as elemental fractionation.  In basic terms 
elemental fractionation can be described as non-representative sampling, i.e. the 
signal response of the ICP-MS is not representative of the components of the sample.  
Although work is still being carried out to fully understand what causes this problem 
it is now generally believed that elemental fractionation can occur at three points 
during the sampling, transport and ionisation processes.  During the sampling process 
bias can take place during the transfer of certain elements into the gas phase based on 
their physical properties such as melting and boiling points, vapour pressure, atomic 
and ionic radius, charge and speciation.64  Generally the particles created during solid 
sampling are much larger than those generated during liquid sample nebulisation.  
These larger solid particles are thought to be significant with regard to deposition 
during sample transport and atomisation and ionisation efficiency within the ICP.64  
For these reasons the degree of elemental fractionation, therefore, differs widely 
between samples.64  The problem of elemental fractionation highlights the necessity 
for matrix matched solid calibration standards which are not available for the majority 
of solid samples. 
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Sample Deposition within an Instrument 
 
Analyte signal may be suppressed as a result of excessive sample deposition on the 
sample and skimmer cones during an analysis or if deposits are allowed to build up 
over time.  If this takes place the orifice of either cone may block and the ion beam 
generated behind the skimmer cone will be affected, a signal of reduced or little 
intensity will result.  This problem can be easily avoided assuming regular instrument 
cleaning and maintenance. 
 
 
Space Charge Effects 
 
“Space charge effect” describes a situation whereby a predominance of positive or 
negative charge causes a mutual repulsion amongst ions.  In ICP-MS, the plasma 
species transported through the sample cone are primarily composed of positively 
charged ions, electrons and neutral atoms and molecules (originating from the analyte, 
plasma gas and entrained atmospheric gases).  Because, throughout the instrument, 
ions and electrons are travelling at different velocities, the potential for the separation 
of charge and a breakaway from neutrality is high.  If charge separation is sufficiently 
strong then repulsion between positive ions will take place.  Such separation can 
influence ion trajectory as the ion beam passes into the mass analyser, unstable 
trajectories can result in a loss of analyte sensitivity.4, 72, 101 
 
 
Ion Kinetic Energy Spread 
 
The degree of variation in kinetic energy (Ek) exhibited between ions of the same 
element can contribute to reductions in ion transmission and mass spectrometer 
resolution.  The Ek of ions passing through the system is an important factor in terms 
of the ability to move between the various electrical environments of the instrument.  
A wide spread in Ek could lead to a significant proportion of ions of the same element 
being eliminated from the mass analyser prior to detection or interference with 
elements of a neighbouring mass.  For a full description of the issue of ion kinetic 
energy effects see section 1.3. 
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With the careful design of an ICP-MS analysis most non-spectroscopic interferences 
can be anticipated and potentially minimised.  The presence of EIE’s in a sample can 
be limited to avoid ionisation bias towards elements of low IP and the evasion of 
highly concentrated samples, as well as regular instrument cleaning, can minimise the 
chances of orifice blocking in the sample and skimmer cones.  Selection of 
appropriate sample pre-treatment and introduction techniques can help avoid some 
non-spectroscopic interferences derived from physical properties of the sample.  
Internal standardisation, standard addition and isotope dilution approaches are 
commonly employed in order to standardise non-spectroscopic interference.4, 22, 28, 39 
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1.3.  Kinetic Energy Issues Associated with ICP-MS Analysis 
 
A subject that has been relatively overlooked with regard to interferences in ICP-MS 
is the kinetic energy (Ek) of ions, generated in the ICP, and the effect that such energy 
has on ion transmission through the instrument.  Ek of ions transmitted through the 
ICP-MS can have both detrimental effects (with regard to ion transmission and mass 
spectral resolution as a result of Ek spread) and advantageous effects (with regard to 
ion control in a collision cell by KED and IKEE) on the determination of isotopes.  
Such effects are discussed in sections 1.3.1, 1.3.2 and 1.3.3. 
 
 
1.3.1.  Causes of Ion Kinetic Energy Spread 
 
The Ek of ions generated in the plasma and transmitted through the plasma-mass 
spectrometer interface, ion optics and mass analyser is a function of an individual 
ion’s mass and velocity.  During passage through the instrument ion velocity can 
change according to the physical characteristics of the environment to which the ion is 
exposed.  Between generation in the ICP source and detection, after filtering in a mass 
analyser, ions are subjected to several different environments in an ICP-MS that result 
in them experiencing a wide range of electrostatic energies.  Such exposure has been 
described by Dexter et al. as an “ion energy rollercoaster”, see Figure 4.102  
Environmental exposure to varying pressures, temperatures and electrical phenomena 
are seen to cause this “rollercoaster” which leads to a wide Ek spread amongst the ions 
transmitted. 
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Figure 4.  The "Ion Energy Rollercoaster" Diagram.102 
 
 
Figure 4 is a diagram that highlights the variation in electrical environment, with 
respect to 0 V, through which ions pass in the ICP-MS.  The thick pink line, of the 
Figure 4 diagram, shows the variation in potential imposed on ions at different stages 
in the instrument relative to the 0 V black line.  Although this diagram is a specific 
description for a Thermo PQ ExCell ICP-MS instrument the premise is similar for all 
quadrupole based ICP-MS instruments.  The different stages, highlighted in Figure 4, 
during which ion energy is influenced significantly are described as follows: 
 
Composed of positively charged ions, electrons and neutral species, the ICP ion 
source is an environment of high plasma potential (+9 V to +11 V) and high 
temperature (7000 K to 10 000 K for an Ar based plasma).4, 39  In this region the 
positive ions are fast moving and highly mobile due to the repulsion forces between 
themselves, the positive potential of the plasma and the high plasma temperatures.39 
 
As positive ions are drawn through the sample cone they are rapidly accelerated to 
supersonic velocities in the expansion chamber that buffers the ICP ion source 
operating at atmospheric pressure and the mass analyser at vacuum conditions.4  This 
acceleration takes place due to the environmental pressure transition (1 Bar to 
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approximately 2 to 4 mBar) and is described in the equation of Figure 86 in section 
5.3.1.4 
 
Following rapid acceleration and skimming of the bulk material in the expansion 
chamber, positive ions are subject to two significant factors that contribute to Ek 
spread.  Firstly there is an attracting force acting on the ions in the form of a large 
negative potential, of approximately -600 V, applied to the extraction lens that sits 
behind the skimmer cone.43  Such a large potential applied to the extraction lens is 
required because the entrance aperture leading into the electrostatic lenses is quite 
small.  The extraction lens voltage is controlled via the instrument software.  
Secondly, between the back of the skimmer cone and the extraction lens “space 
charge effects” are known to be prevalent.  Any mass repulsion between ions, in the 
beam generated after the skimmer cone, will have an affect on ion velocity and 
therefore Ek. 
 
After passage through the extraction lens the bulk flow of ions is decelerated on 
approach to the slide valve that separates the low pressure expansion region and the 
vacuum conditions of the mass analyser multipole.  This deceleration takes place as 
the slide valve is grounded so there are no attracting or repelling forces acting on the 
ions. 
 
Beyond the slide valve the ions passing through are accelerated due to attraction 
towards negative voltage applied to a series of three electrostatic guiding lenses.43  In 
the case of the Thermo PQ ExCell ICP-MS instrument the first of these lenses carries 
a potential of approximately -1 V whilst the second and third lenses carry potentials of 
approximately -50 V and -100 V respectively. 
 
Following acceleration by the electrostatic lenses the ion flow is decelerated on 
entrance to the collision cell multipole, in this case a hexapole.  This takes place due 
to repulsion by the positive potential applied to the multipole (typically +1 V to +10 
V).25  If the collision cell is in operation and a reaction gas has been bled into the 
hexapole then ions can be slowed further as a result of collisions between ionic and 
neutral species.103  It should be noted that a collision cell or dynamic reaction cell 
multipole is not a standard feature of a quadrupole based ICP-MS instrument. 
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The collision cell multipole and mass analyser quadrupole are separated by a further 
guiding lens that carries a negative potential, this lens is responsible for ion 
acceleration before entrance to the quadrupole.43  On passage into the quadrupole 
mass analyser the ion flow is accelerated or decelerated according to the potential 
applied.  During typical analysis a potential of +1 V is applied to the quadrupole 
which has a decelerating effect on the ion flow.43 
 
The dual mode detector employed by the Thermo PQ ExCell ICP-MS typically carries 
a voltage of between -2500 V and -4000 V, therefore on exit of the quadrupole ions 
are subjected to a sudden acceleration into the detector for counting. 
 
 
1.3.2.  The Significance of Ion Kinetic Energy Spread 
 
It is because the ions generated are exposed to the undulating conditions, described in 
section 1.3.1, that the Ek that they exhibit, following passage through the instrument, 
can be quite varied.  The presence of this Ek variation can impair ion resolution and 
transmission, i.e. sensitivity.  This variation in Ek can vary ion trajectory stability on 
passage through the quadrupole and hence determine whether or not it is filtered and 
detected.  It is believed that any instrument modifications that can be made to lessen 
the drastic changes in ion velocity spread whilst maintaining ion transmission would 
improve ICP-MS LOD’s for every element of the periodic table. 
 
 
1.3.3.  Advantageous Ion Energy Effects 
 
As a result of the study of ion Ek within an ICP-MS instrument, with respect to 
collision and dynamic reaction cells, two distinct effects have been recognised.  These 
two effects are known as kinetic energy discrimination (KED) and the ion kinetic 
energy effect (IKEE) and are described as follows: 
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Kinetic Energy Discrimination (KED) 
 
Defined as the exclusion of slow, collision cell formed, ions from the mass analyser, 
kinetic energy discrimination (KED) is a particularly beneficial effect in analysis by 
ICP-MS.  The passage of unwanted secondary or tertiary ions into the mass analyser 
can be limited, by KED, leading to a reduction in levels of interference.83  During 
KED a “kinetic energy barrier” is established, between the collision cell and mass 
analyser multipoles, which ions must overcome in order to enter the mass analyser.83, 
91 
 
The KED effect is achieved by setting the potential of a pressurised collision cell 
multipole slightly less positive than the mass analyser potential.83  When this is the 
case collision product ions from the cell with the same energy as the collision cell 
potential are discriminated against and rejected before reaching the mass analyser.  
Analyte ions, generated within the ICP source, are typically of high energy due to 
exposure to high plasma potential and high temperatures so are allowed through to the 
mass analyser.83, 91, 96  KED can be used to exclude cell formed molecular ions from 
the quadrupole as they have a higher collisional cross section than analyte ions so 
undergo more thermalising collisions with the gaseous collision cell species.104 
 
 
Ion Kinetic Energy Effect (IKEE) 
 
Ion kinetic energy effect (IKEE) is defined as the variation of collision cell reactivity 
by control of the input ion energy.  Dexter et al.83 studied the effects of IKEE and 
observed that the input ion Ek can be varied by alteration of the potential difference 
between the plasma (≈ 9 V) and a collision cell multipole (variable potential) in a 
Thermo PQ ExCell ICP-MS instrument.  Dexter et al.83 observed that increasing the 
collision cell multipole potential with respect to plasma potential resulted in an 
increase in the rate of exothermic reactions and a decrease in the rate of endothermic 
reactions.  Here, IKEE has been highlighted as an area of research that may be 
beneficial for future analysis employing ICP-MS instruments and collision cell 
technology. 
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1.4.  Collision and Dynamic Reaction Cells 
 
Collision and dynamic reaction cells are enclosed, pressurised, multipoles 
(quadrupoles, hexapoles and octapoles) that can be employed as gas phase “test tubes” 
as part of the operation of an ICP-MS.  Due to differences in stability boundaries of 
quadrupoles, hexapoles and octapoles, two types of cell have evolved and are in 
common use in ICP-MS today. 
 
 
1.4.1.  Collision Cells 
 
Typically hexapole or octapole collision cells are positioned between the plasma-mass 
spectrometer interface and the mass analyser.  Operating in an RF only mode these 
cells guide the ion beam that has been generated.  On bleeding a reaction gas into such 
a cell, processes such as collisionally induced dissociation (CID) and ion-molecule 
reactions can be performed with the ionic species of the ion beam.  As these cells are 
operated in an RF only mode the gas being introduced must be inert or of low 
reactivity in order to avoid the formation of secondary or tertiary ions that may have 
stable trajectories in the multipole and potentially interfere with the m/z of the analyte 
of interest.  H2,23, 33, 59, 83, 91, 93, 105-110 Xe,33, 111 CH4,33 He,15, 23, 59, 83, 91, 93, 105-111 O2,33 
and N2O,109 have been well documented as collision cell gases that can provide 
beneficial chemistries with regard to tackling spectroscopic interferences. 
 
 
1.4.2.  Dynamic Reaction Cells 
 
The dynamic reaction cell is a pressurised quadrupole that, like the collision cell, is 
positioned between the instrument interface and the mass analyser.  A reaction gas 
can be bled into the cell whilst being operated in an RF and DC mode.  This type of 
cell can therefore discriminate against ions leaving the cell and entering the mass 
analyser according to the bandpass control.  For this reason more reactive gases can 
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be incorporated into the device than can be in a collision cell as any secondary or 
tertiary reaction products can be removed before reaching the mass analyser.  NH3,17, 
18, 33, 95, 109, 112-117 CH4,18, 33, 95, 112, 114 H2,18, 33, 113, 114, 116 and O2,18, 33, 114, 117, 118 gases 
have been studied in a dynamic reaction cell in order to tackle spectroscopic 
interferences. 
 
 
1.4.3.  Ion-Molecule Chemistry of Collision and Dynamic Reaction 
Cells 
 
During the operation of a collision or dynamic reaction cell several processes are 
known to take place between the components of the ion beam and the 
collision/reaction gas introduced.  A scattering effect on the ions transported through 
the cell multipole can be produced by the cell gas.  Such an effect can limit the 
number of ions reaching the mass analyser and hence reduce the overall sensitivity 
achieved.  This effect is seen to be worse for ions of a lower mass compared to 
heavier ions.33  The other processes that take place in a collision or dynamic reaction 
cell are collisional processes; these describe the interactions between ions and 
collision/reaction gas molecules and are discussed as follows: 
 
 
Energy Transfer 
 
By the means of a non-reactive collision, energy can be transferred from an ion to a 
neutral molecule.  The degree of energy that can be transferred depends on the kinetic 
energy of each species involved in the collision.  If multiple collisions occur in a 
collision or dynamic reaction cell between a high energy ion and a low energy neutral 
species then sequential loss of Ek from the ion occurs, this is known as energy 
damping.  Such damping is extensive when there is a large neutral species to ion mass 
ratio in the cell.33 
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Collisional Fragmentation 
 
As described previously, during the collision between ionic and neutral species energy 
can be transferred to the neutral molecule.  Such transferred energy, transformed 
partly into vibrational energy, can exceed molecular bond strength and a chemical 
bond may break resulting in fragmentation or dissociation of the molecule involved in 
the collision.39  This process is known as collisionally induced dissociation (CID).  In 
a collision or dynamic reaction cell, as part of an ICP-MS instrument, polyatomic ions 
or neutral species can be dissociated by collision with an inert gas such as He or Ar.33  
Such dissociation can occur through a single collision, although multiple collisions 
may be required where internal energy is accumulated until breaking point on each 
single collsion.  Although CID is a very useful tool in the fragmentation of large 
molecular ions in organic based mass spectrometry it is not a particularly efficient 
process for the removal of some low mass interfering polyatomic ions, chemical 
reaction can be a far more effective approach to this.33, 39, 66 
 
An example of the advantageous employment of CID in collision/reaction cell ICP-
MS is the dissociation of the argon dimer (40Ar2+, m/z = 80).  By using Ar as a 
collision gas, in a cell, the dissociation of 40Ar2+ is 86 % efficient for single collision 
fragmentation.33  The same effect can be achieved with He and H2 collision gases but 
multiple collisions (4 or more) are required for dissociation. 
 
 
Ion-Molecule Reactions 
 
Reactive gases, such as H2, can be bled into a collision or dynamic reaction cell to 
remove unwanted low mass ions by chemical reaction.  Typically the reaction gases 
bled into the cell are introduced at low pressures to avoid excessive scattering of ions 
in the cell.33, 66  Due to the presence of ionic and neutral species in the cell several 
important types of reaction are known to occur, as indicated in Table 2.33 
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Table 2.  Reactions Taking Place Between Ionic and Neutral Species in a Collision/Reaction Cell. 
Reaction Type Reaction Process Example 
Charge Transfer A+  +  B  →  B+  +  A 40Ar+  +  14N1H3  →  40Ar  +  14N1H3+ 
Proton Transfer AH+  +  B  →  BH+  +  A 40Ar1H+  +  1H2  →  40Ar  +  1H3+ 
H Atom Transfer A+  +  BH  →  AH+  +  B 40Ar+  +  1H2  →  40Ar1H+  +  1H 
Oxidation A+  +  BO  →  AO+  +  B 136Ce+  +  14N216O  →  136Ce16O+  +  14N2 
Association A+  +  B  →  AB+ 28Ni+  +  14N1H3  →  28Ni+.14N1H3 
 
 
Ion-molecule reactions that can take place in a collision or dynamic reaction cell are 
thermodynamically specific according to their enthalpy of reaction.  For example, it is 
possible for 40Ca+ (m/z = 40) to be resolved from 40Ar+ (m/z = 40) employing a NH3 
reaction gas.  Such resolution is possible because the reaction between the 40Ar+ ion 
and NH3 is fast (rate constant = 1.7 x 10-9 cm3 molecule-1 s-1) compared to the slower 
reaction between the 40Ca+ ion and NH3 (rate constant < 1.0 x 10 -13 cm3 molecule-1 s-
1).  This reaction specificity is also reflected in the ionisation potential of each species; 
Ar = 15.76 eV, NH3 = 10.16 eV and Ca = 6.11 eV.  The result of this is the 
attenuation of the 40Ar+ ion whilst the 40Ca+ ion is almost unaffected.33, 51 
 
By taking advantage of differences in reactivity between the analyte ions of interest 
and unwanted interfering ions selective reactions can be carried out by introducing 
various reaction gases into the cell.  Such reactions have shown that the approach of 
employing these cells has been found to be effective in the reduction of some 
interfering polyatomic ions, with the same m/z value as the analyte ion, entering the 
mass analyser. 
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1.5.  “Cold/Cool Plasma” 
 
In an Ar based, quadrupole, ICP-MS instrument, under conventional operating 
conditions K, Ca and Fe isotopes are particularly difficult to analyse due to intense 
background signals at m/z = 39, 40, 41, 42, 43, 43.5, 44 and 56.4, 6, 98, 99, 119  Such 
background signals occur due to isobaric interferences and spectroscopic interferences 
resulting from the presence of Ar based polyatomic ions and doubly charged 
84,86,87,88Sr isotopes.99  Isobaric and spectroscopic interferences that typically affect the 
analysis of K, Ca and Fe isotopes are listed in Table 3.98, 99, 119 
 
 
Table 3.  A Table of Potential Interferences with Regard to K, Ca and Fe Isotopes. 
Analyte Isotope Isobaric 
Interference 
Polyatomic Ion 
Interference 
Doubly Charged 
Ion Interference 
39K - 38Ar1H+ - 
40K 40Ar+, 40Ca+ 38Ar1H2+ - 
41K - 40Ar1H+ - 
40Ca 40Ar+, 40K+ 38Ar1H2+ - 
42Ca - 40Ar1H2+ 84Sr 
43Ca - - 86Sr 
44Ca - - 88Sr 
48Ca 48Ti+ - - 
54Fe 54Cr+ 38Ar16O+, 40Ar14N+ - 
56Fe - 40Ar16O+ - 
57Fe - 40Ar16O1H+ - 
58Fe 58Ni+ - - 
 
 
For some elements it is acceptable to analyse samples by collecting data at alternate 
isotopes.  For example, for the analysis of Ca the isotope at m/z = 44 (2.09 % 
abundant) may be studied rather than the isotope at m/z = 40 (96.9 % abundant) that 
suffers both isobaric and spectroscopic interferences.  However, for some elements 
the measurement of an alternative isotope is not possible.  Instead, by substantially 
altering the operating conditions of the ICP-MS instrument, it is possible to change 
the composition of the plasma and hence change the dominant background ions in the 
 61
mass spectrum.  By increasing the sampling depth of the plasma torch, lowering the 
plasma forward power and increasing the nebuliser flow a lower temperature 
“cool/cold plasma” is achieved.4  In the analysis of a 0.1 % HNO3 solution under 
standard conditions the dominating ions observed were 40Ar+ (m/z = 40), 40Ar1H+ (m/z 
= 41), 16O+ (m/z = 16) and 14N+ (m/z = 14).4  Large background signals were also seen 
for 40Ar2+ (m/z = 80) and 40Ar16O+ (m/z = 56).4  When the same solution was analysed 
under “cool/cold plasma” conditions the background spectrum was different, being 
dominated by 14N16O+ (m/z = 30) ions.  Under such conditions the formation of 40Ar+ 
(m/z = 40) and 40Ar1H+ (m/z = 41) ions are suppressed leaving ions at m/z = 39, 40 and 
41 relatively interference free.97 
 
The main disadvantage in employing “cool/cold plasma” conditions is that the 
formation of polyatomic ions, particularly oxide ions, originating from the sample 
matrix is more likely within the ICP.  These effects can be reduced by the separation 
of the sample from its matrix or vice versa before introduction into the plasma which 
can be achieved by, for example, hydride generation, electrothermal vaporisation, 
laser ablation or coupled techniques such as HPLC.2, 4 
 
When used in conjunction with techniques for reducing a secondary discharge and 
methods for matrix removal, ”cool/cold plasma” ICP-MS can be a very effective 
approach to analysis.  Several groups have employed the “cool/cold plasma” 
technique in the analysis of 40,42,43,44,48Ca, 39,40,41K and 54,56,57,58Fe isotopes that 
commonly suffer the interferences previously described.97-99  It has been shown that 
employing these conditions during the analysis of Ca, K and Fe isotopes the analyte 
signals can be easily separated from the background signal.  Because of the low 
LOD’s achieved, “cool/cold plasma” has become the approach for ultra-trace analysis 
of acids and waters in the semiconductor industry which has a requirement for high 
purity materials.4, 98, 99 
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1.6.  The Application of ICP-MS in Biological Samples 
 
In recent years there has been an explosion in the number of publications involving 
the study of metals in biological systems by ICP-MS.  The understanding of the role 
of metal species in the human body has become increasingly important and ICP-MS 
has been able to provide accurate quantitative data that could not, previously, have 
been produced by atomic absorption spectroscopy.  Also, on interfacing with 
separation techniques such as HPLC, speciation data has provided enormous 
quantities of information that can describe biological systems. 
 
 
1.6.1.  Biological Samples in Clinical Science 
 
From a clinical point of view there are three main areas in the study of these systems 
that ICP-MS can contribute to.120  These three areas are described as follows: 
 
 
Nutrition 
 
ICP-MS has been used to determine the levels and speciation of metals in human 
body media such as blood, serum, plasma, urine and tissues following digestion or 
dilution.  Such data has been used to associate the deficiency of essential elements 
(for example Cr, Mn, Mo, Fe, Co, Cu, Zn, Se and I) with diseases and disorders.94, 120-
126  As ICP-MS is an isotope specific technique it has also been employed in the 
determination of the efficacy of metal supplementation.  By supplementing the body 
with stable isotope enriched compounds and measuring isotope ratios in blood, serum 
and plasma the degree of metal uptake can be established.  An example of such 
research has been supplementation with iron and selenium compounds.123 
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Toxicology 
 
The occurance of metal poisoning in the body can be determined and quantified by 
employing ICP-MS.  Exposure to As, Hg and Pb have been determined through the 
ICP-MS analysis of blood, plasma, urine and hair samples.127  Such measurements are 
important in occupational medicine.120 
 
Currently there is a lot of research being carried out on implantable devices in the 
human body, particularly hip joint replacements.  Such hip replacements based on two 
metal surfaces moving against each other generate significant quantities of particulate 
wear debris that can reside in the tissues surrounding the joint and can be circulated 
via the blood stream.  ICP-MS has been employed in the quantification of metals such 
as Co, Cr and Mo in blood, serum and urine samples.128-131  At present there is much 
debate with regard to the biological effect, if any, of such debris in the human body. 
 
 
Pharmacology 
 
The employment of ICP-MS in pharmacology can be viewed from two points of view.  
ICP-MS is used extensively in the study of metal based therapeutic compounds, such 
as the platinum based cisplatin and oxaliplatin (see Chapter 4).  Blood, serum, tissues 
and isolated cells have been studied in the determination of drug/target interactions.  
The ICP-MS technique is also employed in the detection of inorganic impurities in 
materials and formulations used and produced in the synthesis of pharmaceutical 
compounds.132, 133  Such impurities typically originate from the use of catalysts and 
reaction vessels and control of which is essential with regard to the quality and safety 
of a drug. 
 
 
1.6.2.  Biological Samples in the Environment 
 
ICP-MS is widely employed in the study of biological systems in the environment.  
Plant and animal life are commonly studied to establish the roles of metal species in 
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their biochemistry and also to determine the uptake of metals as a result of exposure 
to industrial processes.  A very good example of this is the speciation analysis of As.  
Such work has shown that biological systems can absorb significant levels of As, 
however, the metal may not produce any detrimental effects as it can be present as a 
non-toxic species. 
 
 
 
1.7.  Thesis Aims and Objectives 
 
Under sponsorship by the Thermo Electron Corporation (Winsford, Cheshire, United 
Kingdom) the initial aim of the work, carried out to attain the degree of doctor of 
philosophy was the following: 
 
The improvement of limits of detection for the measurement of 31P and 32S 
isotopes by quadrupole based ICP-MS. 
 
The reasons behind carrying out such work are described in sections 1.2.1 and 2.1.1.  
The work carried out towards this initial aim is described in Chapter 2.  During the 
three years over which the work for this thesis was carried out three additional 
objectives evolved from the original aim, these are described as follows: 
 
 
The study of deoxyribose nucleic acid (DNA) by ICP-QMS methods developed 
towards the original aim. 
 
DNA in various matrices was studied as an application of the 31P and 32S methods 
developed.  The DNA molecule consists of approximately 10 % phosphorus, present 
in the phosphate sugar backbone, so was viewed as an ideal compound for study.  
Qualification and quantification of DNA is typically undertaken via robust UV/Vis 
spectroscopy and fluorescence methods.  It was the aim of this work to determine the 
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viability of ICP-QMS as a competing technique for the study of this compound.  The 
work carried out towards this aim is described in Chapter 3. 
 
 
The study of interactions between DNA and platinum based anti-cancer drugs 
(cisplatin and oxaliplatin) by ICP-QMS. 
 
As a direct continuation of some of the work carried out towards the original aim a 
collaboration between the Loughborough University atomic spectroscopy research 
group and the cancer biomarkers and prevention group at the University of Leicester 
was established.  The joint interest between these two groups lay in the study of DNA.  
In the case of the Loughborough group the study of the DNA molecule by ICP-QMS 
was of interest in terms of its phosphorus content.  The interest for the Leicester group 
lay in DNA being the therapeutic target of the platinum based anti-cancer drugs 
cisplatin and oxaliplatin. 
 
The study of the interaction between such drugs and their target should allow the 
calculation of binding constant data that could be used to fulfil one of the overall 
objectives of the Leicester group which is the development of a clinical blood test to 
establish drug efficacy of both cisplatin and oxaliplatin in individual patients.  The 
aim behind this objective was the determination of a binding constant for the 
interaction between the cisplatin and oxaliplatin drugs and their biological target DNA 
(see Chapter 4). 
 
 
The development of alternative ICP-MS interface structures to tackle non-
spectroscopic interferences. 
 
With regard to general instrument development, an area that has changed very little 
since the birth of ICP-MS instruments is the interface region.  The current design of 
this region contributes to two significant forms of non-spectroscopic interference; 
sample deposition on the skimmer cone tip and analyte ion kinetic energy spread.  
Successfully overcoming these issues could improve the limits of detection for all of 
the elements measureable by ICP-MS.  With the understanding of the processes that 
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take place in this region it was the aim of this work to tackle these two forms of 
interference via research into two additional structures that could be incorporated into 
the expansion chamber.  The work carried out towards this third additional objective 
is described in Chapter 5. 
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Chapter 2 
 
Method Development Studies for the 
Determination of Phosphorus and 
Sulphur Isotopes by ICP-QMS 
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2.1.  The Determination of Phosphorus and Sulphur by ICP-
MS 
 
Phosphorus and sulphur are two elements that are crucial to all forms of life.  Both 
elements are important in the steel and semiconductor industries as well as the food 
and petrochemical industries and in the analysis of environmental and geological 
samples, especially with respect to the concentration of sulphur in rain water (or “acid 
rain”), and the presence of phosphorus in ground waters that may establish leaching 
from chemical fertilisers.90, 92, 134 
 
Phosphorus species play a decisive role in the majority of metabolic steps of all 
organisms from the simplest to the most complex.  Phosphorus is an important 
constituent of tissues, bones and teeth and cells.135  Phosphorus forms the basis of the 
linking groups between units of the sugar esters of DNA and RNA, it is also present 
in the energy storing nucleotide triphosphates such as ATP and in coenzymes such as 
NADH and NADPH.135-137 
 
Sulphur plays an enormous role in the biochemistry of cells, particularly in oxidation 
and reduction processes.137  Occurring in the amino acids cysteine and methionine, 
sulphur is therefore present in any peptide containing more than twenty five amino 
acids, i.e. it is approximately 4 % abundant in peptides.136, 137 
 
The determination of phosphorus and sulphur isotopes is, therefore, important in the 
understanding of many biological processes.  During the analysis of clinical samples 
the measurement of these two elements in relation to other elements of the periodic 
table can allow biochemical processes such as phosphorylation and metal based drug 
binding to be followed.136  As mentioned in Chapter 1 ICP-MS exhibits very desirable 
characteristics in elemental analysis, these have been invaluable with regard to 
speciation work.  Although ICP-MS has previously been applied to the analysis of 
complex biological and clinical samples it remains, somewhat, an untapped resource 
compared to techniques such as liquid chromatography mass spectrometry (LC-MS).  
It is hoped that in the coming years the potential of this technique will be fully 
realised. 
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2.1.1.  The Limitations of 31P and 32S Determination by ICP-QMS 
 
Although ICP-MS exhibits low limits of detection for many elements, the 
determination of the isotopes of phosphorus and sulphur (31P, 32S, 33S, 34S and 36S) by 
Ar, quadrupole based, ICP-MS is relatively troublesome for three main reasons.  
Firstly, in relative terms, the ionisation potential of both elements is very high, 10.5 
eV for phosphorus and 10.4 eV for sulphur.6  This means that on, entrance to the ICP, 
only approximately 33 % of phosphorus and sulphur atoms introduced will be 
ionised.138  So, on comparison to other elements, for the same quantity of P or S 
introduced a lower number of ions are generated which restricts the LOD capability of 
the ICP-MS technique from the outset.  Secondly both P and S are subject to two 
types of non-spectroscopic interference.  The high ionisation potential of these 
elements means that they could be subject to ionisation suppression within the plasma 
when in the presence of elements of a lower IP (easily ionisable elements, EIE’s) 
assuming that the species involved are present in high concentrations, see section 
1.2.2.139  Phosphorus and Sulphur are also described as “light elements” with regard 
to their atomic mass; this makes them more prone to matrix induced space charge 
effects, see section 1.2.2.72, 92, 101, 139  Thirdly the phosphorus and sulphur isotopes are 
typically subject to spectroscopic interference from polyatomic ions based on carbon, 
nitrogen, oxygen and hydrogen (elements common to all sample matrices and 
entrained atmospheric gases), see section 1.2.1.6, 7, 38, 73, 74, 79, 100, 139  Examples of these 
polyatomic ions can be seen in Table 4.6, 7, 38, 73, 74, 79, 100, 139 
 
 
Table 4.  A Table of P and S Isotopes, their Abundances, IP and Polyatomic Ion Interferences. 
Analyte 
Isotope 
Abundance 
(%) 
Ionisation 
Potential (eV) 
Polyatomic Ion Interference 
31P 100 10.5 14N16O1H+, 15N15N1H+, 15N16O+, 14N17O+, 13C18O+, 12C18O1H+ 
32S 95 10.4 16O2+, 14N18O+, 15N17O+, 14N17O1H+, 15N16O1H+ 
33S 0.75 10.4 15N18O+, 14N18O1H+, 15N17O1H+, 16O17O+, 16O21H+, 32S1H+ 
34S 4.21 10.4 15N18O1H+, 16O18O+, 17O2+, 16O17O1H+, 33S1H+ 
36S 0.02 10.4 18O2+, 17O18O1H+ 
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Another problem with regard to the determination of P and S is that both elements are 
ubiquitous and are generally difficult to eliminate from blank sample solutions.  This 
is another factor that contributes to the poorer LOD’s observed in the ICP-MS 
technique.  Successful elimination of P and S from blank solutions would require the 
use of ultra-pure reagents prepared in a “clean-room”, such an approach to analysis 
introduces an escalation in cost. 
 
The combination of each of these problems results in the LOD of phosphorus and 
sulphur being two to four orders of magnitude poorer than that of the majority of 
elements in the periodic table that can be analysed by ICP-MS.  There are three main 
options for the reduction of interferences and the improvement of LOD for 
phosphorus and sulphur isotopes, these being: 
 
 
1. The coupling of a high resolution mass spectrometer to an ICP source.  The 
resolution capability of such a mass analyser can allow the analyte and 
interfering polyatomic ion peaks to be resolved.4, 7, 38, 69, 70, 100 
2. The use of collision or dynamic reaction cells to move the analyte m/z to an 
alternate part of the mass spectrum or to move the interfering species m/z to a 
different value.4, 33, 59, 79, 90-96 
3. Alternative sample introduction techniques can be employed to transport the 
sample into the plasma whilst minimising, or eliminating, the presence of 
elements originating from a sample matrix, for example electrothermal 
vaporisation.2, 4, 7, 40, 41, 47, 49, 50 
 
 
The limits of detection capable by the various commercial ICP-MS instruments are 
not widely advertised.  However, Perkin Elmer have published that the LOD 
capability of their ELAN DRC II instrument is 0.01 to 0.1 μg l-1 and 0.1 to 1 μg l-1 for 
31P and 32S isotopes, respectively.140  Bandura et al have also published a DRC 
method for the measurement of 31P and 32S isotopes, employing an O2 reaction gas, 
whereby LOD’s of < 0.1 μg l-1 and < 0.2 μg l-1 were obtained.90 
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2.1.2.  Alternative Techniques for the Determination of 31P and 32S 
 
31P and 32S isotopes may be determined by other elemental analysis techniques, these 
include the following. 
 
 
Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES) 
 
Inductively coupled plasma optical emission spectroscopy (ICP-OES) is in many 
ways a very similar technique to ICP-MS.  Both techniques are almost identical 
between the sample introduction and ICP sections of the instrument but differ on the 
detection of elements present within a sample.  Whereas ICP-MS counts the number 
of ions produced following transport through the plasma via a mass analyser, ICP-
OES quantifies the presence of elements by measurement of the emission of radiation 
released from excited atoms and ions within the ICP ion source.  Elements of the 
periodic table mostly exhibit unique wavelengths of emission; it is these wavelengths 
that are measured.1, 3, 5, 42  The main difference between these two ICP techniques is 
that ICP-OES measures the presence of elements only whilst ICP-MS determines 
isotopes. 
 
Although both ICP-MS and ICP-OES techniques display similarities with regard to 
non-spectroscopic interferences they also exhibit their own benefits.  An ICP-OES 
instrument can be described as a “flow-by” technique compared to the “flow-into” 
description of ICP-MS.  As an ion flow into a detector is not required in ICP-OES this 
technique is well suited to the analysis of highly concentrated samples that contain a 
significant degree of dissolved solids.  Such solutions are problematic for ICP-MS 
with regard to non-spectroscopic interferences.  For this reason, ICP-OES is 
commonly employed in the analysis of environmental samples (such as soil, rock and 
vegetation digests) and biological samples (such as blood, serum and bone). 
 
With regard to the determination of the 31P and 32S isotopes by ICP-OES the main 
limitations of analysis lie in spectroscopic interference from the overlap of emission 
wavelengths.  With regard to the determination of 31P emission can be measured at 
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178.29 nm, 213.62 nm and 214.91 nm.5  However, interfering emission originating 
from Mn, S, Cr and Mo isotopes can be problematic.5  In the case of 32S emission can 
be measured at 180.73 nm and 182.04 nm.5  The average 31P and 32S LOD’s exhibited 
by the ICP-OES technique can be seen in Table 5. 
 
 
Flame Atomic Absorption Spectroscopy (FAAS) 
 
Up to the late 1970’s and early 1980’s flame atomic absorption spectroscopy (FAAS) 
was the most widely used method for the trace analysis of metals.42  A radiation 
source, typically a hollow cathode lamp, is used to emit radiation of a wavelength 
unique to an analyte of interest.  This radiation is directed through a flame atomiser, 
of variable gaseous composition, into which the sample is introduced.  The quantity of 
radiation transmitted through the flame is measured and absorption by analyte atoms 
is calculated.  This takes place when the radiation passes through a monochromator 
and hits a photomultiplier.1, 3, 42 
 
Although elemental analysis is now dominated by ICP based techniques, FAAS is still 
popular for the measurement of metals at the μg l-1 level and above.  FAAS is also 
attractive to the analyst as it is a far less expensive technique than ICP-OES or ICP-
MS.  As with ICP-OES, FAAS measures the presence of metal elements and cannot 
provide information on isotopic content of a sample.  FAAS has difficulties with the 
measurement of phosphorus and cannot be employed for sulphur.  The reason for this 
is that the emission wavelength of each element is below 200 nm which is outside the 
main emission region of standard hollow cathode lamps.1  Under standard FAAS 
analysis the LOD of phosphorus is therefore very poor although its limit can be 
improved by employing a graphite furnace.  Typical 31P and 32S LOD’s exhibited by 
FAAS are given in Table 5. 
 
 
A Comparison of Techniques for the Determination of 31P and 32S 
 
Although there are a number of elemental analytical techniques available, with regard 
to many elements of the periodic table such techniques are complementary rather than 
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competitive as they exhibit similar LOD’s (see Table 5) and dynamic ranges.3  For the 
measurement of 31P and 32S, however, performance varies quite widely.  Average 
LOD’s for these elements, compared between the techniques, can be seen in Table 5.1, 
3, 4, 42, 100, 141 
 
 
Table 5.  A Comparison of 31P and 32S Limit of Detection Data for Elemental Analysis 
Techniques. 
Analytical Technique 31P LOD (µg l-1) 32S LOD (µg l-1) 
ICP-QMS (Perkin Elmer)90 0.01 – 0.1 0.1 – 1 
ICP-QMS (P.D. Winship Data, Four Separate 
Methods - See Sections 2.4.1 to 2.4.7 and 2.5) 
0.69 - 14 1.23 – 80 
ICP-MS (High Resolution)1 0.05 0.01 
ICP-OES1 4 – 50 10 
FAAS42 50 000 – 75 000 - 
GF-AAS4 30 – 130 - 
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2.2.  Aims of Research 
 
It was the aim of the research in this chapter to develop methods to tackle 
instrumental interferences and hence improve the LOD’s of the 31P and 32S isotopes 
by quadrupole based ICP-MS.  LOD’s of these two isotopes are, comparatively, poor 
considering the capabilities of this instrument for many elements.  The most obvious 
means of overcoming polyatomic ion interference in the mass spectrum would be the 
employment of a high resolution ICP-MS instrument; however, as previously 
discussed this is an expensive approach to elemental analysis.  Six methods, via three 
different approaches, were studied in order to overcome some of the instrumental 
interferences described in sections 1.2.1 and 2.1.  These six methods are described as 
follows: 
 
 
Collision Cell Methods 
 
• The determination of 31P16O+ (m/z = 47) and 32S16O+ (m/z = 48) ions formed in 
a hexapole collision cell incorporating He and O2 as a buffer gas and reaction 
gas, respectively, under IKEE conditions.4, 33, 59, 79, 83, 90-96 
• The determination of 31P16O+ (m/z = 47) and 32S16O+ (m/z = 48) ions formed in 
a hexapole collision cell incorporating an O2 only reaction gas under IKEE 
conditions.4, 33, 59, 79, 83, 90-96 
• The selective removal of polyatomic ions at m/z = 31 allowing the 
measurement of 31P+ ions at their native m/z in a hexapole collision cell 
incorporating a He buffer gas under KED conditions.104 
 
 
Cold Plasma Methods 
 
• The determination of 31P16O+ (m/z = 47) and 32S16O+ (m/z = 48) ions formed 
within the ICP under “cold/cool plasma” conditions.4 
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• The determination of 31P16O+ (m/z = 47) and 32S16O+ (m/z = 48) ions formed 
within the ICP under “cold/cool plasma” conditions incorporating an 
additional O2 flow through the nebuliser.4 
 
 
Torch Bonnet Method 
 
• The limitation of atmospheric gas entrainment into the ICP ion source and the 
reduction of polyatomic ion formation at m/z = 31 and 32 employing an 
enclosed ICP source.134 
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2.3.  Experimental Details 
 
The typical PQ ExCell ICP-MS instrumental conditions for the work carried out in 
this and other chapters are described in Table 6.  The magnitude of each of the 
parameters are documented for each individual experiment both within the text 
section in which it is discussed and Appendix 2 (Tables 54, 56, 59, 64, 69, 72 and 74), 
Appendix 3 (Tables 76 to 79, 81, 82, 84 and 85), Appendix 4 (Tables 88, 94, 115, 
121, 122, 131 and 137) and Appendix 5 (Table 141). 
 
 
Table 6.  A Table of Typical PQ ExCell ICP-MS Instrument Parameters. 
Instrument Parameter Parameter Value 
Analyser Pressure ≈ 10-7 mBar 
Expansion Pressure 1.0 to 3.0 mBar 
Nebuliser Pressure 2.6 to 2.8 Bar 
Plasma Forward Power Variable According to the Method Employed 
Plasma Reflected Power < 2 W 
  
Plasma Gas: Cool Flow 12.5 to 13.0 l min-1 
Plasma Gas: Auxilliary Flow 0.80 to 0.90 l min-1 
Plasma Gas: Nebuliser Flow 0.90 to 1.20 l min-1 
  
Torch Position: Sampling Depth 
Torch Position: Vertical 
Torch Position: Horizontal 
 
Variable to Establish Optimum Signal 
  
Extraction Lens Voltage -300 V to -900 V 
D1 Lens Voltage -24 to -30 V 
L1 Lens Voltage -10.0 to +5.0 V 
L2 Lens Voltage -130 to -190 V 
L3 Lens Voltage -110 to -200 V 
Focus Lens Voltage +18 to +27 V 
  
Applied Quadrupole Voltage +1 V 
Applied Hexapole Voltage: Standard Mode -1.97 V 
Applied Hexapole Voltage: Collision Cell Mode +1 V to + 10 V 
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Any specific instrumental parameters that have been varied as part of these studies are 
described within the text associated with the work.  Any other instrumentation that is 
employed during the work discussed in this thesis is described in its relevant section 
as well as associated parameters and their magnitude.  Throughout this chapter the 
various voltage characteristics of the ICP ion source, the hexapole collision cell and 
the quadrupole mass analyser are stated. 
 
Unless otherwise stated, for each experiment carried out three replicate readings were 
taken in order to allow the calculation of mean, standard deviation (SD) and relative 
standard deviation (RSD) data. 
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2.4.  The Development of Methods to Overcome 31P and 32S 
Isotope Interferences 
 
Six separate approaches to the measurement of 31P and 32S were studied, with the aim 
of overcoming the spectroscopic interferences previously described, and subsequent 
quantification experiments were performed, see sections 2.4.1 to 2.4.7.  The hexapole 
collision cell of the PQ ExCell ICP-MS instrument was employed to produce alternate 
analyte oxide species, 31P16O+ and 32S16O+, for measurement at non-interfered m/z’s 
(as described in sections 2.4.1 and 2.4.2) and to remove interfering ions, 14N16O1H+ 
and 16O2+ etc…, at the native m/z (as described in section 2.4.3).  Similar to 
approaches using the collision cell, “cold/cool plasma” conditions were employed in 
order to produce the 31P16O+ and 32S16O+ ions in the ICP for measurement at m/z = 47 
and 48.  The introduction of additional oxygen to the ICP during analysis with 
“cold/cool plasma” conditions was also studied with the aim of maximising analyte 
oxide ion formation.  Additionally, the use of an ICP torch bonnet was studied with 
the aim of reducing the entrainment of the gaseous atmosphere of the torch box into 
the plasma.  By limiting the quantity of entrained gas it may be possible to reduce the 
formation of polyatomic ions based on nitrogen and oxygen. 
 
 
2.4.1.  Method 1: The Determination of 31P16O+ and 32S16O+ Ions in a 
Collision Cell Incorporating He and O2 Under IKEE Conditions 
 
Initial work was carried out into the determination of 31P and 32S isotopes by the 
formation and measurement of 31P16O+ (m/z = 47) and 32S16O+ (m/z = 48) ions in the 
hexapole collision cell incorporating He and O2 collision/reaction gases.  Previous 
research into collision and dynamic reaction cells has highlighted the formation of P 
and S oxide ions for isotope measurement.  The formation of these oxide ion species 
can be appreciated by study of the 31P+, 32S+, 47,48Ti+ and polyatomic ion reaction data, 
see Table 7.90 
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Table 7.  Reaction Data for Oxidation of 31P+, 32S+, 47Ti+ and Associated Polyatomic Ions. 
Reaction Reaction Enthalpy 
Change, ∆Hr (kcal mol-1) 
Reaction Rate Constant, 
kr (molecule-1 cm3 s-1) 
P+ + O2 → PO+ + O -71.4 5.3 x 10-10 
S+ + O2 → SO+ + O -6.2 1.8 x 10-11 
NO+ + O2 → NO2+ + O 57.4 < 1.0 x 10-11 (No Reaction) 
NOH+ + O2 → NO2H+ + O 19.3 No Data 
Ti+ + O2 → TiO+ + O -46.1 5.0 x 10-10 
 
 
According to the reaction data of Table 7 the formation of 31P16O+ readily takes place 
in the presence of 31P+ and O2 as it is strongly exothermic (ΔHr = -71.4 kcal mol-1) 
and proceeds fairly quickly (kr = 5.3 x 10-10 molecule-1 cm3 s-1).  In the case of 
32S16O+, formation does not take place as readily or at as fast a rate (ΔHr = -6.2 kcal 
mol-1 and kr = 1.8 x 10-11 molecule-1 cm3 s-1).90  Oxidation reactions for the 
polyatomic ions present at m/z = 31 and 32 with O2 are endothermic and do not take 
place under thermal conditions.  On the formation of P and S oxide species with 
measurement at m/z = 47 and 48 an issue that would normally have to be considered is 
interference from the presence of contaminating 47,48Ti+ ions.  However, Ti also 
readily reacts with O2 to form the oxide species at m/z = 63 and 64 (ΔHr = -46.1 kcal 
mol-1 and kr = 5.0 x 10-10 molecule-1cm3 s-1) so Ti contamination is not a significant 
problem. 
 
On the introduction of O2 gas into the collision cell two effects of interaction on the 
ion beam passing through the hexapole are recognised.  The result of collision of O2 
molecules with the 31P+ and 32S+ ions can either be the successful formation of analyte 
oxide species or no reaction leaving the interacting species in their original state.  If 
there is no reaction between the species then the collision will lead to a degree of 
scattering of the ionic species.  For use of the collision cell, the hexapole must be 
pressurised.  Due to the size of the O2 molecule and the limitation of control of gases 
entering the cell to 0.1 ml min-1 then at this stage of research it was believed that a 
buffer gas, in this case He, would be required in order to maintain pressurisation 
whilst not relying on the O2 reaction gas that may lead to a detrimental degree of 
analyte ion scattering. 
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The variation of the collision/reaction gas flows in the cell revealed optimum flows of 
0.2 ml min-1 and 0.3 ml min-1 for He and O2, respectively.  Whilst employing these 
optimum gas flows, IKEE was studied to determine whether or not the formation of 
the desired ionic oxide species could be maximised for the improvement of 31P and 
32S LOD.  Normally the applied hexapole (collision cell) voltage is negative compared 
to the quadrupole voltage; this allows a maximum transmission of ions.  Under IKEE 
conditions an opposite polarity is in place (hexapole voltage positive compared to 
quadrupole voltage), here analyte ions are slowed on entrance to the hexapole 
allowing an increased residence time in the cell.  As residence time increases more 
collisions take place between these ions and the He and O2 present in the cell. 
 
 
Experimental Details 
 
Whilst incorporating the He and O2 gas flows into the hexapole, described in this 
section, the m/z = 31, 32, 47 and 48 signals (corresponding to the 31P+, 32S+, 31P16O+ 
and 32S16O+ ions) were studied during the analysis of the following samples: 
 
• 2 % HNO3 (as a blank solution). 
• 1000 µg l-1 P in a 2 % HNO3 matrix. 
• 1000 µg l-1 S in a 2 % HNO3 matrix. 
 
During this study the applied hexapole voltage (Vh) was varied with respect to the 
plasma potential (Vp), which is assumed to be constant at approximately +9 V, in 
order to determine whether an IKEE would be beneficial to the formation of ionic P 
and S oxide species.  The voltage applied to the mass analyser quadrupole (Vq) was 
set at a constant value of +1 V (previous experimentation has shown that the variation 
of Vq contributes little to IKEE).  An unshielded ICP torch was employed during this 
analysis and it should be noted that if a shielded plasma was used the data obtained 
would be associated with different Vh’s.  The general instrumental conditions under 
which this work was carried out can be seen in Table 54 (Appendix 2). 
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Results and Discussion 
 
The data for this study are given in Table 55 (Appendix 2).  Plots for 31P analysis are 
given in Figures 5 and 6 whilst plots for 32S can be seen in Figures 7 and 8. 
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Figure 5.  A Graph Comparing m/z = 31 Signal with Vh for the Analysis of 2% HNO3 Blank and 
1000 µg l-1 P Solutions (Reaction Gases: He = 0.2 ml min-1 and O2 = 0.3 ml min-1) (Vq = +1 V). 
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Figure 6.  A Graph Comparing m/z = 47 Signal with Vh for the Analysis of 2% HNO3 Blank and 
1000 µg l-1 P Solutions (Reaction Gases: He = 0.2 ml min-1 and O2 = 0.3 ml min-1) (Vq = +1 V). 
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Figure 7.  A Graph Comparing m/z = 32 Signal with Vh for the Analysis of 2% HNO3 Blank and 
1000 µg l-1 S Solutions (Reaction Gases: He = 0.2 ml min-1 and O2 = 0.3 ml min-1) (Vq = +1). 
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Figure 8.  A Graph Comparing m/z = 48 Signal with Vh for the Analysis of 2% HNO3 Blank and 
1000 µg l-1 S Solutions (Reaction Gases: He = 0.2 ml min-1 and O2 = 0.3 ml min-1) (Vq = +1 V). 
 
 
Figure 5 shows the variation of m/z = 31 signal with Vh during the analysis of 2 % 
HNO3 blank and 1000 µg l-1 P solutions.  For both solutions analysed the m/z = 31 
signal decreased as Vh tended towards a potential similar to that of the plasma 
potential (≈ +9 V).  The intensity decrease of the m/z = 31 signal observed could be 
best described in the two following sections. 
 
• The m/z = 31 decrease between Vh = -4 V and +8 V. 
• The m/z = 31 decrease between Vh = +8 V and +10 V. 
 
The signal decrease between Vh = -4 V and +8 V can be attributed to the loss of 31P+ 
ions to the formation of 31P16O+, collisional scattering and the elimination of ions 
from the hexapole, via the vacuum pump, following sufficient collisions with the He 
and O2 collision/reaction gases to reduce momentum.  Beyond Vh = +8 V the signal 
plummeted, the reason for this was that the IKEE conditions were such that the 
majority of ions entering the hexapole were slowed sufficiently to result in full 
thermalisation and removal via the vacuum pump. 
 
 84
It should be noted here that there was a significant difference in signal intensity 
between the two samples, i.e. the presence of 1000 µg l-1 P produced a signal that was 
highly elevated above the m/z = 31 signal background.  However, the mean 
background signal (arising from the 2 % HNO3 blank solution) between Vh = -4 V 
and +8 V was approximately 15 000 ion counts per second (cps) which is very high 
compared to that observed at many other m/z’s. 
 
 
Figure 6 shows the variation in m/z = 47 signal with Vh during the analysis of 2 % 
HNO3 blank and 1000 µg l-1 P solutions.  For both of these solutions analysed the m/z 
= 47 signal increased to an optimum value as Vh approached a potential similar to the 
plasma potential (≈ +9 V).  Beyond this optimum value the m/z = 47 signal 
plummeted to approximately one tenth of the signal intensity.  Similar to the m/z = 31 
data in Figure 5, the m/z = 47 signal for the 1000 µg l-1 P solution was highly elevated 
above the m/z = 47 signal background (that is a more reasonable mean signal in the 
order of hundreds of ion counts per second).  This experiment showed that IKEE can 
vary the degree of 31P16O+ ion formation enormously on the introduction of He and O2 
collision/reaction gases to the collision cell. 
 
To describe the data in Figure 6 the graph can be divided into the following two 
sections. 
 
• The m/z = 47 signal increase between Vh = -2 V and +8 V. 
• The m/z = 47 signal decrease between Vh = +8 V and +10 V. 
 
For both 2 % HNO3 blank and 1000 µg l-1 P solutions, the signal increase between Vh 
= -2 V and +8 V was attributed to the formation of 31P16O+ ions.  An increasing Vh 
resulted in the slowing of ions entering the cell leading to a greater number of 
collisions with the collision/reaction gases and therefore an increase in the formation 
of the 31P16O+ ion.83  Similar to the graph in Figure 5, beyond Vh = +8 V there was a 
severe drop in m/z = 47 signal.  Such a drop was attributed to the ions entering the 
hexapole becoming fully thermalised so they do not have the momentum to proceed 
and are removed via the vacuum pump. 
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Figures 5 and 6 show that with regard to IKEE the formation of 31P16O+ (m/z = 47) 
ions from 31P+ and O2 within a collision cell proceeded at an optimum Vh of +8 V 
with respect to Vp for an unshielded ICP torch.  What should also be noted through 
the comparison of ion counts between Figures 5 and 6 is that comparatively little 
31P16O+ was formed considering the concentration of 31P+ ions available.  It can be 
concluded from this data that the oxide ion formation resulting from collision cell ion-
molecule reaction was particularly inefficient. 
 
 
Figure 7 shows the variation in m/z = 32 signal with Vh during the analysis of 2 % 
HNO3 and 1000 µg l-1 S solutions.  Three factors required consideration with regard 
to a description of this graph.  The first factor was the intensity of signals generated 
during this analysis, being in the order of 108 cps.  Secondly there was little difference 
in signal intensity over the Vh range studied between both sample solutions.  Finally 
the shape of both plots in this graph required consideration. 
 
The exceptionally high m/z = 32 signal for both solutions studied, well into the 
analogue range of the detector, implies that a very high number of ions were being 
transmitted through the hexapole and quadrupole.  This suggests a very high level of 
spectroscopic interference, i.e. a large presence of the 16O2+ ion.90, 92, 100  The fact that 
the signal accrued from both sample solutions was very similar means that the 
presence of 1000µg l-1 S did not elevate the signal above the background.  Therefore 
the 32S+ ion did not dominate m/z = 32 at any point during the analysis. 
 
For both solutions analysed the m/z = 32 signal data was best described by separating 
it into the following two sections. 
 
• The m/z = 32 signal increase between Vh = -4 V and +6 V. 
• The m/z = 32 signal decrease between Vh = +6 V and +10 V. 
 
The m/z = 32 signal behaviour between Vh = -4 V and +10 V requires a more in depth 
discussion than previously in this section as there are two potential explanations that 
could lead to the optimum signal observed at Vh = +6 V.  As the m/z = 32 signal over 
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the range of Vh = -4 V to +6 V is in the order of 100 million to 700 million cps, i.e. 
detected well into the analogue region of the detector, then it can be safely said that 
the dominant ion giving rise to these signals is 16O2+.  With regard to this plot the 
question, therefore, is not what the ion species is but why it’s intensity increased and 
then decreased over the range. 
 
One explanation for the signal enhancement in the first section of this graph is that the 
increase in Vh slowed certain ionic species, transmitted through the hexapole, 
resulting in charge transfer reactions with the O2 reaction gas molecules that lead to 
their ionisation.  However, this theory relies on a significant presence of an ionic 
charge donating species.  To eliminate a charge transfer process with O2 as an 
explanation for the enhancement in signal with Vh the mass spectrum survey data, 
taken at the time of the analysis, was studied (see Figure 9).  As can be seen in Figure 
9 there were no peaks in the background mass spectrum that indicate the presence of 
any species that are not typically observed (it should be recognised that the absence of 
peaks at m/z = 40 and 80, i.e. 40Ar+ and 40Ar2+ ion signals, is due to the restriction of 
measurement by the instrument software to prolong the detector lifetime).  This can 
rule out a contamination issue so the only alternative, along this line of thinking, 
could be an interaction with a native polyatomic ion though this seems unlikely. 
 
A more realistic explanation for the enhanced m/z = 32 signal with Vh is an 
optimisation of IKEE conditions with regard to transmission of the ICP formed 16O2+ 
ion.  Slowing the 16O2+ ions entering the hexapole, by increasing Vh with respect to 
Vp, would lead to collisions with the collision cell species that are less energetic in 
nature.  Such collisions would result in a lower degree of ion scattering than when 
ICP formed ions are introduced with a greater momentum. 
 
As described previously, beyond Vh = +6 V the IKEE conditions are such that the ions 
entering the hexapole were fully thermalised and removed via the vacuum pump. 
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Figure 9.  A Survey Data Mass Spectrum Generated During the Method 1 IKEE Experimental Work. 
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Figure 8 shows the variation in m/z = 48 signal with Vh during the analysis of 2 % 
HNO3 blank and 1000 µg l-1 S solutions.  For both solutions analysed the m/z = 48 
signal increased to an optimum intensity, at Vh = +4 V, and then decreased as Vh 
increased further.  Here there was good separation between the signals of the two 
sample solutions allowing differentiation between background and 1000 µg l-1 S. 
 
Similar to the graph concerning 31P16O+ ion formation the plots in Figure 8 can be 
split into the following two sections. 
 
• The m/z = 48 signal increase between Vh = -4 V and +4 V. 
• The m/z = 48 signal decrease between Vh = +4 V and +10 V. 
 
In the case of the 2 % HNO3 solution plot these sections can be described by the 
IKEE process, a positive slowing of the ions passing through the cell up to the point 
where they are slowed too much and then eliminated.  However, there may be a 
complication in terms of the species that result in the enhanced m/z = 48 signal 
between Vh = +2 V and +8 V.  It is possible that the increase in signal in this Vh range 
is due to the oxidation of sulphur that was present in contaminated HNO3.  What is 
more likely, however, is that the conditions in the hexapole are right for the formation 
of ozone ions (16O3+, m/z = 48), this is an additional spectroscopic interference. 
 
In the case of the 1000 µg l-1 S solution plot, again, the two sections can be described 
by IKEE in terms of the relative increase and decrease in signal.  Here the optimum 
Vh range (+4 V to +6 V) is the point at which the formation of 32S16O+ is enhanced.  
However, considering the trends recognised in the 2 % HNO3 plot, there may be a 
contribution to the m/z = 48 signal in the form of interfering 16O3+. 
 
It should be noted here that unlike the graphs for the 1000 µg l-1 P solution (Figures 5 
and 6) a comparison of ion counts between Figures 7 and 8 cannot be commented on 
fairly, for the purpose of assessing reaction efficiency, as data for the determination of 
32S+ cannot be separated from that of 16O2+.  Assuming that there is some similarity 
between the behaviour of 31P and 32S chemistries then it could be postulated that 
32S16O+ ion formation by this method is also inefficient. 
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2.4.2.  Method 2: The Determination of 31P16O+ and 32S16O+ Ions in a 
Collision Cell Incorporating O2 Only Under IKEE Conditions 
 
The work of section 2.4.1 was furthered through the study of the same samples under 
IKEE conditions but only incorporating an O2 reaction gas.  Such work would 
determine the necessity of an additional He collision gas flow to promote the 
thermalisation of ions and ion-molecule reaction.  Again, the formation of the 31P16O+ 
and 32S16O+ ions was measured for the quantification of the 31P and 32S isotopes. 
 
 
Experimental Details 
 
An optimum O2 reaction gas flow was determined at 0.3 ml min-1 for the formation of 
the ionic P and S oxide species.  Mass spectrum signals at m/z = 31, 32, 47 and 48 
were studied when varying Vh with respect to Vp whilst maintaining a constant Vq of 
+1 V.  General experimental conditions can be seen in Table 56 (Appendix 2). 
 
 
Results and Discussion 
 
The data generated are given in Table 57 (Appendix 2).  This data was evaluated via a 
series of graphs constructed to establish the presence of trends.  Plots for 31P analysis 
are given in Figures 10 and 11 whilst plots for 32S analysis can be seen in Figures 12 
and 13. 
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Figure 10.  A Graph Comparing m/z = 31 Signal with Vh for the Analysis of 2% HNO3 Blank and 
1000 µg l-1 P Solutions (Reaction Gas: O2 = 0.3 ml min-1) (Vq = +1 V). 
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Figure 11.  A Graph Comparing m/z = 47 Signal with Vh for the Analysis of 2% HNO3 Blank and 
1000 µg l-1 P Solutions (Reaction Gas: O2 = 0.3 ml min-1) (Vq = +1 V). 
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Figure 12.  A Graph Comparing m/z = 32 Signal with Vh for the Analysis of 2% HNO3 Blank and 
1000 µg l-1 S Solutions (Reaction Gas: O2 = 0.3 ml min-1) (Vq = +1 V). 
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Figure 13.  A Graph Comparing m/z = 48 Signal with Vh for the Analysis of 2% HNO3 Blank and 
1000 µg l-1 S Solutions (Reaction Gas: O2 = 0.3 ml min-1) (Vq = +1 V). 
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Figure 10 shows the variation in m/z = 31 signal with Vh for the analysis of 2 % HNO3 
blank and 1000 µg l-1 P solutions.  For both solutions analysed the m/z = 31 signal 
decreased as Vh increased.  Similar to Figure 5 (section 2.4.1) the m/z = 31 signal 
variation is best explained by reference to the following two sections: 
 
• The m/z = 31 signal decrease between Vh = -2 V and +7 V. 
• The m/z = 31 signal decrease between Vh = +7 V and +10 V. 
 
The signal decrease between Vh = -2 V and +7 V was attributed to both the loss of 
31P+ to the formation of 31P16O+ ions and through collisional scattering as a result of 
collision with O2 molecules within the hexapole and elimination following the 
reduction of momentum with thermalisation.  After Vh = +7 V the signal dropped in 
two sections.  Between Vh = +7 V and +9 V the signal was reduced to approximately 
half of its intensity at Vh = +7 V.  Beyond Vh = +9 V the signal plummeted.  The 
reason for this reduction beyond Vh = +7 V was that the vacuum pump elimination 
following full thermalisation of ions had become the dominant effect within the 
collision cell. 
 
A significant difference existed between signals of the sample solutions, i.e. the 
presence of 1000 µg l-1 P provided a signal significantly elevated above the 
background.  Again, the background signal arising from analysis of the 2 % HNO3 
solution was approximately 35 000 cps which highlights the inability to measure 31P 
at trace levels due to the presence of nitrogen, oxygen and hydrogen based polyatomic 
ions. 
 
 
Figure 11 shows the variation in m/z = 47 signal with Vh for the analysis of the blank 
and P solutions.  Showing an almost identical trend to that in Figure 6, both plots can 
be discussed in terms of two regions with the optimum 31P16O+ formation at Vh = +8 
V, i.e: 
 
• The m/z = 47 signal increase between Vh = -2 V and +8 V. 
• The m/z = 47 signal decrease between Vh = +8 V and +10 V. 
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For both solutions, the signal increase between Vh = -2 V and +8 V was attributed to 
the formation of 31P16O+ ions.  An increasing Vh was responsible for the slowing of 
ions entering the hexapole.  This reduced ion momentum led to a greater number of 
collisions with the O2 reaction gas molecules and therefore an increase in the 
formation of the 31P16O+ ion.83  As described previously the severe signal reduction, 
beyond Vh = +8 V, was attributed to the thermalisation of ions within the hexapole.  
Again the signals generated from both samples are substantially different due to the 
vast difference in P concentration between sample solutions. 
 
 
The data generated with the O2 reaction gas alone is almost identical to the same 
analysis incorporating a combination of He and O2 collision/reaction gases (see 
section 2.4.1).  After studying the data associated with Figures 6 and 11 the necessity 
for He collision gas in the cell, in this case, could be questioned. 
 
 
Figure 12 shows the variation of m/z = 32 signal with Vh for the study of 2 % HNO3 
and 1000 µg l-1 S solutions.  Similar to the plot in Figure 7 (see section 2.4.1) the m/z 
= 32 signals for both solutions were abnormally high, increasing to an optimum, and 
then decreasing over the range of voltages applied to the hexapole collision cell. 
 
Again, the signal intensity at each Vh value suggests a high degree of spectroscopic 
interference from the 16O2+ ion that dominates m/z = 32.  In this case the optimum Vh 
value for both samples was +7 V, higher than for the same analysis incorporating He 
as well where the optimum was +6 V.  As described in section 2.4.1, the most likely 
cause of the increase in signal up to Vh = +7 V was differing IKEE conditions that 
resulted in variations in the degree of ion scattering between species within the 
hexapole.  Beyond Vh = +7 V the loss of signal was the result of vacuum pump 
elimination following ion thermalisation and reduction in momentum. 
 
 
Figure 13 shows the variation of m/z = 48 signal with Vh for the analysis of 2 % 
HNO3 blank and 1000 µg l-1 S solutions.  This graph has almost identical features to 
that seen in Figure 8 where m/z = 48 signal increases with Vh to an optimum value 
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before decreasing.  For the sake of this discussion the two plots were, again, 
considered as two regions, these being: 
 
• The m/z = 48 signal increase between Vh = -2 V and +6 V. 
• The m/z = 48 signal decrease between Vh = +6 V and +10 V. 
 
Between Vh = -2 V and +6 V the signal increase arose due to the IKEE enhanced 
formation of the 32S16O+ ion.  A slight signal reduction was observed between Vh = +6 
V and +7 V, this was similar to that in Figure 8 where there was a short spread of 
optimum Vh values.  As described previously, beyond Vh = +7 V the signal for both 
samples plummeted due to the reduced momentum of ions within the hexapole and 
their inability to exit. 
 
 
From the data accrued during the work for this method, the maximised formation of 
analyte oxide ions by hexapole collision cell ICP-MS incorporating IKEE and O2 
alone as a reaction gas appeared to be a promising approach to the quantitative 
determination of 31P and 32S.  At this point in the study the question of whether the 
presence of a He collision gas in the cell is beneficial to the analysis required an 
answer.  It could be said that He is not required as the formation of analyte oxide ions 
is successful in its absence.  However, close examination of the data revealed that a 
greater oxide ion signal, for both elements of interest, was being generated when He 
was present.  In order to answer this question, and determine whether the difference in 
signal could be explained by day-to-day instrumental drift, ratios of analyte oxide ion 
signal to analyte ion signal were calculated for both 31P and 32S.  These ratios are 
compared in Table 8. 
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Table 8.  Analyte Oxide Ion Signal to Analyte Ion Signal Ratio for Data Generated During IKEE 
He/O2 and O2 Only 31P16O+ and 32S16O+ Formation Maximisation Experiments. 
Sample Vh (V) 31P16O+/31P+ 
Ratio 
(He/O2) 
32S16O+/32S+ 
Ratio 
(He/O2) 
31P16O+/31P+ 
Ratio (O2) 
32S16O+/32S+ 
Ratio (O2) 
1000 µg l-1 P 8 0.098 - 0.074 - 
4 - 3.46 x 10-4 - - 1000 µg l-1 S 
6 - - - 3.86 x 10-4 
 
 
From the data in Table 8 there seems to be very little difference in analyte oxide ion 
signal to analyte ion ratio between the two methods of differing gaseous composition 
for both 31P and 32S analysis.  The ratios calculated for 31P analysis are similar as are 
those calculated for 32S analysis.  As this is the case it can be said that the presence of 
the He collision gas in the cell was unnecessary. 
 
Previously He has been employed as a collision gas in ICP-MS collision and dynamic 
reaction cells for two reasons.  Firstly He has been used to aid the thermalisation of 
ions within a cell and bring about any desired ion-molecule reactions.  Used in 
conjunction with H2 and/or Xe, He can aid in promoting the attenuation of certain 
spectroscopic interferences.59, 91, 92  Secondly He has been used as the inert gas 
required to pressurise a collision cell when establishing a KED for the selective 
removal of certain unwanted cell formed polyatomic ion species.104 
 
In the former case the assumption is that He was required as a buffer gas to contribute 
a greater degree of pressure to the cell and promote thermalisation allowing the 
desired reaction processes to take place as efficiently as possible.  The main reason, 
therefore, why the presence of He in the collision cell with O2 is questionable is that it 
would appear that O2 alone is sufficient to bring about thermalisation.  If this is the 
case then the only question that remains is why there is a difference in signal between 
the analysis with an O2 reaction gas and the same analysis with an O2/He 
collision/reaction gas.  As both series of analysis provide similar oxide ion to analyte 
ion ratios then the differences in signal between the two are most likely due to day to 
day instrumental drift.  Instrumental drift is also reflected in the signal data for the 
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analysis of the 2 % HNO3 solution where the background signal for the O2 only 
analysis is twice that of the O2/He analysis. 
 
 
As the presence of He as a buffer gas was dismissed, of the two methods the O2 gas 
only approach was further studied in order to determine the method LOD’s for the 
two isotopes of interest.  A series of P and S standard solutions were analysed 
employing the optimum conditions described in section 2.4.2.  The data are given in 
Table 58 (Appendix 2) and graphs are presented in Figure 14. 
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Figure 14.  Graphs Exhibiting Signal Response as a Function of Concentration for the 31P and 32S 
Isotopes Employing ‘Method 2’. 
 
 
Linear curves were constructed for the isotopes of interest (R2 = 0.9715 and 0.9355 
for 31P and 32S isotopes respectively).  Two characteristics of these plots must be 
considered when evaluating this protocol for the determination of 31P and 32S 
isotopes.  Firstly the signal background for the 2 % HNO3 blank solution and 
secondly the R2 value of the curve itself. 
 
 97
The background signal at m/z = 47 is in the order of hundreds of ion counts per 
second.  Such a background signal suggests the presence of a small degree of P 
contamination (or residual 47Ti contamination), however, this is far more acceptable 
than the background signals typically observed at m/z = 31 (in the order of tens of 
thousands of ion counts per second).  The R2 value of the P curve (0.9715) describes a 
linear response over the range of P standard solutions studied.  This suggests that the 
degree of formation of the 31P16O+ ion is consistent between standards and dependent 
on 31P concentration.  31P LOD’s under method 2 conditions were calculated to be 
0.69 μg l-1 to 9.50 μg l-1.  These LOD calculations are fully described in section 2.5. 
 
For the S standard solutions the background signal at m/z = 48 is approximately 13 
000 cps.  Such a signal suggests that there is a significant degree of S and/or 48Ti 
contamination, a very different situation than that observed in the equivalent P 
calibration.  As the background signal at m/z = 47 was so low in the P curve then 48Ti 
contamination alone can be dismissed here for the following reasons.  Firstly each of 
these P and S solutions were prepared with the same deionised water source so 
background data should be similar (which it is, see Table 58, Appendix 2).  Secondly 
as the relative abundance of 47Ti and 48Ti is 7.3 % and 73.8 % respectively then a m/z 
= 47 signal of one tenth the intensity of that of the m/z = 48 signal, between the P and 
S calibrations, would be expected.6  The m/z = 47 and 48 signals measured for the 2 % 
HNO3 solution were compared to see whether this was the case.  For each 
measurement the m/z = 47 signal was far less than one tenth of that of the m/z = 48 
signal.  This data suggests that the main contribution to excessive ion counts at the 
m/z = 48 background will be the presence of contaminating 32S that forms oxide ions 
in the collision cell. 
 
However, 13 000 cps is a high background signal but could be described as miniscule 
on comparison to the typical background observed at m/z = 32.  The R2 value of the S 
curve (0.9355) describes a response for the S standard solutions analysed that is less 
linear than that observed in the P analysis.  At first glance the gradient of the two 
curves could be commented on with regard to the efficiency of 31P and 32S oxidation 
within the hexapole.  Based on the gradients of the two curves it could be said that the 
formation of the 32S16O+ ion is more efficient than the 31P16O+ ion.  However, due to 
the more erratic response of the S standard solutions such a comparison is not 
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realistic.  32S LOD’s under method 2 conditions were calculated to be 1.43 μg l-1 to 
6.50 μg l-1.  These LOD calculations are fully described in section 2.5. 
 
 
2.4.3.  Method 3: Selective Removal of Polyatomic Ions in a Collision 
Cell Incorporating He Collision Gas Under KED Conditions 
 
It has previously been demonstrated that the employment of a collision cell 
incorporating He gas under KED conditions can allow the attenuation of some high 
energy ICP or interface-formed polyatomic ion interferences.104  The removal of such 
species occurs due to the selective loss of ion energy following collision between 
polyatomic ions and neutral He atoms.  Within a collision cell, the possible 
occurrence of reactions between species aside, the presence of any gas has a severe 
effect on the transmission of ions due to variation of ion kinetic energy following 
collision.  The frequency and effect of a collision is dependent on the physical and 
chemical characteristics (e.g. collisional cross section and bond strength) and initial 
kinetic energy of each species involved.33, 91 
 
Polyatomic ions exhibit a higher collisional cross section than that of monatomic 
analyte ions.  Such ions collide more frequently with the He atoms present and 
therefore lose kinetic energy and momentum to a greater degree.  This loss of energy 
can lead to the selective removal of polyatomic ions from the ion beam, along with 
low energy cell formed species, assuming that they have lost sufficient energy so 
cannot overcome the energy barrier established as a result of setting up KED 
conditions.83, 104 
 
It has been documented that the intensity of dominating polyatomic Ar based ions, 
such as 40Ar1H+, 40Ar16O+ and 40Ar2+, can be reduced by several orders of magnitude 
when KED conditions are established.  The degree of metal oxide formation can also 
be limited.83, 104 
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Experimental Details 
 
For the determination of the problematic 31P isotope it could be possible to favour the 
transmission of monatomic analyte ions, through the collision cell, over polyatomic 
ions at m/z = 31 (the most common being 14N16O1H+, 15N15N1H+, 15N16O+, 14N17O+, 
13C18O+ and 12C18O1H+) by incorporating He in the cell and establishing KED 
conditions.  A series of experiments were carried out to establish whether or not such 
conditions could be beneficial to the determination of 31P.  For the analytical approach 
described in this section the 31P isotope was studied rather than the 32S isotope as the 
dominant interfering polyatomic ions, at m/z = 31, typically have a larger collisional 
cross section so any effects that can be observed should be greater. 
 
 
Results and Discussion 
 
Varying flows of He (0 to 4 ml min-1) were incorporated and studied whilst 
employing KED voltage spreads (the difference between Vq and Vh) of +1 V, +2 V 
and +3 V.  The data accrued for these experiments can be seen in Tables 60, 61 and 
62 (Appendix 2) whilst general instrumental conditions can be seen in Table 59. 
 
From this data a series of graphs were constructed to compare the blank subtracted 
data and sample : blank ratios that were calculated (see Figures 15, 16, 17, 18, 19 and 
20).  From the comparison of this data it could be determined whether polyatomic 
ions were being selectively removed and whether there were any optimum conditions 
to create such an effect. 
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Figure 15.  A Graph Comparing m/z = 31 Background Subtracted Signal for the Analysis of 2 % 
HNO3 Blank and 200 µg l-1 P Solutions when Varying He Flow Rate (ml min-1) Under Different 
KED Conditions (KED Spread = +1 V). 
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Figure 16.  A Graph Comparing m/z = 31 Signal Sample : Blank Ratio for the Analysis of 2 % 
HNO3 Blank and 200 µg l-1 P Solutions when Varying He Flow Rate (ml min-1) Under Different 
KED Conditions (KED Spread = +1 V). 
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Figure 17.  A Graph Comparing m/z = 31 Background Subtracted Signal for the Analysis of 2 % 
HNO3 Blank and 200 µg l-1 P Solutions when Varying He Flow Rate (ml min-1) Under Different 
KED Conditions (KED Spread = +2 V). 
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Figure 18.  A Graph Comparing m/z = 31 Signal Sample : Blank Ratio for the Analysis of 2 % 
HNO3 Blank and 200 µg l-1 P Solutions when Varying He Flow Rate (ml min-1) Under Different 
KED Conditions (KED Spread = +2 V). 
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Figure 19.  A Graph Comparing m/z = 31 Background Subtracted Signal for the Analysis of 2 % 
HNO3 Blank and 200 µg l-1 P Solutions when Varying He Flow Rate (ml min-1) Under Different 
KED Conditions (KED Spread = +3 V). 
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Figure 20.  A Graph Comparing m/z = 31 Signal Sample : Blank Ratio for the Analysis of 2 % 
HNO3 Blank and 200 µg l-1 P Solutions when Varying He Flow Rate (ml min-1) Under Different 
KED Conditions (KED Spread = +3 V). 
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Figure 15 shows the effect of differing KED conditions (KED spread = +1 V) on the 
m/z = 31 signal when analysing 2 % HNO3 blank and 200 µg l-1 P solutions for 
various He flows to the collision cell.  Generally, as the He flow increased the m/z = 
31 signal decreased.  For the first three KED conditions studied (Vh = -1 V, 0 V and 
+1 V) there was little difference in signal intensity at each He flow used.  When Vh 
was increased, in line with Vq, beyond +1 V the m/z = 31 signal decreased severely 
for each He flow.  Therefore there are two factors here that require discussion; the 
signal reduction dependency on the He flow and the signal reduction dependency on 
the increase in applied hexapole voltage (established in the various KED conditions). 
 
The decreased signals arising from the increased He flow was the result of ion kinetic 
energy reduction following collision with He atoms.  This energy reduction leads to a 
large elimination of ions from the hexapole as they cannot overcome the energy 
barrier established under the KED conditions.  The reduction in signal that was 
generated when increasing the applied hexapole voltage can be described by IKEE.  
As Vh was increased, towards Vp, all species at m/z = 31 were slowed on entrance to 
the hexapole.  The IKEE therefore contributed to a greater number of ions that were 
not capable of overcoming the energy barrier established under the KED conditions. 
 
Figure 16 shows the effect of differing KED conditions (KED spread = +1 V) on the 
ratio of sample to blank signals at m/z = 31 when analysing 2 % HNO3 blank and 200 
µg l-1 P solutions whilst using various He flows.  Such a ratio can be used to 
determine the degree of polyatomic ion removal with regard to this m/z.  For a KED 
spread of +1 V the greatest sample to blank signal ratio was found at a He flow of 3 
ml min-1 and KED conditions of Vh = +1 V and Vq = +2 V, however, at such 
conditions the blank subtracted m/z = 31 signal was 265 cps which is completely 
unusable for analysis.  Therefore, to achieve a realistic signal a lower He flow must be 
employed.  Considering the data in Figure 15, a He flow of 1.5 ml min-1 cannot be 
exceeded in order to maintain a sensible signal.  Because of this a compromise 
between He flow and KED voltages was struck to establish optimum, “working”, 
conditions.  As a standard, between these experiments, it was decided that these 
optimum conditions would have the following requirements: 
 
• A sample : blank signal ratio of >30. 
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• A sample signal in the order of at least x 104 cps. 
• A blank signal in the order of <1000 cps. 
 
For a KED spread of +1 V, the optimum working conditions were He flow rate = 1.5 
ml min-1, Vh = -1 V and Vq = 0 V. 
 
Similar to Figure 15, Figure 17 shows the effect of differing KED conditions (KED 
spread = +2 V) on the m/z = 31 signal when analysing 2 % HNO3 blank and 200 µg l-1 
P solutions at various He flows.  As the He flow incorporated was increased the m/z = 
31 signal decreased.  Again, for the first three KED conditions studied (Vh = -2 V, 0 V 
and +2 V) there was little difference in signal intensity at each He flow rate.  When Vh 
was increased beyond +2 V the m/z = 31 signal decreased significantly for each He 
flow, particularly at the lower flow rates (up to 1.5 ml min-1).  As with Figure 15, the 
signals of the graph in Figure 17 can be described by the ion kinetic energy reduction 
as the result of collision with increasing quantities of He and the loss of ion 
momentum due to the IKEE conditions becoming stronger. 
 
Figure 18 is a graph comparing differing KED conditions (KED spread = +1 V) with 
the ratio of sample to blank signals at m/z = 31 when analysing 2 % HNO3 blank and 
200 µg l-1 P solutions and introducing various He flows.  Similar to Figure 16 at first 
glance the optimum set of conditions for selective removal of polyatomic ions would 
have been a He flow rate of 2 ml min -1 and voltages of Vh = -2 V and Vq = 0 V.  
However, considering the low m/z = 31 signal that was obtained under these 
conditions (4526 cps for the P solution, see Figure 17) optimum working conditions 
were decided on at a He flow of 1.5 ml min-1, Vh = -2 V and Vq = 0 V. 
 
Figure 19 shows the effect of differing KED conditions (KED spread = +3 V) on the 
m/z = 31 signal when analysing 2 % HNO3 blank and 200 µg l-1 P solutions whilst 
using various He flows to the hexapole.  The same general trends are observed in this 
graph as in those of Figures 15 and 17, as the He flow incorporated increased the m/z 
= 31 signal decreased.  For both sets of conditions studied here the m/z = 31 signal 
drops to almost zero on the introduction of 1 ml min-1 He.  The two different sets of 
KED conditions generated very different data for the blank subtracted P standard 
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solution with the higher Vh value producing the lowest m/z = 31 signal.  Again the 
reduced m/z = 31 signal arises due to the effects of collision with He atoms and the 
loss of momentum as Vh tends towards Vp. 
 
Figure 20 shows the effect of differing KED conditions (KED spread = +3 V) on the 
ratio of sample to blank signals at m/z = 31 when analysing 2 % HNO3 blank and 200 
µg l-1 P solutions whilst using various He flows.  For a KED spread of +3 V there 
wasn’t a clear optimum for either set of KED conditions studied, however, what 
should be recognised here is that the sample to blank signal ratios observed were 
much lower than those at KED spreads of +1 V and +2 V. 
 
On comparison of the experiments carried out for this method, it appears that the 
optimum working conditions required to create a selective removal of polyatomic ions 
at m/z = 31 were He flow = 1.5 ml min-1, Vh = -1 V and Vq = 0 V.  As can be seen 
from the data generated from the experiments of this section the wider that the Vh to 
Vq range is then a poorer m/z = 31 signal is obtained.  The reason for this is that a 
wider range produces a greater energy barrier that has to be overcome by ions 
transmitted through the cell.  The optimum Vh/Vq range is a separation of +1 V. 
 
 
Following the study of He flow and KED conditions on the m/z = 31 signal, a series of 
P standard solutions were studied under the optimum working conditions (He = 1.5 ml 
min-1, Vh = -1 V and Vq = 0 V).  The data accrued during this experiment can be seen 
in Table 63 and a graph comparing P concentration with m/z = 31 signal can be seen 
in Figure 21. 
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Figure 21.  A Graph Exhibiting Signal Response as a Function of Concentration for the 31P 
Isotope Employing ‘Method 3’. 
 
 
As can be seen in the Figure 21 a linear graph was obtained (R2 = 0.9877).  On 
comparison to the study of P standards carried out under ‘method 2’ conditions 
(Figure 14) the background for the 31P isotope here was higher, approximately 2000 
ion counts per second.  This will have a detrimental effect on the LOD calculated for 
this method.  Considering that the same standard solutions were studied under method 
2 and 3 conditions, it is more likely that the higher background for method 3 arises as 
the removal of interfering polyatomic ions is not 100 % efficient; 31P contamination 
may also be an issue.  31P LOD’s under method 3 conditions were calculated to be 
1.48 μg l-1 to 7.78 μg l-1.  These LOD calculations are fully described in section 2.5. 
 
 
2.4.4.  Method 4: The Determination of 31P16O+ and 32S16O+ Ions 
Formed Under ‘Cold/Cool Plasma’ 
 
During the work carried out by Wiedemann et al. and whilst optimising conditions for 
the measurements described in sections 2.4.1, 2.4.2 and 2.4.3 it was observed that 
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lowering the forward power of the ICP, from the typical 1350 W to approximately 
800 W, when analysing P and S solutions resulted in enhancement of the m/z = 47 and 
48 signals.138  When employing a ‘cold/cool plasma’ for analysis the increased 
occurrence of measured oxide species is normally considered to be problematic.  In 
this case, however, it can be advantageous by forming the 31P16O+ (m/z = 47) and 
32S16O+ (m/z = 48) ions for the reasons described in sections 2.4.1 and 2.4.2.  The 
work described in this section determines whether this method has potential for the 
determination of 31P and 32S isotopes. 
 
 
Experimental Details 
 
To fulfil the aim of establishing whether a ‘cold/cool plasma’ was a feasible approach 
to the measurement of P and S at trace levels, experiments were first carried out to 
determine the optimum forward power for the formation of these analyte oxide ions.  
A forward power range between 1700 W and 700 W was studied as this incorporates 
powers higher than normally employed down to those of the ‘cold plasma’ region.  
For forward power increments of this range m/z = 31, 32, 47 and 48 signals were 
measured for 2 % HNO3 and 1000 μg l-1 P and S solutions to determine optimum 
intensity and signal to background ratio. 
 
 
Results and Discussion 
 
General instrumental conditions employed during these experiments can be seen in 
Table 64 (Appendix 2) whilst the data generated can be seen in Tables 65, 66 and 67. 
 
Manipulation of the data generated during these experiments has allowed construction 
of a series of graphs to determine the optimum ICP forward power for 31P16O+ and 
32S16O+ ion formation, see Figures 22, 23, 24 and 25. 
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Figure 22.  A Graph Comparing m/z = 31 Signal with Forward Power (W) for the Analysis of 2 
% HNO3 Blank and 1000 µg l-1 P Solutions. 
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Figure 23.  A Graph Comparing m/z = 47 Signal with Forward Power (W) for the Analysis of 2 
% HNO3 Blank and 1000 µg l-1 P Solutions. 
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Figure 24.  A Graph Comparing m/z = 32 Signal with Forward Power (W) for the Analysis of 2 
% HNO3 Blank and 1000 µg l-1 S Solutions. 
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Figure 25.  A Graph Comparing m/z = 48 Signal with Forward Power (W) for the Analysis of 2 
% HNO3 Blank and 1000 µg l-1 S Solutions. 
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Figure 22 shows the variation of m/z = 31 signal with ICP forward power (W) during 
the analysis of 2 % HNO3 blank and 1000 µg l-1 P solutions.  The 2 % HNO3 solution 
plot exhibits a single peak, over the range of forward powers studied, at 800 W.  This 
peak has arisen as at that particular forward power the conditions were ideal for the 
formation of N, O and H based polyatomic ions such as 14N16O1H+.  The 1000 µg l-1 P 
solution plot shows a primary peak (1300 W) and a secondary peak (825 W).  The 
primary peak has arisen due to the massive presence of 31P+ ions whilst the secondary 
peak is a polyatomic ion peak similar to that seen in the 2 % HNO3 solution plot. 
 
Figure 23 shows the variation of m/z = 47 signal with ICP forward power (W) for the 
analysis of 2 % HNO3 blank and 1000 µg l-1 P solutions.  Over the range of forward 
powers studied the signal generated from the 2 % HNO3 solution varied very little, 
only a slight elevation (up to approximately 600 cps) was observed in the region of 
1500 W.  For the signal from the 1000 µg l-1 P solution primary (800 W) and 
secondary (1350 W) peaks were observed.  The primary peak arose due to the 
formation of the 31P16O+ (m/z = 47) ion whilst the secondary peak was most likely 
present due to either a secondary optimum for the formation of 31P16O+ or background 
signal from 47Ti contamination.  At 800 W the signal : background ratio is 363 : 1 so 
this would be the optimum forward power for the formation of 31P16O+ ions in terms 
of both maximum signal and background. 
 
Figure 24 shows the variation in m/z = 32 signal with ICP forward power (W) for the 
analysis of 2 % HNO3 blank and 1000 µg l-1 S solutions.  Over the range of forward 
powers studied, the signals for both 2 % HNO3 blank and 1000 µg l-1 S solutions 
differ very little, again, highlighting the degree of interference at m/z = 32.  A peak for 
both plots is seen at a forward power of 1050 W which suggests the optimum 
conditions for the ionisation of molecular oxygen. 
 
Figure 25 shows the variation in m/z = 48 signal with ICP forward power (W) for the 
analysis of 2 % HNO3 blank and 1000 µg l-1 S solutions.  Over the range of ICP 
forward powers studied primary and secondary signal peaks are exhibited for both 
solutions analysed.  For the 2 % HNO3 blank solution the primary signal peak (1350 
W) appears due to the formation of either the 31P16O1H+ (m/z = 48) polyatomic ion 
from contaminating 31P or the 16O3+ ion.  The secondary signal peak at 800 W is 
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present due to the formation of 32S16O+ from background 32S.  The primary peak (787 
W) of the 1000 µg l-1 S solution arose due to the formation of the 32S16O+ ion whilst 
the secondary peak (1350 W), again, was present due to the formation of 31P16O1H+ 
from contaminating 31P or 16O3+.  At 787 W the signal : background ratio is 12.8 : 1 so 
this is the optimum forward power for the formation of 32S16O+ ions in terms of 
maximum signal and background.  However, on comparison to the 31P experiments 
the measurement of 32S by this approach is far less efficient. 
 
Following study of the data accrued during the forward power experiments optimum 
formation of the 31P16O+ and 32S16O+ ions was observed at 800 W and 787 W 
respectively.  On comparison of the m/z = 31, 32, 47 and 48 signals seen in the graphs 
of Figures 22, 23, 24 and 25 it can be said that, similar to the collision cell work of 
sections 2.4.1 and 2.4.2, the formation of analyte oxide ions by this method is 
particularly inefficient.  Of the two isotopes 31P oxidises, by this approach, to a 
greater degree within the ICP.  As with the collision cell methods described in this 
thesis, the formation of 31P16O+ and 32S16O+ ions by ‘cold/cool plasma’ ICP-MS 
appears to be a promising approach to the determination of 31P and 32S isotopes. 
 
 
Following optimisation, a series of P and S standard solutions were studied employing 
the ‘method 4’ conditions.  The data generated during these measurements can be 
seen in Table 68 and graphs comparing standard concentration with m/z = 47 and 48 
signal for both 31P and 32S isotopes can be seen in Figure 26. 
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Figure 26.  Graphs Exhibiting Signal Response as a Function of Concentration for the 31P and 32S 
Isotopes Under ‘Method 4’. 
 
 
As can be seen in the Figure 26 two linear curves were constructed (R2 = 0.9973 and 
0.9963 for 31P and 32S isotopes respectively).  What should be noted here is a 
comparison between the gradient of each line.  If both curves were parallel then it 
could be argued that the oxidation reaction efficiency for 31P and 32S isotopes was 
similar.  In Figure 26 the gradient data suggests that the formation of the 31P16O+ ion 
could be more prevalent than that of the 32S16O+ ion.  The background signal for the 
31P16O+ formation is desirably low, in the order of hundreds of ion counts per second, 
whilst the background for the 32S16O+ ion is comparatively high, of the order of 
thousands of counts.  This is likely to be due to sulphur contamination of the 
deionised water used in preparation of the calibration standard solutions, a problem 
also highlighted during the work carried out towards methods 1 and 2.  Under method 
4 conditions 31P and 32S LOD’s were calculated to be 0.89 μg l-1 to 6.56 μg l-1 and 
6.84 μg l-1 to 25 μg l-1  respectively.  These LOD calculations are fully described in 
section 2.5. 
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2.4.5.  Method 5: The Determination of 31P16O+ and 32S16O+ Ions 
Formed by ‘Cold/Cool’ Plasma Incorporating an Additional O2 
Nebuliser Flow 
 
Following the promising results evolved from the ‘cold/cool plasma’ work described 
in section 2.4.4, experiments were carried out to determine whether the degree of 
analyte oxide formation could be enhanced by the addition of an O2 gas flow through 
the central channel of the ICP.  By providing the ICP discharge with an additional 
source of O2 it was hoped that oxidation of 31P and 32S could be maximised without 
causing any detrimental effect to the overall atomisation and ionisation capability of 
the plasma. 
 
 
Experimental Details 
 
Via a ‘Y-piece’ tube an O2 gas flow was introduced into the nebuliser gas flow after 
sample passage through an external cyclonic spray chamber.  Initial experiments were 
carried out to determine the effect of such a flow on the 31P16O+ and 32S16O+ ion 
formation whilst employing the optimum ‘cold/cool plasma’ conditions described in 
section 2.4.4. 
 
 
Results and Discussion 
 
The data generated during these experiments, see Table 70, was used to construct 
graphs to determine the effect of additional O2 introduction (see Figures 27 and 28).  
General instrumental conditions employed during this work can be seen in Table 69 
(Appendix 2). 
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Figure 27.  The Variation of m/z = 47 Signal with O2 Nebuliser Gas Flow Introduction for the 
Analysis of 2 % HNO3 Blank and 1000 µg l-1 P Solutions. 
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Figure 28.  The Variation of m/z = 48 Signal with O2 Nebuliser Gas Flow Introduction for the 
Analysis of 2 % HNO3 Blank and 1000 µg l-1 S Solutions. 
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Figure 27 is a graph comparing the variation in m/z = 47 signal with increasing 
introduction of an O2 nebuliser gas flow for the analysis of 2 % HNO3 blank and 1000 
µg l-1 P solutions under ‘cold/cool plasma’ conditions of 800 W forward power.  For 
the 2 % HNO3 blank solution signal there was no significant change between O2 gas 
flows.  However, for the 1000 µg l-1 P solution, over the range of O2 nebuliser flow 
rates studied there appeared to be a small degree of 31P16O+ ion enhancement at 8 ml 
min-1.  At this flow rate, for the 1000 µg l-1 P solution, there was an enhancement of 
approximately 10 000 ion counts per second compared to the analysis of the same 
solution at 0 ml min-1 O2 introduction.  This was an enhancement of approximately 10 
%.  As there was no significant change in the signal for the 2 % HNO3 solution then it 
could be said that the majority of the signal enhancement was due to the formation of 
the 31P16O+ ion. 
 
Figure 28 is a graph comparing variation in m/z = 48 signal with increasing O2 
nebuliser gas flow introduction for the analysis of 2 % HNO3 blank and 1000 µg l-1 S 
solutions under ‘cold/cool plasma’ conditions of 787 W forward power.  For the 2 % 
HNO3 blank solution there was a small degree of signal enhancement, in the region of 
3000 ion counts per second at 10 ml min-1 which probably has arisen due to the 
presence of contaminating S.  Similar to the graph in Figure 27 for the P solution, 
between the 0 and 18 ml min-1 O2 nebuliser flow rate range studied there appears to be 
a small amount of 32S16O+ ion enhancement at 10 ml min-1.  At this flow rate, for the 
1000 µg l-1 S solution, there was an ion count enhancement of approximately 20 000 
cps compared to the same analysis at 0 ml min-1 O2 introduction.  This was an 
enhancement of approximately 40 % which is a significant signal increase even 
considering the 3000 counts increase present in the background. 
 
 
Following optimisation a series of P and S standards were studied under the optimum 
‘method 5’ conditions.  Data accrued and plots generated during this experiment can 
be seen in Table 71 and Figure 29. 
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Figure 29.  Graphs Exhibiting Signal Response as a Function of Concentration for the 31P and 32S 
Isotopes Employing Method 5 Conditions. 
 
 
As can be seen in the graph of Figure 29, two linear curves were constructed (R2 = 
0.9923 and 0.9591 for 31P and 32S isotopes respectively).  Similar to the concentration 
curves produced following ‘method 4’ optimisation (see Figure 26), what should be 
noted here is that these lines are not parallel, i.e. there is a significant difference in 
oxide formation efficiency between the 31P and 32S isotopes.  Also similar to Figure 
26 the background signal for the 31P16O+ formation is desirably low, in the order of 
hundreds of ion counts per second, whilst the background for the 32S16O+ ion is high, 
of the order of thousands of counts.  This is due to the occurrence of the 16O3+ ion at 
m/z = 48.  Under method 5 conditions 31P and 32S LOD’s were calculated to be 0.74 
μg l-1 to 14 μg l-1 and 1.23 μg l-1 to 80 μg l-1 respectively.  These LOD calculations are 
fully described in section 2.5. 
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2.4.6.  Method 6 (Part 1): The Exclusion of Entrained Atmospheric 
Gases from the ICP 
 
The formation of polyatomic ions within the ICP and the ICP-MS interface occurs 
due to the presence of elements originating from the plasma gas, entrained 
atmospheric gases and the sample matrix.  To avoid spectroscopic interference due to 
the formation of these polyatomic ions certain measures can be taken, see sections 
1.1.2 and 1.2.1. 
 
Entrained atmospheric gases are responsible for a significant degree of spectroscopic 
interference, the most obvious examples being the presence of the 14N2+ and 16O2+ 
ions at m/z = 28 and 32 which arise due to atomisation survival of atmospheric N2 and 
O2 within the plasma.  Previously it was recognised that an ICP discharge was more 
stable when enclosed with a flared torch extension.134  Enclosed ICP ion sources have 
also been employed in ICP-OES for quite some time and it is now standard 
practise.142, 143 
 
The work in this section describes attempts made to limit the entrainment of 
atmospheric gases into the plasma to determine any analytical benefit.  By limiting 
entrainment, the aim was to reduce spectroscopic interference.  This limitation was 
attempted by enclosing the ICP within a ‘trumpet-end’ shaped torch bonnet positioned 
over the last 20 to 30 mm of the ICP torch and flush against the sample cone.  This 
bonnet was held in place within the load coil. 
 
By enclosing the ICP ion source it was believed that the surface area of the plasma 
open to the torch box atmosphere could be reduced, potentially limiting entrainment.  
Produced from silica, the bonnet design was composed of two sections; a tube of 
internal diameter (20.4 mm) slightly greater than that of the ICP torch and a widened 
‘trumpet-end’ section to compensate for the lack of atmosphere at the sample cone 
that typically causes a compression at the tip of the plasma (see Figure 30). 
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 Figure 30.  A Schematic of the Torch Bonnet Design (Dimensions Measured in mm). 
 
 
Photographs of the torch bonnet, after its production, and its placement within the 
instrument torch box can be seen in Figures 91 and 92 (Appendix 2).  There were 
initial concerns about carrying out this work with regard to whether the plasma 
generation would be affected by the presence of a second layer of silica from the torch 
bonnet and the tolerance of the silica with regard to its exposure to the high 
temperatures generated by the ICP.  Initial experiments were cautiously carried out 
where an ICP was generated with the torch bonnet in place.  On successful ICP 
generation, the bonnet was observed for periods of up to an hour after which, with no 
signs of deformity, the question of silica tolerance to plasma temperature was 
satisfactorily answered. 
 
At this point experimentation was carried out to establish whether or not this approach 
would be beneficial with regard to tackling spectroscopic interferences. 
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Experimental Details 
 
A series of P and S standard solutions, spiked with 1 µg l-1 In as an internal standard, 
were studied by ICP-MS both with and without the torch bonnet in position.  Prior to 
analysis the ICP-MS instrument was stabilised and tuned as with the bonnet in place 
the torch box position could not be adjusted as the trumpet end sat closely against the 
sample cone.  The general instrumental conditions employed during this study can be 
seen in Table 72 (Appendix 2) and the data generated can be seen in Table 73. 
 
 
Results and Discussion 
 
From the data generated three graphs were constructed that compare m/z = 31, 32 and 
115 signals with and without the torch bonnet in position (see Figures 31, 32 and 33).  
It should be noted that under standard conditions the m/z = 32 signal for each standard 
solution was zero.  This was because the number of ions being counted was so high, 
due to the presence of 16O2+, that the detector stops counting ions to preserve lifetime. 
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Figure 31.  A Comparison of P Standard Concentration (µg l-1) with m/z = 31 Signal (cps) for 
Analysis Under Standard Conditions and with the Torch Bonnet in Position. 
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Figure 32.  A Graph Comparing S Standard Concentration (µg l-1) with m/z = 32 Signal (cps) for 
Analysis Under Standard Conditions and with the Torch Bonnet in Position. 
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Figure 33.  A Graph Comparing P and S Standard Concentration (µg l-1) with m/z = 115 Signal 
(cps) for Analysis Under Standard Conditions and with the Torch Bonnet in Position. 
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As can be seen in Figure 31 when the torch bonnet was in position there was a 
reduction in signal, for each solution, compared to standard conditions.  The m/z = 31 
signal reduction for each solution studied was calculated and can be seen in Table 9. 
 
 
Table 9.  The m/z = 31 Signal Reduction Observed when the Torch Bonnet was in Position. 
P Standard Concn (µg l-1) m/z = 31 Signal Ratio 
(Standard Conditions : Torch Bonnet) 
2 % HNO3 Blank 3.57 
0.5 4.43 
1 6.27 
2 4.59 
5 6.47 
10 7.91 
20 8.25 
50 8.04 
75 8.55 
 
 
From the ratio data seen in Table 9 it would appear that there is not a uniform 
reduction of the m/z = 31 signal over the range of standard solutions studied.  
However, with the exception of three of the ratios calculated there is an approximate 
consistent reduction.  The fact that the signal generated from the blank solution is 
reduced and that Figure 31 shows that with the torch bonnet in position the signal 
response for the range of solutions analysed maintains linearity suggests that the 
bonnet is in fact having a beneficial effect to a certain degree. 
 
What should be understood, however, is that the enclosure of the ICP leads to a 
change in the discharge shape and length compared to the standard ICP-MS 
configuration whereby the last 20 to 30 mm of the plasma is open to the atmosphere 
of the torch box.  Under the standard configuration, due to the incredibly high 
temperatures that the ICP reaches, as the discharge exits the torch it immediately 
contracts on contact with the lower temperature atmosphere of the torch box.  When 
enclosed the ICP does not contract so technically should be longer and different in 
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shape (continuing in length rather than coming to a tip).  Under the standard 
configuration the ICP ion source is very close to the sample cone so such changes to 
shape and length, when enclosed, would not be particularly noticeable.  Under such an 
experimental approach to enclosing the ICP, drastically different signals compared to 
the standard data were to be expected. 
 
As can be seen in the data of Table 73 and Figure 32 when the torch bonnet is in 
position there is a severe reduction in the m/z = 32 signal, from the region of hundreds 
of millions of ion counts per second to approximately 100 000 cps for each solution 
studied.  Initially, this may sound as if the torch bonnet has been successful in 
excluding atmospheric O2 from the plasma and limiting the generation of the 16O2+ 
ion.  However, as the signals generated from each S sample solution studied are very 
similar then it is more likely that, in the case of m/z = 32, the bonnet is having a 
severe effect on ion sampling at the sample cone due to the change in characteristics 
of the ICP discharge. 
 
As can be seen in Figure 33, similar to the m/z = 31 signal, when the torch bonnet was 
in position there was a reduction in m/z = 115 signal, for each solution, compared to 
standard conditions.  Unfortunately this data confirmed that there was a blanket signal 
reduction rather than simply a reduction of polyatomic ion species that contribute to 
individual m/z signals.  However, this reduction for each solution was still calculated 
and can be seen in Table 10. 
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Table 10.  The m/z = 115 Signal Reduction Observed when the Torch Bonnet was in Position. 
P and S Standard Concn (µg l-1) 
(1 µg l-1 In Spike) 
m/z = 115 Signal Ratio 
(Standard Conditions : Torch Bonnet) 
2 % HNO3 Blank 2.40 
0.5 6.91 
1 11.25 
2 11.13 
5 4.25 
10 12.14 
20 10.08 
50 8.69 
75 10.57 
 
 
Similar to the m/z = 31 data in Table 9 there is some consistency in signal reduction 
over the range of solutions studied but it is not uniform as would be desired. 
 
It is possible that the signal reductions observed as a result of this work could be due 
to a hindrance of ion sampling as the plasma gases are being directed onto the sample 
cone with a limited possibility of exhaust into the main body of the torch box.  
Because this is a possibility and the data accrued was not particularly promising, a 
second torch bonnet was designed and manufactured to allow gas exhaust, see section 
2.4.7. 
 
 
2.4.7.  Method 6 (Part 2): The Exclusion of Entrained Atmospheric 
Gases from the ICP 
 
Following the sensitivity reduction observed when completely enclosing the ICP with 
the torch bonnet described in section 2.4.6 a second bonnet was designed with the aim 
of allowing the exhaust of plasma gases at the sample cone.  This design was very 
similar to the first but differed with the incorporation of a series of spacers at the 
‘trumpet’ end.  Figure 34 shows a schematic of the second torch bonnet design that 
has been compared in appearance to a castle turret. 
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 Figure 34.  A Schematic of the Second Torch Bonnet Design (Dimensions Measured in mm). 
 
 
Photographs of the second torch bonnet design, and its placement within the 
instrument torch box can be seen in Figures 91 and 93 (Appendix 2). 
 
 
Experimental Details 
 
As with the first torch bonnet design, a series of 1 µg l-1 In spiked P and S standard 
solutions, of increasing concentration, were studied with and without the second torch 
bonnet in position.  Prior to this analysis the ICP-MS instrument was stabilised and 
tuned, for the reason that the torch box position could not be adjusted when the bonnet 
was in place.  The general instrument conditions employed during this study can be 
seen in Table 74 (Appendix 2). 
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Results and Discussion 
 
The data generated following study of the P and S solutions can be seen in Table 75 
(Appendix 2).  From the data generated during this study a series of graphs were 
constructed that compare m/z = 31, 32 and 115 signals with and without the torch 
bonnet in place (see Figures 35, 36 and 37). 
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Figure 35.  A Graph Comparing P Standard Concentration (µg l-1) with m/z = 31 Signal (cps) for 
Analysis Under Standard Conditions and with the Second Torch Bonnet Design in Place. 
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Figure 36.  A Graph Comparing S Standard Concentration (µg l-1) with m/z = 32 Signal (cps) for 
Analysis Under Standard Conditions and with the Second Torch Bonnet Design in Place. 
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Figure 37.  A Graph Comparing P and S Standard Concentration (µg l-1) with m/z = 115 Signal 
(cps) for Analysis Under Standard Conditions and with the Second Torch Bonnet Design in 
Place. 
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As can be seen in Figure 35 when this second torch bonnet was in position there was a 
reduction in signal, for each solution, compared to standard conditions.  The m/z = 31 
signal reduction for each solution studied was calculated and can be seen in Table 11. 
 
 
Table 11.  The m/z = 31 Signal Reduction Observed when the Second Torch Bonnet was in 
Position. 
P Standard Concn (µg l-1) m/z = 31 Signal Ratio 
(Standard Conditions : Torch Bonnet) 
2 % HNO3 Blank 0.81 
0.5 1.04 
1 1.31 
2 1.06 
5 1.43 
10 1.65 
20 1.59 
50 1.44 
75 1.96 
 
 
Similar to the m/z = 31 ratio data associated with the first torch bonnet design (see 
Table 9), the data in Table 11 shows that with the second torch bonnet in position 
there was an approximate consistent signal reduction over the range of sample 
solutions studied.  Again, this m/z = 31 data suggests that with the bonnet in position 
there may have been a beneficial effect taking place as the signal response maintains 
linearity. 
 
As can be seen in the data of Table 75 and Figure 36 when this second design was in 
position, with the exception of the 50 and 75 µg l-1 S solutions, there was a drastic 
reduction in m/z = 32 signal.  In the case of this second bonnet design the signal 
reduction was far greater than that observed when the first was in position for each 
sample studied (to approximately 10 000 cps compared to approximately 100 000 
cps).  However, as the signal reduction for each sample resulted in a m/z = 32 
response that did not represent any kind of gradual increase then there was obviously 
no selective species reduction taking place.  This data suggests that the presence of the 
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bonnet was having a severe effect on ion sampling at the sample cone due to the 
change in characteristics of the ICP discharge. 
 
Similar to the m/z = 31 signal, Figure 37 shows that when the second torch bonnet 
design was in position there was a reduction in m/z = 115 signal for each solution 
analysed when compared to standard conditions.  The degree of signal reduction 
observed for each sample solution was calculated and can be seen in Table 12. 
 
 
Table 12.  The m/z = 115 Signal Reduction Observed when the Second Torch Bonnet was in 
Position. 
P and S Standard Concn (µg l-1) 
(1 µg l-1 In Spike) 
m/z = 115 Signal Ratio 
(Standard Conditions : Torch Bonnet) 
2 % HNO3 Blank 2.03 
0.5 2.23 
1 2.26 
2 2.36 
5 2.42 
10 2.36 
20 2.79 
50 3.45 
75 5.69 
 
 
The signal reduction data in Table 12 shows that, with the exception of two samples 
(50 and 75 µg l-1 P and S), the signal generated from each sample was reduced to a 
similar degree.  Unfortunately this m/z = 115 data has confirmed that the presence of 
this second bonnet resulted in a blanket signal reduction rather than the desired 
selective polyatomic ion species reduction.  The significant difference for m/z = 115 
between the two bonnet designs was that the signals were suppressed to a slightly 
different degree.  To the high hundreds and low thousands of ion counts for 1 µg l-1 In 
for the first bonnet design and to thousands of ion counts for the second bonnet 
design. 
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As can be seen from the data accrued during study of both torch bonnet designs the 
sensitivity reduction observed applies to all m/z signals studied rather than those of 
specific isotopes.  Although this is not the desired result such an approach shows 
promise with regard to the 31P and 32S isotopes as the m/z = 31 signal maintains 
linearity and the m/z = 32 signal was pulled into the detectable range.  So far the work 
carried out in this area has shown promise, however, further study is required.  With 
further modification and careful fabrication it may be possible to produce a torch 
bonnet that successfully limits atmospheric gas entrainment, and hence polyatomic 
ion formation, with minimal effect on the ion sampling process. 
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2.5.  The Calculation of Method Limit of Detection (LOD) 
 
The LOD for each method was calculated by two separate approaches.  The reason for 
this was to provide fair LOD data for comparison with data already published by other 
research groups and instrument manufacturers.  Although the more common approach 
to calculation of LOD (instrumental LOD) may provide a lower limit such a figure 
may not be realistic. 
 
 
2.5.1.  LOD Calculation 1 
 
The most common method for LOD calculation incorporates the error associated with 
the blank solution only, i.e. an instrumental LOD.  Here LOD was calculated using 
the equation in Figure 38 whereby the standard deviation of the 2 % HNO3 blank ICP-
MS signal and the slope of the calibration curve are manipulated.144 
 
 
 
Limit of Detection  =  -3sB  /  m 
 
Where: sB  =  Standard Deviation of the Blank Solution 
  m  =  Slope of the Calibration Curve 
 
Figure 38.  The Common Approach to the Calculation of Limit of Detection. 
 
 
2.5.2.  LOD Calculation 2 
 
A more realistic approach to the calculation of LOD is to sum the ICP-MS signal 
corresponding to the blank solution with the standard error associated with the 
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calibration curve (multiplied by three) to produce a signal equivalent to LOD, i.e. a 
method LOD, see Figure 39.144 
 
 
 
Limit of Detection Signal  =  yB  +  3sy/x 
 
Where: yB  =  Blank Signal 
  Sy/x  =  Standard Error of the Calibration Curve 
 
Figure 39.  The Equation used to Calculate Limit of Detection Signal (More Realistic Approach). 
 
 
To determine standard error of the calibration curve a regression is carried out on the 
data generated during the calibration experiments.  Following determination of the 
signal equivalent to the LOD the figure is fed back into the calibration curve equation 
to produce the limit. 
 
 
2.5.3.  A Comparison of LOD’s 
 
For the four successful approaches to 31P and 32S measurement discussed in section 
2.4 (methods 2, 3, 4 and 5) LOD was calculated via the above two approaches.  These 
calculated limits can be seen in Table 13. 
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Table 13.  LOD's Calculated by both Approaches for Methods 2, 3, 4 and 5. 
Method 
Number 
31P 
(Instrumental 
LOD) 
(µg l-1) 
32S 
(Instrumental 
LOD) 
(µg l-1) 
31P 
(Method LOD)
(µg l-1) 
32S 
(Method LOD) 
(µg l-1) 
2 0.69 1.43 9.50 6.50 
3 1.48 - 7.78 - 
4 0.89 25 6.56 6.84 
5 0.74 1.23 14 80 
 
 
As can be seen in Table 13 the methods developed provide a range of LOD’s for the 
31P and 32S isotopes. 
 
For the 31P LOD by calculation 1 the limits obtained are very similar for methods 2, 4 
and 5 (< 1 µg l-1) whilst that for method 3 is slightly higher (1.48 µg l-1) but not 
significantly.  For 32S LOD by calculation 1, methods 2 and 5 exhibit similar values of 
approximately 1 µg l-1 whilst for method 4 the value is much higher at 25 µg l-1.  The 
reason for this is that the gradient of the calibration curve for method 4 is only 57.318 
which is far more shallow than the other methods studied so results in a higher LOD.  
This suggests that the efficiency of formation of the 32S16O+ ion by method 4 is lower 
than that of methods 2 and 5. 
 
For the 31P LOD by calculation 2 the limits obtained are similar between the four 
calibrated methods.  The limit calculated for method 5 is slightly higher but not 
greatly so.  For 32S LOD by calculation 2 methods 2 and 4 exhibit similar values (≈ 7 
µg l-1) whilst the value for method 5 is far higher at 80 µg l-1. 
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2.6.  Conclusions 
 
As a result of the work carried out four methods, of six overall ideas, were 
successfully developed for the measurement of 31P and 32S isotopes by quadrupole 
based ICP-MS.  Instrumental and method LOD’s were calculated via two approaches, 
described in section 2.5, some of which are comparable to those quoted by other 
rsearchers whilst others are poorer (see Tables 13 and 14).  However, an appraisal of 
the LOD data that has been calculated does not simply allow the selection of the best 
analytical method. 
 
In this case the best LOD data was produced by methods 2, 4 and 5 (the collision cell 
oxygen reaction gas, the ‘cold/cool plasma’ and the ‘cold/cool plasma’ with additional 
oxygen nebuliser gas flow methods).  Before selecting the most appropriate method 
for analysis other factors must be considered.  The method precision and dynamic 
range require assessment and have not been considered during this work.  Also, the 
application of the method is very important.  Method 2 is very different from 4 and 5 
in terms of the ICP power that was employed.  Unfortunately, in the case of methods 
4 and 5, there is a limit to the type of sample that the low power ICP can accept.  
Complex samples, containing a significant quantity of dissolved solids, would most 
likely extinguish the low power ICP.  For this reason methods 4 and 5 would be 
limited to simple samples.  A higher power plasma, like that employed in method 2, 
would accept more complex samples and efficiently atomise and ionise them.  
Therefore a choice of employment between these methods would be based on sample 
application.  The use of a ‘cold/cool plasma’ for the measurement of the 31P isotope 
has only been mentioned once (Wiedemann et al.138) and has not been employed in 
the measurement of the 32S isotope.  On the other hand the use of a collision/reaction 
cell with an oxidising gas is a common approach to the measurement of these 
isotopes. 
 
The enclosed ICP approach (method 3), although not fruitful, showed some promise 
with regard to the possible reduction of spectroscopic interferences.  So far there has 
not been a torch bonnet successfully developed for this purpose, however, further 
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work on this idea and careful design of the enclosing bonnet may prove to be 
beneficial. 
 
Although exhibiting slightly poorer LOD’s than those quoted by the instrument 
manufacturer Perkin Elmer and in the method developed by Bandura et al.90 (see 
section 2.1.1) it should be noted that the methods described were developed in a 
standard laboratory with standard reagents rather than under ‘clean room’ conditions 
with ultra pure reagents.  Under such ‘clean’ conditions the methods described may be 
capable of superior LOD’s for 31P and 32S.  Many of the ICP-MS spectroscopic 
interferences that afflict the m/z = 31 and 32 ratios can be overcome or eleviated, 
however, during the course of this research it was appreciated that the 31P and 32S 
isotopes are at a significant disadvantage with regard to ionisation within the ICP, due 
to their primary ionisation potential.  It is this disadvantage that dominates the 
determination of 31P and 32S isotopes at trace levels by ICP-MS regardless of the type 
of mass spectrometry in use. 
 
To conclude this chapter, the merits and limitations of methods 2, 3, 4 and 5 and 
methods developed by other researchers are summarised and compared, see Table 14.  
Following the successful development work described in this chapter, methods 2, 3, 4 
and 5 were each employed in the quantification of 31P in DNA as an application in 
genomics, see Chapter 3. 
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Table 14.  A Summary and Comparison of Methods Developed for the Measurement of 31P and 32S Isotopes by ICP-MS. 
Method 
Identification 
Method Authors Reference Method Description Merits Limitations 
Method 2 P.D. Winship - The use of O2 in a collision cell to 
oxidise 31P and 32S for alternative 
measurement at m/z = 47 and 48 
LOD’s of 0.7 to 9.50 μg l-1 and 1.43 to 
6.50 μg l-1 for 31P and 32S respectively, 
normal ICP forward power 
Specific for phosphorus 
and sulphur measurement 
Method 3 P.D. Winship - The use of He and KED in a collision 
cell to remove polyatomic ions at m/z = 
31 
LOD’s of 1.43 to 7.78 μg l-1 for 31P, 
normal ICP forward power 
Specific for phosphorus 
measurement 
Method 4 P.D. Winship - The use of a low forward power ICP to 
promote 31P and 32S oxidation for 
measurement at m/z = 47 and 48 
LOD’s of 0.89 to 6.56 μg l-1 and 6.84 
to 25 μg l-1 for 31P and 32S 
respectively, no collision/reaction cell 
requirement 
Specific for phosphorus 
and sulphur measurement, 
less robust ICP 
Method 5 P.D. Winship - The use of a low forward power ICP to 
promote 31P and 32S oxidation for 
measurement at m/z = 47 and 48 
LOD’s of 0.74 to 14 μg l-1 and 1.23 to 
80 μg l-1 for 31P and 32S respectively, 
no collision/reaction cell requirement 
Specific for phosphorus 
and sulphur measurement, 
less robust ICP 
Hexapole 
Collision Cell 
(He, H2 + Xe) 
P. R. D. Mason et al. J. Anal. At. Spectrom., 1999, 
14, 1067-1074 
The use of H2 and Xe to remove 
polyatomic ions at m/z = 32, 33 and 34 
LOD’s of 20 – 50 μg l-1 for S isotope 
measurement, normal ICP forward 
power 
Specific for sulphur 
measurement 
Dynamic Reaction 
Cell (O2) 
D. R. Bandura et al. Anal Chem. 2002, 74, 1497-
1502 
The use of O2 in a dynamic reaction cell 
to oxidise 31P and 32S for alternative 
measurement at m/z = 47 and 48 
LOD’s of < 100 ng l1 and < 200 ng l-1 
for 31P and 32S respectively, normal 
ICP forward power 
Specific for phosphorus 
and sulphur measurement 
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Chapter 3 
 
The Application of Methods Developed 
for the Determination of 31P and 32S and 
the Study of DNA and Related Material 
by ICP-MS 
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3.1.  Genomics 
 
Following the successful method development described in Chapter 2 it was decided 
to apply some of these methods to study within the field of genomics, i.e. the nucleic 
acids carrying genetic information, particularly DNA.137  DNA was selected as an 
application of the methods developed as 31P constitutes approximately 10 %, by mass, 
of the molecule.  Table 15 compares the overall molecular mass of each nucleotide 
(base molecule and phosphate-sugar molecule) present in a DNA molecule and 
provides a mean mass to highlight how the 10 % 31P component has been reached. 
 
 
Table 15.  The Overall Molecular Mass of Individual DNA Nucleotides. 
Nucleotide Identification Overall Molecular Mass 
Adenine (A) 330 
Guanine (G) 306 
Cytosine (C) 346 
Thymine (T) 321 
Mean Nucleotide (Free State) 325.75 
Mean Nucleotide (Bound State) 307.75 
 
 
From the data in Table 15 it was calculated that the mean molecular mass of a DNA 
nucleotide in a free state is 325.75 and when bound in a helix 307.75.  Therefore the 
31P content in the free state and bound state is 9.52 % and 10.07 % respectively. 
 
An alternative application area, for these ICP-MS methods, could have been 
proteomics due to the prevalence of phosphorylation processes taking place as part of 
the biochemistry of the human body.137  Such study could have involved the analysis 
of both 31P and 32S isotopes due to the presence of S in the cysteine and methionine 
amino acids.  However, work is currently being carried out in this area by numerous 
research groups so the decision was to employ these ICP-MS methods in the lesser 
studied area of genomics. 
 138
Figure 40 is a structural diagram of the nucleotide sequences present in a DNA 
molecule.  This diagram highlights the presence of 31P within the structure of the 
molecule.  P is the key element in the bridging structures that link the five membered 
ring sugar molecules providing a backbone to the base molecules adenine (A), 
guanine (G), cytosine (C) and thymine (T).137, 145 
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Figure 40.  A Structural Diagram of Nucleotides That Make Up The DNA Molecule. 
 
 
There has been very little work carried out on direct measurements of DNA by ICP-
MS.  Currently most work in the area of DNA study by ICP-MS can be divided into 
two types.  Firstly the measurement of particular elements of species that interact with 
DNA, i.e. non direct study of the DNA molecule.  For example the interaction 
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between DNA, or component nucleotides, and metal based therapeutic agents.  
Examples of such interactions are described in detail in Chapter 4.  The second type 
of DNA study by ICP-MS involves the measurement of metal ‘tags’ that have been 
attached to DNA or DNA nucleotides.  Nanoparticulate gold is one such tag and has 
been used in the determination of various nucleotide sequences by ICP-MS.  This is 
an area of research that is being pursued by the Loughborough University atomic 
spectroscopy research group and shows great potential as an application of ICP-MS in 
the biological sciences. 
 
 
3.2.  Aims of Research 
 
Currently DNA is commonly quantified by UV/Vis and fluorescence techniques that 
are well established and capable of the detection of single DNA molecules.145  It was 
the aim of this work to determine the feasibility of quadrupole based ICP-MS as an 
alternative approach to the quantification of DNA via the measurement of the 31P 
isotope. 
 
 
3.3.  The Application of Developed Methods 
 
Following the development work that was carried out (see Chapter 2) the four 
successful methods for the determination of 31P (methods 2, 3, 4 and 5) were applied 
to the quantification of DNA in solution via a standard additions approach.  Beyond 
this method 2 was employed in the study of DNA separated within an agarose gel and 
sections of DNA amplified via a polymerase chain reaction (PCR).  Methods 2 and 4 
were also used in the analysis of single nucleotide polymorphisms (SNP’s) following 
separation by HPLC. 
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3.4.  DNA Quantification by Methods 2, 3, 4 and 5 
 
Initial experimentation was carried out to determine the capabilities of these ICP-MS 
methods with regard to the analysis of ‘real’ DNA samples in solution.  Whilst 
evaluating the application of the methods developed the question of the effect of the 
DNA carbon content on the ICP was considered.  Previous work has shown that the 
presence of a certain amount of carbon based material within a sample can have a 
beneficial effect on overall analytical sensitivity.  Volatile carbon compounds in a 
sample, in certain quantities, can aid in the sample introduction process through a 
spray chamber and nebuliser.146  However, the presence of a high level of carbon in a 
sample can have detrimental affects on an analysis, contributing increases in carbon 
based polyatomic ions and sample and skimmer cone deposition.4  The DNA 
molecular structure is predominantly composed of carbon so through these 
experiments the potential for spectroscopic and non-spectroscopic interference (i.e. 
presence of polyatomic ions and reduced sensitivity as a result of a lowering of 
plasma temperature and cone clogging) was monitored by the comparison of 
measured 31P concentration with the expected concentration.  Concern was also raised 
with regard to the nebulisation efficiency of a DNA solution, this was also studied 
during initial experimentation. 
 
 
Experimental Details 
 
DNA samples were studied, under method 2, 3, 4 and 5 conditions, via a standard 
additions approach in order to quantify the concentration present and evaluate the 
occurrence of non-spectroscopic interference.  In this case such interference may have 
originated from the presence of carbon originating from the DNA molecule or 
nebulisation problems.  A series of DNA/31P and 31P standard solutions were prepared 
from calf thymus DNA (Sigma-Aldrich) and 1000 µg ml-1 single element P standard 
solution (Fisher Chemicals, Loughborough, UK) and simultaneously analysed 
employing methods 2, 3, 4 and 5.  As this work was carried out over a long period of 
time there was some variation between the application of these methods for the study 
of DNA.  In the case of methods 2 and 4 2000 µg l-1 DNA samples were studied 
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whereas 200 µg l-1 DNA samples were studied via methods 3 and 5.  There is no data 
available for the analysis of standard solutions under method 2 as P standards were 
not simultaneously analysed.  The general instrumental conditions under which this 
work was carried out can be seen in Tables 76 to 79 (Appendix 3). 
 
 
Results and Discussion 
 
The data for the analysis of the prepared DNA and 31P solutions can be seen in Table 
80 (Appendix 3).  Using this data a series of graphs were constructed to compare the 
analysis of DNA via the four methods studied, see Figures 41, 42, 43 and 44. 
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Figure 41.  A Standard Additions Graph Comparing P Standard Concn (µg l-1) with m/z = 47 
Signal (cps) for a Series of P Spiked 2000 µg l-1 DNA Solns Under Method 2 Conditions. 
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Figure 42.  A Standard Additions Graph Comparing P Standard Concn (µg l-1) with m/z = 31 
Signal (cps) for a Series of P Standard Solns and P Spiked 200 µg l-1 DNA Solns Under Method 3 
Conditions. 
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Figure 43.  A Standard Additions Graph Comparing P Standard Concn (µg l-1) with m/z = 47 
Signal (cps) for a Series of P Standard Solns and P Spiked 200 µg l-1 DNA Solns Under Method 4 
Conditions. 
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Figure 44.  A Standard Additions Graph Comparing P Standard Concn (µg l-1) with m/z = 47 
Signal (cps) for a Series of P Standard Solns and P Spiked 200 µg l-1 DNA Solns Under Method 5 
Conditions. 
 
 
Figures 41, 42, 43 and 44 are graphs comparing the m/z = 31 or 47 signal with the 31P 
concentration of standard inorganic salt solutions and P spiked, 200 or 2000 µg l-1, 
DNA solutions for ICP-MS analysis by methods 2, 3, 4 and 5.  Linearity of the points 
on each line amongst these graphs is very good.  Extrapolation of the DNA solution 
line backwards allows quantification as the difference between the origin and the 
point at which the line intercepts the x-axis yields the 31P concentration of the 200 or 
2000 µg l-1 DNA solution.147  The DNA quantification data for these standard addition 
studies can be seen in Table 16. 
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Table 16.  Quantification Data for the Analysis of 200 and 2000 µg l-1 DNA Solutions by Methods 
2, 3, 4 and 5. 
Method 
Number 
Standard 
Additions Curve 
Equation 
31P Concn Present 
in a 200 or 2000 µg l-1 
DNA Solution (µg l-1) 
31P Composition 
of DNA 
Sample (%) 
2 y = 223.32x + 43394 194.31 9.72 
3 y = 152.62x + 3533.4 23.15 11.58 
4 y = 149.32x + 34466 230.82 11.54 
5 y = 125.72x + 1312.9 10.44 5.22 
 
 
The data of Table 16 shows that all four methods are capable, to a certain degree, of 
the determination of DNA in a simple H2O matrix.  In the case of the 200 or 2000 µg 
l-1 DNA solutions studied the 31P content should be in the order of 20 or 200 µg l-1 
respectively and three methods (2, 3 and 4) provided a 31P concentration close to what 
was expected.  Method 5 exhibited a 31P concentration approximately half of what 
was expected.  It is possible in the case of this method that the atomisation of the 
DNA molecule and ionisation of the 31P atom may not have been as efficient in the 
lower forward power Ar/O2 mixed gas ICP as in the plasma run under the other three 
methods. 
 
The most important information that has been obtained through the work described in 
this section is that, with the exception of the method 5 data, the DNA molecule in 
solution was successfully nebulised without difficulty and introduced to the ICP ion 
source.  On comparison with P standard information the data accrued from methods 2, 
3 and 4 has shown that non-spectroscopic interference was not a significant problem.  
Although this analysis was very simple in terms of the sample matrix it allowed the 
progression of the study of DNA by quadrupole based ICP-MS.  It would appear, 
however, that at trace levels ICP-MS may struggle in the measurement of DNA 
compared to the capabilities of the robust UV/Vis and fluorescence techniques. 
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3.5.  The Analysis of DNA Samples Separated on an Agarose 
Gel Plate by ICP-MS Employing Method 2 
 
Following the successful analysis of DNA in solution employing three of the four 
methods developed, further study was carried out on DNA samples separated on 
agarose gel plates (2 % Agarose).  Such a separation is commonly carried out to 
determine the presence of DNA polymorphisms during profiling experiments.148  
Again fluorescence techniques are normally employed in the determination of DNA 
present in such gels.145  The aim of this section of work was to establish the feasibility 
of measuring DNA, via method 2 - 31P isotope analysis, within a gel following a 
digestion procedure.  Method 2 was selected as, of the four, it was the most sensitive 
and robust, operating at a standard ICP forward power (see section 2.5.3). 
 
 
Experimental Details 
 
Agarose gel (2 %) was prepared by dissolving agarose (2 g) in tris-borate buffer, 
TBE, (100 ml) containing ethidium bromide (0.5 μg ml-1) at 100 °C in a microwave.  
Following casting of the gel, DNA was separated through it with application of 125 V 
for a period of 1 hour.  Sections of separated DNA were then identified under UV 
radiation and removed for ICP-MS study. 
 
Digestion of the gel was originally attempted with a HNO3/H2O2/H2O digest solution, 
however, initial analysis revealed a problem.  The blank solutions analysed appeared 
to contain significant quantities of 31P.  The obvious explanation was that 
contamination of the HNO3 and H2O2 solutions was the cause of this, but it was also 
possible that the digestion solution was leaching 31P from the pump tubing and sample 
introduction glassware before transport into the plasma.  Even with thorough cleaning 
of the glassware and new pump tubing, this problem remained.  Eventually a simple 
H2O leachate was carried out to remove the DNA from the agarose gel whilst 
avoiding the contamination problems previously encountered. 
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Agarose gel (0.22 g, with an ensured quantity of DNA present determined by staining 
with ethidium bromide and observation under UV radiation) was transferred to a 
Nalgene bottle to which deionised H2O was added giving the gel and H2O a combined 
mass of 10 g.  The bottle was sealed and incubated in a water bath at 80°C for a 
period of 3 hours.  A similar bottle containing 10 g H2O only was subjected to the 
same conditions to act as a crude blank (an ideal blank sample would have been a 
similarly treated agarose gel without DNA present). 
 
 
Results and Discussion 
 
Following the treatment described previously both solutions were analysed by ICP-
MS employing method 2 conditions, see Table 81 (Appendix 3) for the general 
instrumental conditions employed.  The data for this work can be seen in Table 17. 
 
 
Table 17.  Data Accrued During the Analysis of the Agarose Gel Leachate by ICP-MS Employing 
Method 2 Conditions. 
Sample 31P+ 
(m/z = 31) Signal (cps) 
31P16O+ 
(m/z = 47) Signal (cps) 
Deionised H2O Blank 62633 6979 
Agarose/H2O ‘Leachate’ 107609 18762 
 
 
Table 17 shows that the quantity of 31P present in the leachate sample was 
approximately twice that in the blank solution.  Although the agarose was not being 
completely broken down it does appear that a significant quantity of DNA was being 
transferred into solution.  A leachate or digestion process shows potential as an 
approach to the determination of the presence of DNA within an agarose gel band.  It 
may be possible to carry out a quantitative analysis of a leached/digested agarose gel 
by the preparation of a series of agarose standards that have been impregnated with 
known concentrations of DNA. 
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The analysis of the agarose gel leachate by ICP-MS showed it to be a potentially 
useful tool in genomics as well as other biological fields.  Although the trace 
measurement of the 31P isotope by quadrupole based ICP-MS is not as straight 
forward as for many elements of the periodic table, considering the high concentration 
present in many biological samples such analyses might be a feasible approach for 
some samples.  With further work the analysis of such gels, containing separated 
DNA, could prove to be an effective approach to quantitative determination of DNA.  
However, it is apparent that this cannot compete with the robustness of UV/Vis and 
the sensitivity of the fluorescence methods commonly employed for this analysis. 
 
Alternatively it may be possible to approach agarose gel analysis by the use of laser 
ablation (LA-ICP-MS).  By the ablation of a stained gel plate, impregnated with 
DNA, the sample could be transported into the ICP ion source without the need for a 
leachate or digestion treatment.  Some initial experimentation was carried out using 
such an approach to determine validity, however, there were difficulties in sample 
introduction as the sample was desiccated under the heat and gas flows of the laser 
cell before ablation could be carried out.  At this point the analysis was abandoned 
and it was decided that any further work pursued would involve DNA separated on 
polyacrylamide gel plates that would be more resistant to the heat and gas flows of the 
laser ablation cell. 
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3.6.  The Study of DNA Replication by Polymerase Chain 
Reaction 
 
Polymerase Chain Reaction (PCR) is an artificial process by which sections of DNA 
or RNA can be replicated.  If a particular sequence of a nucleic acid is of interest it 
can be chemically synthesised by the PCR process for further study.149 
 
The PCR replication occurs through a series of sequences known as thermocycles 
whereby the DNA strands are denatured and separated on heating to a temperature of 
94°C.  The separated strands are then exposed to short chain nucleotide sections 
(primers), of complementary base pairing, that anneal to one end of each DNA strand.  
These primer molecules are required to flank the region of interest that is to be 
amplified to control the process.  From these primer molecules 
deoxynucleotidetriphosphate (dNTP) molecules polymerise along the length of the 
strand (at 72°C over a period of 2 minutes), catalysed by the enzyme DNA 
polymerase.  The result of this process is the formation of two new DNA sequences 
formed from the original sequence.  At this point the thermocycling process continues 
until the source of primers and dNTP’s is exhausted.149 
 
Typically the progression of a PCR process is determined by separation on an agarose 
gel plate, staining with ethidium bromide and study by fluorescence which is a very 
sensitive analytical method, having the capability of studying single DNA 
molecules.145  Similar to section 4.5. the aim behind this work was to establish 
whether ICP-MS is a feasible alternative, to the well established fluorescence methods 
commonly in use, for PCR monitoring and quantification. 
 
 
Experimental Details 
 
A PCR experiment was carried out on a DNA sequence 490 base pairs in length.  This 
PCR process employed 25 µl reactions incorporating genomic DNA (0.5 µg), primers 
(200 pmol of each), deoxy-ATP, GTP, CTP and TTP (0.5 mM each), MgCl2 (3 mM), 
Taq DNA polymerase (1 unit), gelatine (0.001 %) and Tris-HCl (10 mM, pH 8.3).  
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Two sets of ten separate PCR mixture solutions were prepared, nine of each ten were 
allowed through the process whilst the remaining two were kept as control solutions.  
The purpose of preparing two sets in this way was to double up the volume of sample 
solution available so to make ICP-MS analysis easier in terms of sample introduction.  
During the replication process, one of these sample mixtures was removed after every 
four thermocycles.  The idea behind this removal was the preparation of a series of 
DNA solutions that had undergone different degrees of amplification. 
 
A third set of sample solutions was also prepared, similarly amplified employing the 
PCR process, and separated on 2 % agarose gel containing ethidium bromide to 
confirm amplification via UV/Vis fluorescence.  This agarose gel separation revealed 
successful DNA amplification that should also be observed during ICP-MS analysis. 
 
Following completion of the PCR process the problem faced was that each sample 
solution contained quantities of each of the four main PCR components.  Therefore, 
prior to analysis the amplified DNA sequences required separation from the remaining 
31P containing components, i.e. the sequence primers and the dNTP’s.  Separation of 
these components was attempted through a centrifugation process whereby the sample 
solutions (50 µl, due to the combination of the two sample sets) were centrifuged in 
microcon centrifugal filter tubes (Micon Bioseparations) of 100 000 molecular weight 
cut-off (MWCO) for 5 minutes at 800 RPM.  Such filter tubes separate molecules of a 
molecular weight less than 100 000 from those of a higher molecular weight, 
therefore the amplified DNA sequences could be removed from the smaller primer 
and dNTP molecules.  The amplified DNA sequences remaining on the filters 
following centrifugation were resuspended in deionised water (100 µl). 
 
 
Results and Discussion 
 
The DNA solutions obtained following the PCR and centrifugation processes were 
analysed by ICP-MS employing method 2 for the 31P isotope content.  For this 
analysis a Micromist 100 µl min-1 concentric nebuliser was used in conjunction with 
an impact bead spray chamber.  The general instrumental conditions employed during 
this work can be seen in Table 82 (Appendix 3) and the data generated during the 
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study of these amplified DNA solutions can be seen in Table 83.  From the data in 
Table 83 a graph was constructed charting the progress of the PCR amplification via 
determination of the 31P16O+ ion (m/z = 47), see Figure 45. 
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Figure 45.  A Graph Comparing Number of Thermocycles with m/z = 47 Signal for the Analysis 
of a PCR Process Employing ICP-MS Method 2. 
 
 
Figure 45 compares the m/z = 47 signal with the number of thermocycles that the 
DNA solutions under study were passed through.  PCR has been described as an 
exponential amplification so, theoretically, what should be observed is an exponential 
increase in m/z = 47 signal.  Such an increase was not observed in the ICP-MS data as 
a significant increase in m/z = 47 signal did not appear until beyond thermocycle 20.  
This suggests that either the method in place was not sensitive enough to detect 
smaller changes in amplification or that the separation of amplified sequences, 
primers and dNTP’s was not particularly efficient. 
 
It should be noted that PCR is an artificial process, whereby the DNA strands are 
initially separated as a result of exposure to a high temperature (94°C), compared to 
replication processes that take place in cells at body temperature.  Therefore, DNA 
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replication carried out by PCR cannot be compared fairly to that which takes place in 
the body where enzymes separate the strands.  However, recently Vincent et al.150  
published a new approach to artificial DNA replication that is more comparable to 
that taking place in the human body.  Helicase enzymes were employed to separate 
DNA strands and lower temperatures were employed during the replication. 
 
Following this study it can be concluded that ICP-MS does not appear to be a 
successful approach to monitoring the PCR process.  However it is believed that, in 
conjunction with PCR, ICP-MS may be a useful tool in the study of metal interaction 
in DNA replication processes.  The exposure of cells, either accidentally (through 
occupation for example) or intentionally (i.e. through medication) to complexes of As, 
Cr, Cd, Ni and Pt can lead to nucleic acid interaction causing disruption to replication 
processes.  A similar exposure to nucleic acid fragments in a PCR process, which is 
monitored by ICP-MS, may provide useful information.  Such information could be 
related, to a certain degree, to the inhibition of DNA replication processes in the 
human body on exposure to such metals.  Further work in this area could be fruitful in 
anti-cancer research. 
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3.7.  The Study of Single Nucleotide Polymorphisms by 
HPLC-ICP-MS 
 
The cause and progression of a disease in humans is mostly influenced by 
environmental factors and lifestyle as well as genetics.  The “genetic background” of 
an individual is responsible for susceptibility to infectious or auto-immune diseases so 
changes in nucleic acid sequence can have far reaching effects and it is thought that 
certain changes can influence the manifestation and course of a disease.148  In the case 
of the work described in this section the potential of an individual to develop a disease 
based on the genetic background, i.e. nucleic acid sequences, is the issue of 
importance.  The ability to determine changes, or mutations, in nucleic acid sequences 
is, therefore, one of the most important tools available in genetic research.151 
 
The majority of these changes are in the form of a single nucleotide polymorphism 
(SNP).  SNP is a small genetic variation that can occur within a nucleic acid sequence 
whereby one nucleotide base is substituted for another (for example an A base could 
be changed to a G, T or C base), a base is deleted from the sequence or a base is 
inserted into the sequence.  Because genetic background is linked to certain diseases it 
is believed that certain SNP’s can predispose an individual to a disease and possibly 
influence drug efficacy.  For these reasons it is desirable to be able to determine 
changes in nucleic acid sequence and research into this area is fruitful with regard to 
forecasting illness. 
 
A popular approach to the detection of SNP’s is polymerase chain reaction single 
strand confirmation polymorphism (PCR-SSCP) which has so far proved to be an 
effective method.148  PCR-SSCP involves amplification of nucleotide sequences 
followed by separation via electrophoresis and detection by autoradiography or 
ethidium bromide or silver staining.148  HPLC has also been employed in the study of 
SNPs.152  The aim of the work in this section was to employ the 31P methods 
developed in sections 2.4.2 to 2.4.5 to the study of SNP’s.  The development of an in 
vitro method to separate and detect specific nucleotide sequences that differ according 
to variations in single, or a small number of, bases by HPLC-ICP-MS may reveal an 
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alternative approach to the analysis of SNP’s.  Such a method may be faster than 
PCR-SSCP and allow a higher throughput of samples. 
 
 
Experimental Details 
 
Two oligonucleotide molecules (25 bases in length, see Table 18) differing by one 
base were separated using on-line anion exchange HPLC-ICP-MS.  Such a coupling 
has been extensively employed in the analysis of nucleic acids.  From such an 
analysis both UV data (via presence of chromophore groups) and mass spectrometric 
data (via measurement of the 31P isotope content) was obtained during detection. 
 
 
Table 18.  The Oligonucleotide Sequences Studied by HPLC-ICP-MS. 
Oligonucleotide 
Identification Number 
Oligonucleotide Sequence (5’ to 3’) Molecular 
Mass 
2 TGA AGA AAT TCA GTT CAT AGC TTG T 7696 
3 TGA AGA AAT TCA GTT CAT AGC TTG G 7721 
 
 
A HP 1090 series 2 HPLC instrument (Agilent) in conjunction with a TSKgel-DNA-
NPR anion exchange column (Tosoh Bioscience, Germany.  7.5 cm x 4.6 mm, 2.5 µm 
particle size) was employed in the separation of the oligonucleotides.  This instrument 
was directly coupled to the PQ ExCell ICP-MS (operated under time resolved analysis 
(TRA) mode) which employed methods 2 and 4 for the detection of 31P during two 
separate analyses, see Tables 84 and 85 (Appendix 3) for general instrument 
parameters.  Chromatographic conditions employed can be seen in Table 19.  The 
separation of oligonucleotides used here was developed by Miss S. L. Kerr of the 
Loughborough University atomic spectroscopy research group. 
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Table 19.  Chromatographic Conditions Employed During the Study of Oligonucleotide 
Sequences by HPLC-ICP-MS. 
Parameter Description 
Mobile Phase Composition A = 20 mM Tris-HCl, pH 9 
B = 20 mM Tris + 0.3 M Citrate + 0.1 M NH4Cl, pH 9 
Mobile Phase Flow Rate (ml min-1) 0.7 
Sample Injection Volume (µl) 5 
UV Detector Wavelength (nm) 257 
Time (min) % B 
0 40 
Mobile Phase Gradient 
15 100 
Stop Time (min) 17 
Post Time (min) 4 
 
 
Prior to analysis oligonucleotide samples (Invitrogen, Paisley) were diluted in 20 mM 
Tris-HCL buffer (pH 9) to a concentration of 10 µM. 
 
 
Results and Discussion 
 
Of the two analyses carried out the first, employing method 2, was successful (with 
regard to both UV and ICP-MS detection) with complete resolution of the two peaks 
well above the background.  For the second analysis, that employing method 4, the 
UV detection was successful but neither of the emerging peaks was visible above the 
background signal for the ICP-MS detection.  It would appear that in this case the 
formation of the 31P16O+ ion was being suppressed due to the introduction of the 
mobile phase into such a low forward power plasma.  Over the time period studied for 
this separation, for both analyses, the background signal rose with the increasing 
concentration of mobile phase B introduced to the anion exchange column.  The 
reason for this was an increase in the formation of interfering polyatomic ions, present 
at m/z = 47, as a result of an increasing contribution of N and O isotopes from the 
mobile phase.  For the first analysis, employing method 2, the UV and ICP-MS 
chromatograms can be seen in Figures 46 and 47. 
 
 155
 Figure 46.  The UV Chromatogram of Oligonucleotides 2 and 3 Separated and Detected by 
HPLC-ICP-MS (Absorbance Versus Retention Time (Minutes)). 
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Figure 47.  The ICP-MS Chromatogram of Oligonucleotides 2 and 3 Separated and Detected by 
HPLC-ICP-MS. 
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The retention times and resolution of peaks for the two separated oligonucleotides, 
from UV and ICP-MS data, are highlighted in Table 20.  There is an additional effect 
that should be noted here.  The ripple of the m/z = 47 signal trace of Figure 47 is due 
to the fluctuation of sample introduction via the peristaltic pump.  This effect becomes 
more noticeable as the experiment time increases. 
 
 
Table 20.  Retention Times Acquired Following the Study of Oligonucleotides by HPLC-ICP-MS 
Employing Method 2. 
 Retention Time (min) 
Oligonucleotide Identity 
Number 
Method 2 
UV 
Method 2 
ICP-MS 
2 15.18 15.12 
3 15.95 15.90 
Resolution 0.96 1.03 
 
 
As can be seen in Table 20 the UV and ICP-MS data acquired following this analysis 
agree with regard to the retention time of each oligonucleotide passed through the 
anion exchange column.  This analysis is a good example of the application of one of 
the methods developed and described in Chapter 2.  Again, however, the success of 
this analysis was based on the prevalence of 31P in the sample and, considering the 
background signals observed during this work, ultra-trace levels of the 
oligonucleotides would not be compatible with the method conditions. 
 
Of the two analyses carried out that employing method 2 showed promise with regard 
to the analysis of SNP’s.  Although this was a simple experiment studying short chain 
nucleotides, with appropriate pre-treatment and separation processes in place HPLC-
ICP-MS could be a useful tool in the study of SNP’s in vivo. 
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3.8.  Conclusions for the Application of 31P and 32S ICP-MS 
Methods 
 
It has been shown through the work described in this chapter that quadrupole based 
ICP-MS is promising with regard to the analysis of DNA via the measurement of the 
31P isotope. 
 
The simple analysis of DNA in a water matrix revealed that such a biological 
molecule can be studied without any problematic non-spectroscopic interferences.  
However, when considering ‘real’ biological samples, containing DNA, the matrix 
involved would be far more complicated so such interferences would be a significant 
issue.  Either DNA would be analysed as a sample close to that of its native form or as 
a component following a separation approach.  Either way the molecule of interest 
would be present within a sample rich in elements that would cause problems.  For the 
sample close to its native form such elements may be Na or K which could cause 
signal degradation via blockage of the skimmer cone.  31P contamination would also 
be an issue in such a sample from a number of sources, for example proteins.  For the 
sample prepared following a separation process, such as HPLC, the DNA molecule 
may be present in a mobile phase or other eluent containing a high concentration of C, 
N and O containing species that would contribute to a high level of interfering 
polyatomic ions. 
 
For the latter type of sample (that within a mobile phase or eluent) the background 
signals associated with the analysis carried out into the DNA within an agarose gel 
and the SNP’s analysis demonstrated that such ‘real’ samples may be problematic.  
However, given a sufficient concentration of 31P within such a sample then ICP-MS 
analysis would be satisfactory due to the elevated signal to background ratio.  
Difficulties may arise if the requirement of the sample was measurement of 31P at 
trace levels specifically. 
 
Overall, through the work described in Chapter 2 and this applications chapter and 
previous research carried out by other groups, it can be said that ICP-MS has the 
potential to provide useful data from the analysis of the nucleic acids and associated 
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biological species containing 31P.  Although the matrix of such samples may be 
problematic on introduction to the ICP ion source, and with regard to sample and 
skimmer cone deposition, such elemental data would be valuable to the genomics 
field. 
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4.1.  Disease and Metal Based Complexes 
 
Over the past seventy years studies have been carried out relating the chemical 
structure and therapeutic efficacy, or toxicity, of metal based complexes with regard 
to various diseases.153  Amongst other elements, complexes of Au,154-156 Cu,156 Fe,157 
Ga,157 Pd,153, 158-160 Pt,153-156, 158, 159, 161-163 Rh,164 Ru,153, 156, 164-166 Sn,167, 168 Ti155 and 
Zn156 have been studied for therapeutic benefit particularly in the fields of alzheimer’s 
disease, arthritis, cancer diseases and malaria.  There are many examples of metal 
based complexes that are employed in the treatment of cancers, of these there are 
several based on Pt employed in cancer chemotherapies.  ICP-MS is therefore an ideal 
analytical technique that can be, and has been, employed in the qualitative and 
quantitative measurement of such metal based complexes in numerous types of 
sample matrix. 
 
 
4.2.  Cancer and Cancer Treatments 
 
Although loosely defined as the growth of cells without the restraints that regulate 
normal tissue growth, a cancer is a disease not easily categorised.169  A cancer can 
evolve in any organ of the body initiated by various factors.  Interaction with 
carcinogenic chemicals, industrial pollutants, radiation, oncogenic viruses and 
parasitic infection can be the cause of uncontrolled growth as can dietary factors, 
genetic predisposition and the aging process.169 
 
Surgery, radiotherapy and chemotherapy have all proved to be effective treatments for 
cancer being used either individually or in combination depending on the type of the 
disease and on how far it has progressed.  However, such treatments can be 
particularly difficult for the patient with radiotherapy and chemotherapy, particularly, 
exhibiting some harsh side effects.  Although such approaches can be successful in 
the treatment of tumours they cannot guarantee the total eradication of a cancer as, in 
theory, if one cancer cell survives then uncontrolled growth can continue through the 
replication of that single cell.  Metastasis (the spreading of a tumour resulting in the 
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formation of secondary tumours in other parts of the body) is also a significant 
problem that makes tackling the occurrence of a cancer far more complex.169 
 
The ultimate requirement of an anticancer drug (chemotherapy) is that it eliminates 
tumour cells at doses that allow the survival of a sufficient number of healthy cells in 
critical tissues, such as bone marrow and the gastrointestinal tract.169  The search for 
drugs that are capable of either destroying a greater number of tumour cells than 
healthy cells, or differentiating between the two completely, is ongoing and for many 
types of cancer the survival rate following diagnosis is steadily improving.  With 
regard to chemotherapies, currently there are several approaches to the limitation of 
tumour growth or the termination of tumour cells.  Alkylating agents, antimetabolites, 
antibiotics and hormones have all proved to be beneficial treatments with their 
success dependent on the properties of a tumour and its location. 
 
Prior to the discussion of the research carried out for this chapter, what follows is a 
description of two Pt based anti-cancer complexes that are in common use today as 
well as a summary of some of the previous work by other researchers that has been 
carried out into them. 
 
 
4.2.1.  Cisplatin 
 
Approved for clinical use by the Food and Drug Administration (FDA) in 1978 cis-
diamminedichloroplatinum (II), or cisplatin, is described as a first generation anti-
cancer drug that is still used regularly today.  Successful use of this drug has been 
observed in the treatment of testicular, cervical, ovarian, head, neck and oesophageal 
cancers.155, 156, 164, 170-173  Composed of a Pt atom, two amine groups and two Cl atoms 
in the cis isomer configuration (see Figure 48), cisplatin is a simple molecule.  The 
success of this drug lies in its binding to nucleic acid molecules within cancer cells, 
particularly DNA, followed by the inhibition of replication and transcription 
processes, cell cycle arrest and apoptosis.156, 164, 170, 174 
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Figure 48.  A Structural Diagram of Cisplatin. 
 
 
Despite its successes, cisplatin suffers limitations in that it binds to many biological 
cell components not just the nucleic acid target.  The drug is known to react with 
cellular proteins, cell membrane phospholipids and cytoskeleton microfilaments.162  
Cisplatin treatment is also hindered by resistance problems, see section 4.2.5.  The 
result of these limitations is that a patient must be exposed to high drug doses in order 
to obtain the desired effect, such that μg l-1 levels of cisplatin are typically observed in 
patient blood samples following treatment.171  There are further limitations, however, 
in that the administration of high doses can lead to neurotoxicity.  Due to this, large 
numbers of patients are unable to complete a full cisplatin therapy.172 
 
The result of this is a very difficult experience for the patient.  The reaction of the 
human body to such a treatment includes nausea, vomiting and elevations in blood 
urea nitrogen and creatine levels.  Renal toxicity is common in many patients but this 
can be overcome with hydration therapy followed by diuresis.  These physical 
problems limit the dose of cisplatin, that can be received by a patient, which is 
typically an intravenous injection of 50 – 120 mg/m2 every three to four weeks for the 
duration of the treatment.162, 171  Not only is the use of cisplatin limited by the side 
effects that it inflicts but the development of an acquired resistance, by the patient, to 
the drug can be problematic. 
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4.2.2.  Oxaliplatin 
 
trans-L-diaminocyclohexaneoxalatoplatinum (II), or oxaliplatin, is a third generation 
anticancer drug that is successfully used in the treatment of colorectal cancers.175-178  
An analogue of cisplatin, oxaliplatin is a slightly more complex molecule being 
composed of a Pt atom linking an oxalic group with a cyclohexane ring and two 
amine groups, see Figure 49.162, 164, 173, 176  Similar to cisplatin, the success of oxaliplatin 
lies in the binding of the drug molecule to nucleic acid molecules of cancer cells 
leading to the inhibition of cellular replication processes and apoptosis.173 
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Figure 49.  A Structural Diagram of Oxaliplatin. 
 
 
For some types of cancer, oxaliplatin treatment has proved to be an excellent 
alternative to that of cisplatin as it exhibits a broad spectrum of antitumour activity in 
tumours that are intrinsically cisplatin resistant.173, 175-177  With regard to clinical 
toxicity, oxaliplatin is a less severe drug than cisplatin so for certain types of tumour 
its use would be preferential for the patient.178  Previous study has shown that 
oxaliplatin is at least as successful as cisplatin in the instigation of apoptosis, 
however, recent data suggests that fewer drug-DNA adducts are formed by oxaliplatin 
and that it is simply more efficient at inducing cell death.175, 176  For this reason, drug 
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doses (lower than those for cisplatin) can be administered to patients to obtain a 
beneficial effect.  Following the success of oxaliplatin as an alternative therapeutic 
agent the search has continued for analogues that could provide a greater degree of 
efficacy with a reduction in side effects.  So far a number of promising molecules 
have been synthesised and tested, a number of these exhibiting additional side chains 
to the cyclohexane ring.  However, an analogue exhibiting vastly superior efficacy 
and safety to the patient is yet to be discovered.179 
 
 
4.2.3.  Types of Drug-Target Interaction Exhibited by Cisplatin and 
Oxaliplatin and Other Metal Based Drug Complexes 
 
As mentioned in sections 4.2.1 and 4.2.2, the primary target for both cisplatin and 
oxaliplatin drugs is DNA, this is also the primary target of many other metal based 
drug complexes.  The interaction between these drug and target species results in the 
formation of adducts that are known to disrupt the DNA transcription and translation 
processes and it is widely believed, without repair, can therefore bring about apoptosis 
(programmed cell death).162, 176  The main type of interaction that can take place 
between these drug and target species is that of a covalent binding or cross linking.  
There are two types of such binding and these are described shortly.  Other, minority, 
types of binding are also considered. 
 
Covalent binding, or cross linking, between metal based drugs and the constituent 
base molecules of their DNA target is a very important process and certainly in the 
case of cisplatin and oxaliplatin such binding is believed to be the dominant 
interaction between the species.  As metal centres are positively charged they favour 
binding to biomolecules that are negatively charged.  Sections of proteins and nucleic 
acids, for example, act as ideal binding targets.156  Such binding involves a chemical 
change of the drug molecule following passage into the cell, during which the 
environmental chloride concentration drops.162  In the case of cisplatin, once inside 
the cell, the molecule undergoes hydrolysis resulting in the formation of the activated 
cis-[Pt(NH3)2Cl(OH2)]+ ion which is more readily capable of reaction with the DNA 
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target.162  For the oxaliplatin drug molecule it is believed that, once inside the cell, the 
oxalic group is replaced by two Cl atoms that are then, themselves, replaced by H2O 
molecules.176  Therefore it is suggested that the activated form of oxaliplatin, within 
the cell, is [Pt(H2O)2(NH2)2C6H8]2+.176 
 
Such adducts can form between bases on the same DNA strand (intrastrand binding) 
or bridging from one strand to another (interstrand binding).162  It has previously been 
shown (via enzymatic digestion of cisplatin treated salmon sperm DNA, 
chromatographic separation of the digested components and 1H NMR analysis) that 
the most common forms of cisplatin-DNA and oxaliplatin-DNA adduct are that 
whereby the Pt atom binds between two guanine (G) bases or one guanine and one 
adenine (A) base, i.e. the purine bases, within the same DNA strand (intrastrand).156, 
162, 173, 175, 180  Such binding can be seen in the diagrams of Figures 50 and 51.173, 180, 181 
 
 
DNA Double Helix 
Section
A
Pt
G
NH3
NH3
G
Pt
G
NH3
NH3
A Pt G
NH3
NH3
G Pt G
NH3
NH3
Intrastrand binding of a cis-diammine Pt adduct between 
adenine (A) and guanine (G) DNA base molecules
Intrastrand binding of a cis-diammine Pt adduct 
between two guanine (G) DNA base molecules
Interstrand binding of a cis-diammine Pt adduct between 
adenine (A) and guanine (G) DNA base molecules
Interstrand binding of a cis-diammine Pt adduct 
between two guanine (G) DNA base molecules
 
Figure 50.  A Diagram of the Most Common Binding Interactions between cis-diammine Pt 
Adducts and the Purine Molecular Bases of a DNA Strand (Not to Scale). 
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Figure 51.  A Diagram of the Most Common Binding Interactions between (trans-R,R)-diamino-
cyclohexane Pt Adducts and the Purine Molecular Bases of a DNA Strand (Not to Scale). 
 
 
Intercalation between a drug and its DNA target has proved to be a highly successful 
approach to the formation of drug-target adducts that can lead to interference with 
cellular replication processes.  A large number of intercalating agents have been 
identified (e.g. proflavin, ethidium, actinomycin D, daunomycin and adriamycin) that 
exhibit a common structural characteristic, the presence of a planar polycyclic 
aromatic chromophore.164, 182  It is this polycyclic aromatic structure that can be 
inserted between adjacent base pairs of the target DNA helix, acting as the initial 
component for the interaction which takes place between the molecule and adjacent 
base pairs via van der waals forces and electrostatic stabilisation.182, 183  Further 
chemical components that reside within the drug molecule are also influential with 
regard to the degree of interaction between drug and target by this approach.182  The 
study of intercalating agents that include a metal atom(s) as part of their structure is 
ongoing.  Researchers have proposed and developed a number of metal based 
molecules exhibiting intercalating structures that interact with the DNA target.182  
Neither cisplatin nor oxaliplatin molecules exhibit a polycyclic aromatic structure so 
their ability to interact with DNA by this intercalative approach would be nil, however 
 167
some Pt based intercalating drugs have been developed that exhibit enhanced 
antitumour activity.156 
 
Intercalation is an example of a non-covalent binding between drug and DNA target.  
Other types of drug are available that interact with the DNA target in a different way 
but do not bind covalently, such interactions take place via hydrogen bonding with 
base pairs.183 
 
 
4.2.4.  The Effect of Cisplatin and Oxaliplatin Binding on DNA 
Structure 
 
The formation of drug-DNA adducts, following cisplatin or oxalipatin treatment, has 
been shown by NMR and X-ray crystallography to lead to the distortion of sections of 
the DNA molecule.162  Such distortion can exist in the form of either bending of the 
helix molecule or a change in the degree of twisting, or untwisting, of the DNA 
strands (or both).156, 162, 164, 180  Such distortions contribute a rigidity to these affected 
sections that, it is believed, lead to the hindrance of the DNA strand winding and 
unwinding involved in the replication processes. 
 
 
4.2.5.  DNA Repair Mechanisms and Drug Resistance 
 
Similar to many pharmaceutical compounds, one of the main reasons for the failure of 
a cisplatin or oxaliplatin treatment is the resistance of cancer cells to the action of the 
drug molecules.  Resistance to cisplatin or oxaliplatin by cancer cells can be either 
inherent or acquired following initial exposure (such as in the case of ovarian 
cancer).162, 173  The degree of resistance of a cell to the drug treatment is best 
described in terms of that cell’s ability to repair itself following exposure or to 
detoxify itself.  The recognition of the problem of cisplatin resistance spurred the 
study of the cytotoxicity of molecular analogues in order to develop different Pt based 
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drugs without such a limitation.  Oxaliplatin is one such analogue and does not exhibit 
treatment resistance to such a degree. 
 
As mentioned in section 4.2.4, when a cisplatin-DNA or oxaliplatin-DNA adduct is 
formed the structure of that section of the DNA molecule is changed.  Although such 
structural changes are desired with regard to inhibition of cellular processes, to bring 
about cell death, they also provide a site for the action of repair mechanisms.173  
Previous studies on yeast and mammalian cells have shown that the drug-DNA 
adducts formed following exposure can be recognised and acted on by nucleotide 
excision repair, recombination repair and translesion DNA synthesis pathways that 
can lead to the removal of adducts and the restoration of the DNA molecule.156, 170, 173  
Cells have a degree of ability to detoxify themselves following penetration by foreign 
molecules.  In the case of Pt based drug molecules this can be mediated by glutathione 
or metallothionein.175 
 
The progress and efficiency of these pathways is dependant on the type of DNA 
bound drug molecule, hence the difference in degree of resistance between cisplatin 
and oxaliplatin. 
 
 
4.2.6.  Cancer Treatments and Drug Efficacy 
 
The treatment of a patient with any kind of drug will result in side effects.  For many 
drugs such side effects are not noticeable but in the case of certain cancer treatments 
they can be very severe.  Therefore, when treating cancers by chemotherapy, drug 
efficacy must be weighed up against potential negative effects.  There are two 
significant issues that must be considered when deciding to expose a harsh anticancer 
drug (such as cisplatin or oxaliplatin) to a patient, these are drug efficacy and drug 
resistance.  The drug efficacy of cisplatin and oxaliplatin varies considerably from 
patient to patient though it remains very low.  The reason for such variation lies in 
physiological differences, i.e. the person to person differences in DNA sequence (the 
drug molecule target).  Drug efficacy is also significantly affected by the second issue 
of drug resistance (see section 4.2.5).  It would therefore be very useful to the 
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clinician to have drug efficacy data for an individual patient prior to, or soon after, 
exposure to establish the best course of tackling a cancer that would typically be 
treated by cisplatin or oxaliplatin.  However, a fast and low cost test to establish such 
data for individual patients is currently not available. 
 
 
4.2.7.  Previous Studies of Cisplatin and Oxaliplatin Exposure to 
DNA 
 
A number of researchers have conducted studies into the destination and modes of 
action of both cisplatin and oxaliplatin following drug administration.  Research has 
also been carried out to study the problem of resistance to these drugs and to establish 
how much of each drug species is required to bring about apoptosis.  One of the 
results of this type of research has been the further study of cisplatin and oxaliplatin 
analogues, the aim of which being the development of drug molecules that are just as 
efficient in causing apoptosis but with a reduced degree of cellular resistance and side 
effects.  Such research has made good use of a wide range of analytical techniques, 
some of which is described as follows. 
 
As was mentioned in section 4.2.3 there are a number of ways in which the cisplatin 
and oxaliplatin drugs, as well as their analogues, can interact with the primary target 
DNA.  To confirm that the formation of drug-DNA adducts takes place following 
exposure elemental analytical techniques such as atomic absorption spectrometry 
(AAS), inductively coupled plasma mass spectrometry (ICP-MS) and inductively 
coupled plasma optical emission spectrometry (ICP-OES) have all been employed via 
the measurement of Pt isotopes.158, 159, 175, 184 
 
The types of drug-DNA binding and the resulting adduct structures have previously 
been established via NMR and X-ray crystallography.159, 161, 162, 173, 185  The data 
accrued from such work has allowed researchers to associate cytotoxicity with both 
drug and adduct structures allowing the comparison of cisplatin and oxaliplatin and 
their analogues.  The interactions between cisplatin and some cellular components 
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have previously been quantified by radiochemical methods.  195Pt-radiolabeled 
cisplatin was exposed to HeLa cells at the mean lethal concentration during studies by 
Akaboshi et al.186  After exposure periods of 1, 2 and 3 hours the distribution of the 
radiolabeled cisplatin was determined in DNA, RNA and protein components by 
scintillation counting.  From the data accrued during this analysis it was determined 
that at the mean lethal concentration approximately 9 Pt atoms bind to each DNA 
molecule.  Similar data has also been published by Harder et al and Howle et al 
stating that approximately 22 Pt atoms bind to each DNA molecule.162 
 
When considering the treatment of patients with cisplatin or oxaliplatin, at the 
molecular level, there are two major factors that must be appreciated.  The first of 
these factors considers how the drug molecules pass through the cell membrane to 
reach their binding target.  This passage takes place via passive diffusion rather than 
some type of active transport involving the use of energy.156, 184  Therefore, there must 
be a limit to the quantity of drug species that can pass into a cell according to the 
equilibrium of a diffusion process.  This is one reason for the requirement of high 
doses of cisplatin and oxaliplatin being administered to patients. 
 
The second factor that must be considered is that these foreign drug molecules do not 
simply seek out their DNA binding target without interaction with other intra- and 
extra-cellular species.  Following study by various analytical techniques, it has been 
shown that these drug molecules also have an affinity for numerous intra- and extra-
cellular species that are encountered prior to meeting the cell nucleus, following 
exposure.174, 186  Phospholipids, peptides, oligosaccharides and cholesterol are just 
some of the biomolecules that can offer potential binding sites to metal based drug 
species.174  Cisplatin and oxaliplatin are also known to interact with haemoglobin 
causing structural changes which can result in severe side effects for the patient, such 
as anemia.171, 187 
 
The issue of drug resistance in molecules of the type discussed in this chapter is one 
of great importance.  Analytical techniques have been employed in the identification 
of cancerous cell lines that do not respond to drug treatment as efficiently as others.  
Such work allows the evaluation of certain pharmaceuticals with regard to their 
efficacy.  Previously the degree of drug accumulation and binding has been 
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established in numerous types of cell line (some drug resistant and others drug 
sensitive) via elemental analysis techniques such as AAS.175  Cisplatin and oxaliplatin 
resistance and repair mechanisms have been investigated via the study of elevations in 
certain cellular species.  It has recently been suggested that the cellular repair 
mechanisms for cisplatin and oxaliplatin are very similar, although they differ in their 
degree of cytotoxicity.175 
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4.3.  Aims of Research 
 
Researchers at Leicester University are investigating the interaction between the Pt 
based complexes cisplatin and oxaliplatin and their biological target DNA.  The 
overall aim of their work is to establish a clinical test to determine the efficacy of 
these drugs for individual patients.  Such a test would prevent the unnecessary 
exposure of these drugs to patients that would not benefit significantly. 
 
The study of metal based drugs in cancer chemotherapies is an area of research that 
can take advantage of the low limits of detection in analysis by ICP-MS with or 
without the use of radiolabels.  Previous study by ICP-MS has shown that biological 
samples, such as whole DNA molecules, may be analysed without difficulty via 
nebuliser and spray chamber sample introduction.  In collaboration with researchers at 
Leicester University, it was proposed that ICP-MS could be employed in the study of 
the drug/target interaction.  If, following such study, it was determined that ICP-MS 
was sensitive enough to measure the presence of Pt in a sample at clinical levels then 
the degree of binding could then be calculated and a clinical test established. 
 
Prior to the commencement of work towards this aim, the idea of separating drug 
exposed DNA by electrophoresis followed by LA-ICP-MS was floated.  Although 
such an approach may allow a fast analysis time for an established test, it was decided 
that for initial work there would be too many complications.  Therefore the work 
carried out to meet the aims described above was based on the interaction between 
drug and target in solution.  The simultaneous measurement of 31P (via the methods 
established in Chapter 2) and 190,192,194,195,196,198Pt isotopes would allow their signal 
ratios to be used in a calculation to determine a binding constant.  Such a binding 
constant may be used as the basis of a clinical efficacy test. 
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4.4.  The Study of DNA and Pt Based Drug Interactions In 
Vitro by ICP-QMS 
 
A significant degree of experimentation was carried out on determining the interaction 
of cisplatin and oxaliplatin with their DNA target by measurement of the 31P and 
190,192,194,195,196,198Pt isotopes by ICP-QMS.  Divided into five studies, this 
experimentation is described as follows. 
 
 
4.4.1.  Study 1 
 
Initial experiments were carried out to determine the 31P and 190,192,194,195,196,198Pt 
isotope content of a series of DNA samples exposed to varying concentrations of 
cisplatin (in vitro) by ICP-QMS.  The main aim of this initial experimentation was to 
evaluate the capability of the PQ ExCell ICP-QMS instrument with regard to the 
analysis of such samples.  A concentration of 0.5 mg ml-1 was originally agreed, on 
between researchers of both Leicester and Loughborough Universities, as being 
appropriate for the DNA samples studied during this work with regard to both 
drug/target binding and ICP-MS analysis.  Typically, such a sample concentration 
would be considered as high for routine ICP-MS analysis so this initial work would 
establish the presence of any matrix effects. 
 
 
Experimental Details 
 
For this study of Pt based drug and DNA target interaction the experimental detail is 
very extensive.  These experimental details could be considered in two parts, the first 
describing sample preparation (carried out by researchers at both Leicester and 
Loughborough Universities) and the second describing instrumental analysis (carried 
out at Loughborough University). 
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Prior to sample preparation certain information obtained by calculation was required.  
Firstly, the binding between drug and DNA was based on the mean molecular weight 
of a nucleotide.  This mean molecular weight has, initially, been calculated to be 
325.61 after multiplying nucleotide molecular weight with nucleotide abundance for 
each and dividing the total obtained by 100.  This mean nucleotide molecular weight 
assumes that the majority of nucleotides that are being studied are in a free state.  In 
this work however, this is not the case.  The bulk of our DNA nucleotides are bound 
in a polymer form and if nucleotides were to polymerise via the combination of one 
nucleotide at the three prime end and the phosphate linking group attached to the five 
prime end of another then the result would be the elimination of a water molecule 
(molecular weight equal to 18).  So, a molecular weight of 18 is subtracted from 
325.61 to give a final mean molecular weight of a DNA nucleotide as 307.61. 
 
As genetic variation ensures that DNA sequence is different between individuals there 
is no accepted molecular weight for a DNA molecule.  So, for the sake of this work 
DNA is described in terms of constituent nucleotides of which molecular weight is 
known.  It is believed that the therapeutic region for these types of Pt based drugs, 
with respect to their DNA target, is one drug molecule to 400 000 DNA nucleotides 
(this therapeutic level is set out and discussed in Carcinogenesis, 1997, 18, 9, 1767-
1774).  To assess the capability of the ICP-QMS a series of samples were prepared for 
analysis with the aim of achieving ratios of drug molecule to nucleotide 
approximately equivalent to a range of 1 : 100 to 1 : 1 000 000 to buffer the 
therapeutic region.  Details of the preparation of these samples are in Table 21. 
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Table 21.  Preparation Details for the Samples Investigated During Study 1. 
Solution 
Number 
Solution Description Procedure Nucleotide 
Concn (μM) 
Cisplatin 
Concn (μM) 
Drug : 
Nucleotide Ratio 
      
Stock Solutions 
1 DNA Stock Solution DNA (1 mg in 1 ml) 3250 - - 
2 Cisplatin Stock Solution Cisplatin (1 mg in 1 ml) - 3330 - 
      
Cisplatin Preparative Solutions 
3 10 Fold Dilution of Soln 2 with H2O - 333 - 
4 10 Fold Dilution of Soln 3 with H2O - 33.3 - 
5 10 Fold Dilution of Soln 4 with H2O - 3.33 - 
6 10 Fold Dilution of Soln 5 with H2O - 0.333 - 
7 
 
Serial Dilution of 
Cisplatin Stock Solution 
10 Fold Dilution of Soln 6 with H2O - 0.033 - 
      
Final Sample Solutions 
8 Soln 1 (2600 μl) + Phosphate Buffer (100 μl) + H2O (2300 μl) - - Control 
9 Soln 1 (2600 μl) + Phosphate Buffer (100 μl) + Soln 3 (300 μl) + H2O (2000 μl) - - 1 : 100 
10 Soln 1 (2600 μl) + Phosphate Buffer (100 μl) + Soln 4 (600 μl) + H2O (1700 μl) - - 1 : 500 
11 Soln 1 (2600 μl) + Phosphate Buffer (100 μl) + Soln 4 (300 μl) + H2O (2000 μl) - - 1 : 1 000 
12 Soln 1 (2600 μl) + Phosphate Buffer (100 μl) + Soln 5 (600 μl) + H2O (1700 μl) - - 1 : 5 000 
13 Soln 1 (2600 μl) + Phosphate Buffer (100 μl) + Soln 5 (300 μl) + H2O (2000 μl) - - 1 : 10 000 
14 Soln 1 (2600 μl) + Phosphate Buffer (100 μl) + Soln 6 (600 μl) + H2O (1700 μl) - - 1 : 50 000 
15 Soln 1 (2600 μl) + Phosphate Buffer (100 μl) + Soln 6 (300 μl) + H2O (2000 μl) - - 1 : 100 000 
16 Soln 1 (2600 μl) + Phosphate Buffer (100 μl) + Soln 7 (600 μl) + H2O (1700 μl) - - 1 : 500 000 
17 
 
 
 
Final Sample 
Preparation, Exposure 
of Solution 1 to 
Solutions 3 to 7 
Soln 1 (2600 μl) + Phosphate Buffer (100 μl) + Soln 7 (300 μl) + H2O (2000 μl) - - 1 : 1 000 000 
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As described in Table 21 a DNA solution was used as the basis for exposure of 
nucleotides to varying concentrations of cisplatin.  DNA nucleotide samples (3250 
μM) were exposed to the cisplatin solutions at Leicester University by Dr Rachel Le 
Pla and transported to Loughborough University for study.  Calf thymus DNA (Sigma 
Aldrich) was dissolved in deionised water and exposed to the cisplatin, of varying 
concentration, for a period of 24 hours.  Different volumes of the cisplatin solutions 
were used in order to prepare the desired exposed DNA nucleotide samples.  The 
exposed DNA was then precipitated and washed twice with ethanol to remove 
unbound drug molecules prior to being redissolved in deionised water (≈ 5 ml).  Each 
sample was prepared in duplicate.  Following preparation the amount of recovered 
DNA was calculated using OD260.  The details of sample preparation and DNA 
recovery are seen in Table 87.  From the original exposed DNA sample solutions, a 
series of P and Pt spiked samples were prepared in order to study the interaction 
between drug and target via a standard additions approach (see Table 87 for spiked 
sample details).  Five solutions were evolved for each sample duplicate at this point 
incorporating a one hundred fold dilution, see Table 87 (Appendix 4), with a 
deionised water diluent. 
 
The instrument used in analysis of the samples was as described previously in this 
thesis, see sections Chapters 2 and 3.  A Micromist (100 µl min-1) nebuliser and a 
silica impact bead spray chamber were used.  ICP-MS 31P determination Method 2, as 
described in section 2.4.2, was employed in the analysis of the DNA/Cisplatin 
samples prepared for the study of the 31P and 190,192,194,195,196,198Pt isotopes.  External 
standards of P and Pt were prepared from 1000 µg ml-1 single element standard 
solutions (Fisher Chemicals, Loughborough, UK) by sequential dilution with high 
purity deionised water produced using a Maxima Ultra (Elga) water purification 
system.  Measurements were conducted using a peristaltic pump to introduce sample 
solutions into the plasma via the nebuliser and spray chamber arrangement.  The ICP-
MS was optimised to produce standard operating conditions (see Table 88, Appendix 
4), from which adjustments were made to accommodate the additional ‘method 2’ 
conditions required.  When the required ICP-MS instrument conditions were 
established the prepared samples were analysed for 31P and 190,192,194,195,196,198Pt 
isotope content.  Data for each of these isotopes was collected by the software of the 
PQ ExCell (Thermo Plasmalab).  Three replicate readings were taken for each isotope 
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measurement allowing mean, standard deviation and relative standard deviation data 
to be established.  Results of the analysis of the samples are given in the next section. 
 
 
Results and Discussion 
 
The mean data generated during the ICP-MS analysis of the DNA/Cisplatin samples 
discussed previously can be seen in Table 89.  From this data a series of standard 
addition graphs were constructed, with a graph for each of the m/z = 47, 194 and 195 
signals per sample.  Due to the large number of graphs produced, examples of graphs 
for each signal are shown in Figures 52 to 54.  The remaining graphs are shown in 
Figures 94 to 141 (Appendix 4).  The curve equations were used to calculate the 31P, 
194Pt and 195Pt concentration associated with each of the samples prepared.  
Quantification of the 31P isotope was carried out via measurement of the 31P16O+ ion 
at m/z = 47 and the 194,195Pt isotopes were looked at specifically as they are the most 
abundant. 
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Figure 52.  A Graph Comparing P Spike Concentration (μg l-1) with m/z = 47 Signal (cps) for 
Sample 1 : 1 000 000 and External Standards. 
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Figure 53.  A Graph Comparing Pt Spike Concentration (μg l-1) with m/z = 194 Signal (cps) for 
Sample 1 : 1 000 000 and External Standards. 
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Figure 54.  A Graph Comparing Pt Spike Concentration (μg l-1) with m/z = 195 Signal (cps) for 
Sample 1 : 1 000 000 and External Standards. 
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Following construction of the graphs in Figures 52 to 54 and 94 to 141 it was clear 
that there were significant quantities of 31P detected in each sample whilst there was 
very little, if any, Pt detected.  Manipulation of the data generated following analysis 
of the prepared samples, by use of the equations associated with the m/z = 47, 194 and 
195 graphs constructed previously, determined the 31P, 194Pt and 195Pt isotope content.  
In the case of a standard additions graph, for the y = mx + c equation, when assuming 
that the y value is equal to zero the resulting negative x value provided the parameter 
of interest.  Here the x value is the desired isotope concentration data.  An alternative 
external calibration approach for the determination of isotope concentration was also 
carried out.  Using these methods the 31P, 194Pt and 195Pt isotope content of each 
sample studied was calculated and can be seen in Tables 22, 23 and 24. 
 
 
Table 22.  31P Isotope Content of the DNA/Cisplatin Samples Studied by ICP-MS. 
Sample 
Identity 
Graph 
Figure 
No 
Sample 
Curve 
Equation 
31P Concn, 
µg l-1  
Stds Curve 
Equation 
31P Concn, 
µg l-1 
   m/z = 47 
Measurement 
(Std Add) 
 m/z = 47 
Measurement
(Ext Cal) 
1:1 000 000 52 y = 56.172x + 15964 284 y = 52.431x + 3267.7 230 
1:1 000 000 (2) 97 y = 84.589x + 15051 178 y = 52.431x + 3267.7 211 
1:500 000 100 y = 102.48x + 21651 211 y = 47.008x + 3858.6 359 
1:500 000 (2) 103 y = 70.529x + 23945 340 y = 47.008x + 3858.6 410 
1:100 000 106 y = 101.81x + 25273 248 y = 48.354x + 3730.7 430 
1:100 000 (2) 109 y = 54.731x + 28762 526 y = 48.354x + 3730.7 514 
1:50 000 112 y = 73.687x + 23839 324 y = 45.916x + 3788.5 451 
1:50 000 (2) 115 y = 53.23x + 25345 476 y = 45.916x + 3788.5 475 
1:10 000 118 y = 86.551x + 31556 365 y = 49.297x + 3648.6 591 
1:10 000 (2) 121 y = 235.17x + 29746 126 y = 49.297x + 3648.6 614 
1:5 000 124 y = 89.018x + 33153 372 y = 51.908x + 3714.6 577 
1:5 000 (2) 127 y = 94.161x + 31183 331 y = 51.908x + 3714.6 496 
1:1 000 130 y = 113.2x + 34475 305 y = 50.664x + 3747 552 
1:1 000 (2) 133 y = 132.3x + 35711 270 y = 50.664x + 3747 602 
Control 136 y = 157.28x + 33357 212 y = 47.179x + 3477.2 590 
Control (2) 139 y = 54.692x + 39836 728 y = 47.179x + 3477.2 777 
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Table 23.  194Pt Isotope Content of the DNA/Cisplatin Samples Studied by ICP-MS. 
Sample 
Identity 
Graph 
Figure 
No 
Sample 
Curve 
Equation 
194Pt 
Concn, µg 
l-1 
Stds Curve 
Equation 
194Pt 
Concn, µg 
l-1 
   m/z = 47 
Measurement
(Std Add) 
 m/z = 47 
Measurement
(Ext Cal) 
1:1 000 000 53 y = 37777x – 12536 - y = 35468x – 71268 2.26 
1:1 000 000 (2) 98 y = 39207x – 3936.6 - y = 35468x – 71268 2.24 
1:500 000 101 y = 40041x - 28533 - y = 39446x – 12578 0.64 
1:500 000 (2) 104 y = 39198x + 21095 0.54 y = 39446x – 12578 0.63 
1:100 000 107 y = 39586x - 33284 - y = 38263x + 23519 - 
1:100 000 (2) 110 y = 38687x + 39574 1.03 y = 38263x + 23519 - 
1:50 000 113 y = 38788x - 35786 - y = 38731x – 48454 1.57 
1:50 000 (2) 116 y = 38702x - 25568 - y = 38731x – 48454 1.45 
1:10 000 119 y = 38518x - 49974 - y = 37094x – 32754 1.34 
1:10 000 (2) 122 y = 38978x - 55141 - y = 37094x – 32754 1.23 
1:5 000 125 y = 35984x - 4085 - y = 36164x – 25204 0.98 
1:5 000 (2) 128 y = 35910x - 12934 - y = 36164x – 25204 1.21 
1:1 000 131 y = 36324x - 24926 - y = 34899x – 22944 1.27 
1:1 000 (2) 134 y = 35019x - 27275 - y = 34899x – 22944 1.15 
Control 137 y = 32496x - 7259.5 - y = 32049x + 9507.1 0.28 
Control (2) 140 y = 32146x - 17847 - y = 32049x + 9507.1 - 
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Table 24.  195Pt Isotope Content of the DNA/Cisplatin Samples Studied by ICP-MS. 
Sample 
Identity 
Graph 
Figure 
No 
Sample 
Curve 
Equation 
195Pt 
Concn, µg l-
1 
Stds Curve 
Equation 
195Pt Concn, 
µg l-1 
   m/z = 47 
Measurement 
(Std Add) 
 m/z = 47 
Measurement 
(Ext Cal) 
1:1 000 000 54 y = 39315x - 10497 - y = 36798x - 67913 2.10 
1:1 000 000 (2) 99 y = 40661x + 735.3 0.02 y = 36798x - 67913 2.07 
1:500 000 102 y = 41710x - 28805 - y = 40993x - 7950.5 0.52 
1:500 000 (2) 105 y = 40797x + 25640 0.63 y = 40993x - 7950.5 0.51 
1:100 000 108 y = 41185x - 31431 - y = 39754x + 28424 - 
1:100 000 (2) 111 y = 40290x + 42108 1.05 y = 39754x + 28424 - 
1:50 000 114 y = 40416x -36083 - y = 40315x - 47456 1.50 
1:50 000 (2) 117 y = 40265x - 23436 - y = 40315x - 47456 1.38 
1:10 000 120 y = 39991x - 50533 - y = 38472x - 27041 1.16 
1:10 000 (2) 123 y = 40400x - 51315 - y = 38472x – 27041 1.05 
1:5 000 126 y = 37380x – 291.01 - y = 37655x – 23798 0.91 
1:5 000 (2) 129 y = 37391x - 11624 - y = 37655x – 23798 1.15 
1:1 000 132 y = 37602x - 18083 - y = 36203x – 16885 1.09 
1:1 000 (2) 135 y = 36509x - 31351 - y = 36203x – 16885 0.96 
Control 138 y = 33887x – 5543.7 - y = 33518x + 9065.1 0.31 
Control (2) 141 y = 33615x - 19251 - y = 33518x + 9065.1 0.02 
 
 
As can be seen from the concentrations of 31P and 194,195Pt present in the samples 
studied there is an abundance of 31P (in each case the concentration measured is 
approximately one tenth of the concentration of DNA present which shows agreement 
with known content) whilst there is no, or little, 194,195Pt.  At first glance the initial 
conclusions are that there were large quantities of DNA present in each solution but 
no Pt based drug, i.e. the suggestion that either no drug binding took place.  However, 
it is more likely that the measurement of Pt isotopes was not compatible with the 
instrument conditions established for the formation of 31P16O+ in the collision cell.  It 
is likely that the majority of Pt ions being transmitted through the hexapole collision 
cell are slowed, destabilised and eliminated following collision with O2 molecules 
under IKEE conditions. 
 182
Due to this absence of Pt in the samples that are expected to be Pt rich aliquots of the 
original most concentrated samples (1 : 1 000 000 and 1 : 500 000) were diluted, this 
time only ten fold, and analysed again.  These measurements revealed no significant 
difference compared to the quantities of Pt present in the hundred fold diluted samples 
originally studied showing that the degree of dilution is not the cause of this issue. 
 
 
4.4.2.  Study 2 
 
Following the initial failure of the ICP-MS study of cisplatin exposed DNA samples a 
second attempt at the analysis was carried out.  This time however, with similarly 
prepared samples, an answer was required as to whether the absence of Pt isotopes in 
study 1 was the result of a lack of drug/target binding or the use of instrumental 
conditions that were not appropriate.  In order to try and answer at least one aspect of 
this question the approach to study of these samples was changed. 
 
For this repeat of the study, however, the measurement of the 31P isotope was 
reconsidered.  As the employment of the collision cell and an O2 reaction gas, for the 
measurement of the 31P16O+ ion, raised a question mark with regard to simultaneous 
determination of Pt isotopes the ICP-MS method was changed.  As, prior to arrival at 
Loughborough University, the concentration of DNA present in each sample was 
determined by UV/Vis analysis it was decided to concentrate on the study of the Pt 
isotopes.  This being the case, to simplify the analysis and limit any non-spectroscopic 
interference arising from the C-based structure of DNA and degree of dissolved 
material, for this repeat analysis the sample treatment following preparation was also 
approached differently.  It was decided to chemically cleave the Pt based drug 
molecules from the target DNA molecules and analyse the drug component alone. 
 
 
Experimental Details 
 
A new series of drug exposed DNA samples, similar to that of study 1, were prepared 
by Dr R. Le Pla at Leicester University and transported to Loughborough University 
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for analysis.  For this second attempt the analysis was again limited to the study of 
cisplatin only.  As with section 4.4.1 the experimental details are discussed in terms of 
sample preparation and instrumental analysis. 
 
A 1 mg ml-1 DNA solution (3.25 mM DNA nucleotide) was exposed to a series of 
three cisplatin solutions of various concentrations, prepared from a 1 mg ml-1 cisplatin 
stock solution (3.33 mM).  Different volumes of the three cisplatin solutions were 
added to 4.223 ml of the 1 mg ml-1 DNA solution (3.25 mM) to prepare a series of 
DNA/cisplatin samples similar to those described in Study 1.  Similar to the previous 
preparation the exposed DNA samples were incubated at 37°C for 24 hours.  The 
exposed DNA was precipitated, washed with ethanol to remove excess drug 
molecules and the precipitated DNA was then redissolved in deionised water.  The 
final sample volume was approximately 5 ml and for this preparation there was no 
duplication of samples.  Details of the full preparation of the samples investigated 
during this second study are in Table 25. 
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Table 25.  Preparation Details for the Samples Investigated During Study 2. 
Solution 
Number 
Solution Description Procedure Nucleotide 
Concn (μM) 
Cisplatin 
Concn (μM) 
Drug : 
Nucleotide Ratio 
      
Stock Solutions 
1 DNA Stock Solution DNA (1 mg in 1 ml) 3250 - - 
2 Cisplatin Stock Solution Cisplatin (1 mg in 1 ml) - 3330 - 
      
Cisplatin Preparative Solutions 
3 1000 Fold Dilution of Soln 2 with H2O - 3.077 - 
4 100 Fold Dilution of Soln 3 with H2O - 0.0308 - 
5 
Serial Dilution of 
Cisplatin Stock Solution 
100 Fold Dilution of Soln 4 with H2O - 0.0003 - 
      
Final Sample Solutions 
6 Soln 1 (4223 μl) + H2O (777 μl) - - Control 
7 Soln 1 (4223 μl) + Soln 3 (500 μl) + H2O (277 μl) - - 1 : 10 000 
8 Soln 1 (4223 μl) + Soln 3 (100 μl) + H2O (677 μl) - - 1 : 50 000 
9 Soln 1 (4223 μl) + Soln 3 (50 μl) + H2O (727 μl) - - 1 : 100 000 
10 Soln 1 (4223 μl) + Soln 3 (10 μl) + H2O (767 μl) - - 1 : 500 000 
11 Soln 1 (4223 μl) + Soln 4 (500 μl) + H2O (277 μl) - - 1 : 1 000 000 
12 Soln 1 (4223 μl) + Soln 4 (100 μl) + H2O (677 μl) - - 1 : 5 000 000 
13 Soln 1 (4223 μl) + Soln 4 (50 μl) + H2O (727 μl) - - 1 : 10 000 000 
14 Soln 1 (4223 μl) + Soln 4 (10 μl) + H2O (767 μl) - - 1 : 50 000 000 
15 Soln 1 (4223 μl) + Soln 5 (500 μl) + H2O (277 μl) - - 1 : 100 000 000 
16 Soln 1 (4223 μl) + Soln 5 (100 μl) + H2O (677 μl)   1 : 500 000 000 
17 
 
 
 
 
Final Sample 
Preparation, Exposure 
of Solution 1 to 
Solutions 3 to 5 
Soln 1 (4223 μl) + Soln 5 (50 μl) + H2O (727 μl)   1 : 1 000 000 000 
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Following this preparation, aliquots (5 μl) of each sample were diluted (to 195 μl in 
H2O) and analysed by UV spectroscopy to determine final DNA concentration, see 
Table 90. 
 
Following preparation, at Leicester University, the samples were subject to further 
pre-analysis treatment for the separation of the bound drug molecule from the target 
DNA.  Each sample (≈ 500 µl) was treated one to one with 25% NH3 (≈ 500 µl) in 
sealed 1 ml centrifuge tubes and heated to 70ºC in a water bath for 48 hours.  As this 
initial step incorporated a two fold dilution, and the resulting 12.5% NH3 solution 
would prove difficult to analyse by ICP-MS, a volume reduction step was employed.  
The caps of each centrifuge tube were removed and each tube was heated at 40ºC in a 
water bath until the volume was reduced to approximately 500 µl.  The aim of this 
step was to evaporate the ammonia and concentrate the samples taking them back to 
close to the original concentration prior to dilution. 
 
The resulting, reduced, solution would contain whole DNA and the cleaved drug 
molecules, these two species therefore required separation prior to ICP-MS analysis.  
Separation was carried out via a centrifuge method.  3 ml VectaSpin 3 centrifuge 
tubes containing a 100 000 MWCO filter were employed, the aim here being to retain 
the large DNA molecules on the filter and allow the cleaved drug molecules to reach 
the tube space beneath during centrifugation.  The approximate 500 µl (accurately 
weighed) of each sample was transferred to a tube and centrifuged at 8000 RPM for 2 
hours.  The solution that passed through the filter of each tube was weighed and 
transferred to a sample vial for analysis.  Details of the pre-treatment carried out on 
each sample can be seen in Tables 91 and 92 and final details, including correction 
factors, can be seen in Table 93.  In this case the samples, which should only contain 
the cleaved drug molecules, were analysed by ICP-MS in standard mode, i.e. without 
the use of a collision cell or the presence of any reaction gas. 
 
The instrument used in analysis of these samples was as described previously in this 
chapter as was the sample introduction apparatus.  As the measurement of the 31P 
isotope was not required for this second study the DNA/cisplatin samples were 
analysed by ICP-MS under standard mode for the presence of 190,192,194,195,196,198Pt 
isotopes, i.e. without the use of specific conditions such as collision cell or cold 
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plasma.  However, to provide additional information, the m/z = 31 and 47 signals (i.e. 
31P+ and 31P16O+ ions) were also monitored to establish, qualitatively, whether 
significant quantities of 31P based components penetrated the filter of the centrifuge 
tubes.  External standards of Pt were prepared from a 1000 μg ml-1 single element 
standard solution (Fisher Chemicals, Loughborough, UK) by sequential dilution with 
high purity deionised water produced using a Maxima Ultra (Elga) water purification 
system.  Prior to carrying out these measurements, the ICP-MS instrument was 
optimised to produce standard operating conditions (see Table 94, Appendix 4). 
 
When the optimum ICP-MS conditions were established the prepared samples 
together with a series of Pt standard solutions for external calibration were analysed 
for 190,192,194,195,196,198Pt isotope content.  Data for each of these isotopes was collected 
by the software of the PQ ExCell (Thermo Plasmalab) and, as with study 1, three 
replicate readings were taken for each isotope measurement allowing mean, standard 
deviation and relative standard deviation data to be established.  Results of the 
analysis of the samples are given in the next section. 
 
 
Results and Discussion 
 
The mean data generated during the ICP-MS analysis of the DNA/cisplatin samples 
for this second study can be seen in Table 95.  This mean data was then corrected to 
account for variations in volume, i.e. concentration variation, following the reduction 
step, see Table 96.  All data were corrected in relation to 500 μl.  From this corrected 
data Figure 55 was constructed to establish the concentration of 194,195Pt isotopes and 
the degree of linearity over the sample range.  The data accrued from analysis of the 
Pt standard solutions can be seen in Table 97 and calibration curves constructed from 
this data can be seen in Figure 56.  A bar chart was also constructed from the 31P data 
to highlight the presence of any significant 31P based components in the sample 
analysed, see Figure 57.  Figure 57 is a qualitative comparison of m/z = 31 signal 
between samples, the blank sample signal provides data to account for the presence of 
background polyatomic ions to which other samples can be compared. 
 
 
 187
y = 1E+09x + 2096.3
R2 = 0.9959
y = 1E+09x + 2174.2
R2 = 0.9959
0
20000
40000
60000
80000
100000
120000
140000
0 0.00002 0.00004 0.00006 0.00008 0.0001 0.00012
Number of Cisplatin Molecules Per DNA Nucleotide
m
/z
 =
 1
94
 a
nd
 1
95
 S
ig
na
l (
cp
s)
m/z = 194
m/z = 195
Linear (m/z = 194)
Linear (m/z = 195)
 
Figure 55.  A Graph Comparing Number of Cisplatin Molecules Per DNA Nucleotide with 
Corrected m/z = 194 and 195 Signal (cps). 
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Figure 56.  A Graph Comparing Pt Standard Concentration (μg l-1) with m/z = 194 and 195 
Signal (cps). 
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Figure 57.  A Bar Chart Comparing m/z = 31 Signals (cps) Between DNA/Cisplatin Samples 
Studied During Study 2. 
 
 
Following study of the data accrued, from analysis of the DNA/Cisplatin sample 
solutions, and construction of the graph in Figure 55 and bar chart in Figure 57 a 
number of issues became apparent. 
 
Firstly in each cisplatin exposed DNA sample studied there were significant quantities 
of the Pt isotopes.  As can be seen in Figure 55 a linear response was observed 
between the number of cisplatin molecules per DNA nucleotide and the m/z = 194 and 
195 signal.  Such a relationship is what would have been expected at the beginning of 
this work, this suggests that the absence of Pt in the samples analysed in study 1 was 
due to the employment of instrument conditions not conducive to the determination of 
Pt isotopes.  Secondly, the ion counts generated through analysis of the sample series 
show that the limit of measurement by this method with regard to the study of 
platinum associated with these samples lies within the region of 100 000 to 500 000 
nucleotides per cisplatin molecule.  This is the equivalent of 2 to 10 μg l-1, however, 
the limit of detection of Pt by ICP-MS is less than 1 ng l-1 which suggests that there 
may be suppression of the Pt signal.  Although this may be the case, this is the desired 
analytical range as for therapeutic activity it is believed that a cisplatin molecule 
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bound every 400 000 DNA nucleotides is required to inhibit replication processes.  
Here the ion counts generated from the 100 000 nucleotides sample is significantly 
elevated above that of the blank and control solutions, however, the ion counts for the 
500 000 nucleotides sample were not.  The concentration of each sample analysed 
was established via the external calibration equations of Figure 56.  The calculated 
concentration values can be seen in Tables 26 and 27. 
 
 
Table 26.  194Pt Isotope Content of the DNA/Cisplatin Samples Analysed During Study 2. 
N° of DNA 
Nucleotides Per 
Cisplatin 
N° of Cisplatins 
Per DNA 
Nucleotide 
194Pt Stds 
Curve 
Equation 
m/z = 194 
Sample 
Signal (cps) 
194Pt Concn 
(μg l-1) 
Blank Blank y = 21889x – 6519.8 2952 0.43 
Control Control y = 21889x – 6519.8 1225 0.35 
10 000 0.0001 y = 21889x – 6519.8 116226 5.61 
50 000 0.0005 y = 21889x – 6519.8 23095 1.35 
100 000 0.00001 y = 21889x – 6519.8 8465 0.68 
500 000 0.00005 y = 21889x – 6519.8 3863 0.47 
1 000 000 0.000001 y = 21889x – 6519.8 3082 0.44 
5 000 000 0.000005 y = 21889x – 6519.8 3461 0.46 
10 000 000 0.0000001 y = 21889x – 6519.8 4299 0.49 
50 000 000 0.0000005 y = 21889x – 6519.8 3096 0.44 
100 000 000 0.00000001 y = 21889x – 6519.8 2485 0.41 
500 000 000 0.00000005 y = 21889x – 6519.8 2382 0.41 
1 000 000 000 0.000000001 y = 21889x – 6519.8 2307 0.40 
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Table 27.  195Pt Isotope Content of the DNA/Cisplatin Samples Analysed During Study 2. 
N° of DNA 
Nucleotides Per 
Cisplatin 
N° of Cisplatins 
Per DNA 
Nucleotide 
195Pt Stds 
Curve 
Equation 
m/z = 195 
Sample 
Signal (cps) 
195Pt Concn 
(μg l-1) 
Blank Blank y = 22871x – 6930.6 3128 0.44 
Control Control y = 22871x – 6930.6 1238 0.36 
10 000 0.0001 y = 22871x – 6930.6 121648 5.62 
50 000 0.0005 y = 22871x – 6930.6 24142 1.36 
100 000 0.00001 y = 22871x – 6930.6 8832 0.69 
500 000 0.00005 y = 22871x – 6930.6 4045 0.48 
1 000 000 0.000001 y = 22871x – 6930.6 3171 0.44 
5 000 000 0.000005 y = 22871x – 6930.6 3613 0.46 
10 000 000 0.0000001 y = 22871x – 6930.6 4479 0.50 
50 000 000 0.0000005 y = 22871x – 6930.6 3261 0.45 
100 000 000 0.00000001 y = 22871x – 6930.6 2598 0.42 
500 000 000 0.00000005 y = 22871x – 6930.6 2478 0.41 
1 000 000 000 0.000000001 y = 22871x – 6930.6 2412 0.41 
 
 
As can be seen in Tables 26 and 27 the background concentration of Pt present 
appears to be in the order of 0.40 μg l-1.  From this background it can be said that, as 
mentioned previously, the method LOD could be found between 100 000 and 500 000 
DNA nucleotides per cisplatin molecule.  This background concentration is quite high 
for Pt so it could confidently be said that there is a likely source of Pt contamination 
affecting the analysis.  Leaching from the peristaltic pump tubing and centrifuge tubes 
used would be a likely source of such contamination.  Finally, as can be seen in the 
bar chart of Figure 57, there are large quantities of 31P present in a majority of the 
final sample solutions analysed.  The presence of such 31P implies that 31P based 
fragments of DNA are passing through the centrifuge filter during the separation 
procedure.  As 31P appears in large quantities in most of the samples studied then it 
could be said that either these centrifuge filters were not as efficient as desired or that 
the NH3 treatment was too harsh resulting in DNA fragmentation allowing passage 
through the two tube compartments. 
 
As this second study of the interaction between DNA and cisplatin (in vitro) was 
successful, with regard to producing data that described an increased degree of 
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binding with increasing drug exposure, work could then commence on establishing 
binding constant data that could be used as the basis of a clinical test for cisplatin 
efficacy for individual patients.  The calculation of binding constants and ratios is 
described in detail in section 4.5 and compared to constants and ratios determined 
following further studies to establish the viability of a clinical test.  Unfortunately, 
due to the preparation error, the sample series analysed during this second study was 
flawed slightly as many of the samples were out of the range of detection of the ICP-
QMS.  At this point it was intended to repeat the work with a more realistic sample 
series to establish a greater amount of data.  However, the more important point that 
this study has established is that the lack of Pt data in study 1 was not the result of 
binding failure but instead the result of instrumental conditions that were suitable for 
31P measurement only. 
 
 
4.4.3.  Studies 3 and 4 
 
Following the success of the second study of DNA and Pt based drug interaction the 
binding of drug to target and subsequent measurement of 194,195Pt isotopes was 
repeated with both cisplatin and oxaliplatin drugs.  Such further study (studies 3 and 
4) should determine both the repeatability of data and establish a better understanding 
of the limits of the ICP-QMS for this work.  A third and fourth study of this 
drug/target binding were conducted.  The third study was a simple repeat of study 2 
with a more realistic sample series whilst the fourth study involved the analysis of a 
wider range of samples that would allow the limits of the ICP-QMS to be tested. 
 
 
Experimental Details 
 
For studies 3 and 4 DNA samples were prepared and exposed to both cisplatin and 
oxaliplatin in a similar fashion to that described previously.  For studies 3 and 4, 
exposed DNA samples were prepared based on the mean molecular weight of a DNA 
nucleotide, bound in the helix, being 307.61 and the molecular weight of cisplatin and 
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oxaliplatin being 300 and 397, respectively.  Details of the full preparation of the 
samples investigated during these studies are in Tables 28, 29, 30 and 31. 
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Table 28.  Preparation Details for the Cisplatin Samples Investigated During Study 3. 
Solution 
Number 
Solution Description Procedure Nucleotide 
Concn (μM) 
Cisplatin 
Concn (μM) 
Drug : 
Nucleotide Ratio 
      
Stock Solutions 
1 DNA Stock Solution DNA (1 mg in 1 ml) 3250 - - 
2 Cisplatin Stock Solution Cisplatin (1 mg in 1 ml) - 3330 - 
      
Cisplatin Preparative Solutions 
3 1.023 Fold Dilution of Soln 2 with H2O - 3250 - 
4 
Serial Dilution of 
Cisplatin Stock Solution 1000 Fold Dilution of Soln 3 with H2O - 3.25 - 
      
Final Sample Solutions 
5 Soln 1 (3000 μl) + H2O (3000 μl) - - Control 
6 Soln 1 (3000 μl) + Soln 3 (60 μl) + H2O (2940 μl) - - 1 : 50 
7 Soln 1 (3000 μl) + Soln 3 (30 μl) + H2O (2970 μl) - - 1 : 100 
8 Soln 1 (3000 μl) + Soln 3 (6 μl) + H2O (2994 μl) - - 1 : 500 
9 Soln 1 (3000 μl) + Soln 4 (3000 μl) - - 1 : 1 000 
10 Soln 1 (3000 μl) + Soln 4 (600 μl) + H2O (2400 μl) - - 1 : 5 000 
11 Soln 1 (3000 μl) + Soln 4 (300 μl) + H2O (2700 μl) - - 1 : 10 000 
12 Soln 1 (3000 μl) + Soln 4 (60 μl) + H2O (2940 μl) - - 1 : 50 000 
13 Soln 1 (3000 μl) + Soln 4 (30 μl) + H2O (2970 μl) - - 1 : 100 000 
14 Soln 1 (3000 μl) + Soln 4 (6 μl) + H2O (2994 μl) - - 1 : 500 000 
15 
 
 
 
 
Final Sample 
Preparation, Exposure 
of Solution 1 to 
Solutions 3 and 4 
Soln 1 (3000 μl) + Soln 4 (3 μl) + H2O (2997 μl)   1 : 1 000 000 
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Table 29.  Preparation Details for the Oxaliplatin Samples Investigated During Study 3. 
Solution 
Number 
Solution Description Procedure Nucleotide 
Concn (μM) 
Oxaliplatin 
Concn (μM) 
Drug : 
Nucleotide Ratio 
      
Stock Solutions 
1 DNA Stock Solution DNA (1 mg in 1 ml) 3250 - - 
2 Oxaliplatin Stock Solution Oxaliplatin (2 mg in 1 ml) - 5040 - 
      
Cisplatin Preparative Solutions 
3 1.550 Fold Dilution of Soln 2 with H2O - 3250 - 
4 
Serial Dilution of 
Oxaliplatin Stock Solution 100 Fold Dilution of Soln 3 with H2O - 3.25 - 
      
Final Sample Solutions 
5 Soln 1 (3000 μl) + H2O (3000 μl) - - Control 
6 Soln 1 (3000 μl) + Soln 3 (60 μl) + H2O (2940 μl) - - 1 : 50 
7 Soln 1 (3000 μl) + Soln 3 (30 μl) + H2O (2970 μl) - - 1 : 100 
12 Soln 1 (3000 μl) + Soln 3 (6 μl) + H2O (2994 μl) - - 1 : 500 
13 Soln 1 (3000 μl) + Soln 4 (3000 μl) - - 1 : 1 000 
14 Soln 1 (3000 μl) + Soln 4 (600 μl) + H2O (2400 μl) - - 1 : 5 000 
15 Soln 1 (3000 μl) + Soln 4 (300 μl) + H2O (2700 μl) - - 1 : 10 000 
16 Soln 1 (3000 μl) + Soln 4 (60 μl) + H2O (2940 μl) - - 1 : 50 000 
17 Soln 1 (3000 μl) + Soln 4 (30 μl) + H2O (2970 μl) - - 1 : 100 000 
18 Soln 1 (3000 μl) + Soln 4 (6 μl) + H2O (2994 μl) - - 1 : 500 000 
19 
 
 
 
 
Final Sample Preparation, 
Exposure of Solution 1 to 
Solutions 3 and 4 
Soln 1 (3000 μl) + Soln 4 (3 μl) + H2O (2997 μl)   1 : 1 000 000 
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Table 30.  Preparation Details for the Cisplatin Samples Investigated During Study 4. 
Solution 
Number 
Solution Description Procedure Nucleotide 
Concn (μM) 
Cisplatin 
Concn (μM) 
Drug : 
Nucleotide Ratio 
      
Stock Solutions 
1 DNA Stock Solution DNA (1 mg in 1 ml) 3250 - - 
2 Cisplatin Stock Solution Cisplatin (1 mg in 1 ml) - 3330 - 
      
Cisplatin Preparative Solutions 
3 1.023 Fold Dilution of Soln 2 with H2O - 3250 - 
4 
Serial Dilution of 
Cisplatin Stock Solution 1000 Fold Dilution of Soln 3 with H2O - 3.25 - 
      
Final Sample Solutions 
5 Soln 1 (3000 μl) + H2O (3000 μl) - - Control 
6 Soln 1 (3000 μl) + Soln 3 (30 μl) + H2O (2970 μl) - - 1 : 100 
7 Soln 1 (3000 μl) + Soln 3 (20 μl) + H2O (2980 μl) - - 1 : 150 
8 Soln 1 (3000 μl) + Soln 3 (10 μl) + H2O (2990 μl) - - 1 : 300 
9 Soln 1 (3000 μl) + Soln 4 (6 μl) + H2O (2994 μl) - - 1 : 500 
10 Soln 1 (3000 μl) + Soln 4 (3000 μl) - - 1 : 1 000 
11 Soln 1 (3000 μl) + Soln 4 (600 μl) + H2O (2400 μl) - - 1 : 5 000 
12 Soln 1 (3000 μl) + Soln 4 (300 μl) + H2O (2700 μl) - - 1 : 10 000 
13 Soln 1 (3000 μl) + Soln 4 (60 μl) + H2O (2940 μl) - - 1 : 50 000 
14 Soln 1 (3000 μl) + Soln 4 (30 μl) + H2O (2970 μl) - - 1 : 100 000 
15 Soln 1 (3000 μl) + Soln 4 (12 μl) + H2O (2988 μl)   1 : 250 000 
16 
 
 
 
 
Final Sample 
Preparation, Exposure 
of Solution 1 to 
Solutions 3 and 4 
Soln 1 (3000 μl) + Soln 4 (6 μl) + H2O (2994 μl)   1 : 500 000 
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Table 31.  Preparation Details for the Oxaliplatin Samples Investigated During Study 4. 
Solution 
Number 
Solution Description Procedure Nucleotide 
Concn (μM) 
Oxaliplatin 
Concn (μM) 
Drug : 
Nucleotide Ratio 
      
Stock Solutions 
1 DNA Stock Solution DNA (1 mg in 1 ml) 3250 - - 
2 Oxaliplatin Stock Solution Oxaliplatin (2 mg in 1 ml) - 5040 - 
      
Cisplatin Preparative Solutions 
3 1.550 Fold Dilution of Soln 2 with H2O - 3250 - 
4 
Serial Dilution of 
Oxaliplatin Stock Solution 100 Fold Dilution of Soln 3 with H2O - 3.25 - 
      
Final Sample Solutions 
5 Soln 1 (3000 μl) + H2O (3000 μl) - - Control 
6 Soln 1 (3000 μl) + Soln 3 (30 μl) + H2O (2970 μl) - - 1 : 100 
7 Soln 1 (3000 μl) + Soln 3 (20 μl) + H2O (2980 μl) - - 1 : 150 
8 Soln 1 (3000 μl) + Soln 3 (10 μl) + H2O (2990 μl) - - 1 : 300 
9 Soln 1 (3000 μl) + Soln 4 (6 μl) + H2O (2994 μl) - - 1 : 500 
10 Soln 1 (3000 μl) + Soln 4 (3000 μl) - - 1 : 1 000 
11 Soln 1 (3000 μl) + Soln 4 (600 μl) + H2O (2400 μl) - - 1 : 5 000 
12 Soln 1 (3000 μl) + Soln 4 (300 μl) + H2O (2700 μl) - - 1 : 10 000 
13 Soln 1 (3000 μl) + Soln 4 (60 μl) + H2O (2940 μl) - - 1 : 50 000 
14 Soln 1 (3000 μl) + Soln 4 (30 μl) + H2O (2970 μl) - - 1 : 100 000 
15 Soln 1 (3000 μl) + Soln 4 (12 μl) + H2O (2988 μl)   1 : 250 000 
16 
 
 
 
 
Final Sample Preparation, 
Exposure of Solution 1 to 
Solutions 3 and 4 
Soln 1 (3000 μl) + Soln 4 (6 μl) + H2O (2994 μl)   1 : 500 000 
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As with previous studies the final DNA concentration of each sample was determined 
by UV spectroscopy, see Tables 98, 99, 100 and 101.  Following preparation the 
samples were treated further, as described in Study 2.  Compared to previous analysis 
there was twice as much sample available so a two-fold preconcentration was carried 
out with the aim of measuring lower drug molecule : nucleotide ratios.  Details of the 
pre-treatment carried out on each sample, for both studies, can be seen in Tables 102 
to 107 and final details, including correction factors, can be seen in Tables 108, 109 
and 110.  The final sample solutions, as well as Pt standard solutions, were then 
analysed by ICP-QMS under standard mode.  Instrumental conditions employed 
during this analysis can be seen in Tables 111, 117 and 118 (Appendix 4).  Results of 
the sample analysis are in the next section. 
 
 
Results and Discussion 
 
Data generated during the ICP-MS analysis of these DNA/cisplatin and 
DNA/oxaliplatin samples, of study 3 and 4, as well as Pt standard solutions can be 
seen in Tables 112 to 116 and 119 to 124.  It should be noted that two sets of standard 
Pt solutions were measured for external calibration data for Study 4 as cisplatin and 
oxaliplatin samples were analysed on different days.  From this data a series of graphs 
were constructed comparing the number of cisplatin and oxaliplatin molecules per 
DNA nucleotide versus the Pt isotope signal in order to determine the presence of the 
major Pt isotopes (194,195Pt) in each sample prepared (see Figures 58, 59, 63 and 64).  
Calibration graphs were also constructed from the standard solution data to determine 
the Pt concentration of each sample via external quantification (see Figures 60, 65 and 
66). 
 
As in Study 2 the m/z = 31 data for each sample analysed was also used to construct 
bar charts to ascertain the degree of passage of 31P based DNA fragments through the 
centrifuge filter tubes used, see Figures 61, 62, 67 and 68. 
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Figure 58.  A Graph Comparing Number of Cisplatin Molecules Per DNA Nucleotide with 
Corrected m/z = 194 and 195 Signal (cps) for Study 3. 
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Figure 59.  A Graph Comparing Number of Oxaliplatin Molecules Per DNA Nucleotide with 
Corrected m/z = 194 and 195 Signal (cps) for Study 3. 
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Figure 60.  An External Calibration Graph Comparing Pt Standard Concentration (μg l-1) with 
m/z = 194 and 195 Signal (cps) for both DNA/Cisplatin and DNA/Oxaliplatin Samples Studied 
During Study 3. 
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Figure 61.  A Bar Chart Comparing m/z = 31 Signals (cps) Between DNA/Cisplatin Samples 
Studied During Study 3. 
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Figure 62.  A Bar Chart Comparing m/z = 31 Signals (cps) Between DNA/Oxaliplatin Samples 
Studied During Study 3. 
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Figure 63.  A Graph Comparing Number of Cisplatin Molecules Per DNA Nucleotide with 
Corrected m/z = 194 and 195 Signal (cps) for Study 4. 
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Figure 64.  A Graph Comparing Number of Oxaliplatin Molecules Per DNA Nucleotide with 
Corrected m/z = 194 and 195 Signal (cps) for Study 4. 
 
 
y = 5753.8x + 352.44
R2 = 0.9781
y = 5925.1x + 221.44
R2 = 0.9774
0
20000
40000
60000
80000
100000
120000
140000
0 5 10 15 20 25
Pt Standard Concentration (ug/l)
m
/z
 =
 1
94
 a
nd
 1
95
 S
ig
na
l (
cp
s)
m/z = 194
m/z = 195
Linear (m/z = 194)
Linear (m/z = 195)
 
Figure 65.  An External Calibration Graph Comparing Pt Standard Concentration (μg l-1) with 
m/z = 194 and 195 Signal (cps) for DNA/Cisplatin Samples Studied During Study 4. 
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Figure 66.  An External Calibration Graph Comparing Pt Standard Concentration (μg l-1) with 
m/z = 194 and 195 Signal (cps) for DNA/Oxaliplatin Samples Studied During Study 4. 
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Figure 67.  A Bar Chart Comparing m/z = 31 Signals (cps) Between DNA/Cisplatin Samples 
Studied During Study 4. 
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Figure 68.  A Bar Chart Comparing m/z = 31 Signals (cps) Between DNA/Oxaliplatin Samples 
Studied During Study 4. 
 
 
Following study of the data generated, from analysis of the DNA/Cisplatin and 
DNA/Oxaliplatin sample solutions (studies 3 and 4), and construction of the graphs in 
Figures 58, 59, 60, 63, 64, 65 and 66 and bar charts in Figures 61, 62, 67 and 68 a 
number of issues became apparent.  These issues are described as follows: 
 
 
Study 3 
 
The first issue is that in each cisplatin and oxaliplatin exposed DNA sample analysed 
there were significant quantities of the Pt isotopes present.  As can be seen in Figure 
59 a linear response was observed between the number of oxaliplatin molecules per 
DNA nucleotide and the m/z = 194 and 195 signal.  Although a similar response was 
seen in the analysis of DNA/cisplatin samples the graph linearity of Figure 58 was 
determined by the dominating signal of the most concentrated sample.  As mentioned 
during the discussion of study 2 (see section 4.4.2) such trends were as expected but 
the successful repetition of this work shows the reproducibility of the exposure and 
separation methods employed during these last two studies.  Such method 
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reproducibility confirms that the analytical failure observed during study 1 was due to 
the incompatibility of instrument conditions with Pt isotope measurement. 
 
Secondly, the ion counts for the samples in study 3 show that, as in study 2, a limit of 
measurement for cisplatin exposed DNA lies in the region of 1 cisplatin per 100 000 
DNA nucleotides to 1 cisplatin to 500 000 DNA nucleotides.  A limit of measurement 
for the oxaliplatin exposed DNA samples was seen to be slightly different, tending 
more towards the region of 1 oxaliplatin molecule per 500 000 DNA nucleotides.  
This is in the desired range for therapeutic activity so this third study has, again, 
shown that ICP-MS is a promising approach to the analysis of these Pt based anti-
cancer complexes.  For both cisplatin and oxaliplatin the ion counts generated from 
the 1 drug to 100 000 DNA nucleotides sample are significantly elevated above that 
of the blank and control solutions, however, the ion counts for the 1: 500 000 
nucleotides were not elevated sufficiently to confidently say state that it could be 
differentiated from the background.  The concentration of each sample analysed was 
established via the external calibration equations of the graphs in Figure 60.  The 
calculated concentration values can be seen in Tables 32 to 35. 
 
 
Table 32.  194Pt Isotope Content of the DNA/Cisplatin Samples Analysed During Study 3. 
N° of DNA 
Nucleotides Per 
Cisplatin 
N° of Cisplatins 
Per DNA 
Nucleotide 
194Pt Stds 
Curve 
Equation 
m/z = 194 
Sample 
Signal (cps) 
194Pt Concn 
(μg l-1) 
Blank Blank y = 26022x + 5550.7 3071.78 <0.17 
Control Control y = 26022x + 5550.7 10064.1 0.17 
50 0.02 y = 26022x + 5550.7 0 ↑ >117.52 
100 0.01 y = 26022x + 5550.7 3063635 117.52 
500 0.002 y = 26022x + 5550.7 592193 22.54 
1 000 0.001 y = 26022x + 5550.7 670908 25.57 
5 000 0.0002 y = 26022x + 5550.7 117662 4.31 
10 000 0.0001 y = 26022x + 5550.7 119239 4.37 
50 000 0.00002 y = 26022x + 5550.7 27843.3 0.86 
100 000 0.00001 y = 26022x + 5550.7 12310.0 0.26 
500 000 0.000002 y = 26022x + 5550.7 10554.3 0.19 
1 000 000 0.000001 y = 26022x + 5550.7 35341.7 1.14 
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Table 33.  195Pt Isotope Content of the DNA/Cisplatin Samples Analysed During Study 3. 
N° of DNA 
Nucleotides Per 
Cisplatin 
N° of Cisplatins 
Per DNA 
Nucleotide 
195Pt Stds 
Curve 
Equation 
m/z = 195 
Sample 
Signal (cps) 
195Pt Concn 
(μg l-1) 
Blank Blank y = 27220x + 5868.1 3189.49 <0.17 
Control Control y = 27220x + 5868.1 10408.1 0.17 
50 0.02 y = 27220x + 5868.1 0 ↑ >116.16 
100 0.01 y = 27220x + 5868.1 3167829 116.16 
500 0.002 y = 27220x + 5868.1 618678 22.51 
1 000 0.001 y = 27220x + 5868.1 699919 25.50 
5 000 0.0002 y = 27220x + 5868.1 122543 4.29 
10 000 0.0001 y = 27220x + 5868.1 124226 4.35 
50 000 0.00002 y = 27220x + 5868.1 28870.0 0.85 
100 000 0.00001 y = 27220x + 5868.1 12802.3 0.25 
500 000 0.000002 y = 27220x + 5868.1 11066.9 0.19 
1 000 000 0.000001 y = 27220x + 5868.1 36880.0 1.14 
 
 
Table 34.  194Pt Isotope Content of the DNA/Oxaliplatin Samples Analysed During Study 3. 
N° of DNA 
Nucleotides Per 
Oxaliplatin 
N° of Oxaliplatins 
Per DNA 
Nucleotide 
194Pt Stds 
Curve 
Equation 
m/z = 194 
Sample 
Signal (cps) 
194Pt Concn 
(μg l-1) 
Blank Blank y = 26022x + 5550.7 4038.34 <0.05 
Control Control y = 26022x + 5550.7 6828.81 0.05 
50 0.02 y = 26022x + 5550.7 0 ↑ >166.23 
100 0.01 y = 26022x + 5550.7 4331231 166.23 
500 0.002 y = 26022x + 5550.7 1051619 40.20 
1 000 0.001 y = 26022x + 5550.7 601475 22.90 
5 000 0.0002 y = 26022x + 5550.7 141180 5.21 
10 000 0.0001 y = 26022x + 5550.7 99130.8 3.60 
50 000 0.00002 y = 26022x + 5550.7 61830.6 2.16 
100 000 0.00001 y = 26022x + 5550.7 20252.1 0.56 
500 000 0.000002 y = 26022x + 5550.7 16939.9 0.44 
1 000 000 0.000001 y = 26022x + 5550.7 15902.8 0.40 
 
 
 
 206
Table 35.  195Pt Isotope Content of the DNA/Oxaliplatin Samples Analysed During Study 3. 
N° of DNA 
Nucleotides Per 
Oxaliplatin 
N° of Oxaliplatins 
Per DNA 
Nucleotide 
195Pt Stds 
Curve 
Equation 
m/z = 195 
Sample 
Signal (cps) 
195Pt Concn 
(μg l-1) 
Blank Blank y = 27220x + 5868.1 4202.82 <0.30 
Control Control y = 27220x + 5868.1 14103.4 0.30 
50 0.02 y = 27220x + 5868.1 0 ↑ >141.87 
100 0.01 y = 27220x + 5868.1 3867462 141.87 
500 0.002 y = 27220x + 5868.1 1100346 40.21 
1 000 0.001 y = 27220x + 5868.1 630667 22.95 
5 000 0.0002 y = 27220x + 5868.1 148305 5.23 
10 000 0.0001 y = 27220x + 5868.1 103905 3.60 
50 000 0.00002 y = 27220x + 5868.1 65132.5 2.18 
100 000 0.00001 y = 27220x + 5868.1 21021.0 0.56 
500 000 0.000002 y = 27220x + 5868.1 17646.3 0.43 
1 000 000 0.000001 y = 27220x + 5868.1 16508.0 0.39 
 
 
As can be seen in Tables 32 to 35 the background concentration of Pt present over the 
sample ranges for both cisplatin and oxaliplatin drugs was of the order of 0.20 to 0.30 
μg l-1.  From these established backgrounds and the spurious data for the lowest level 
samples (1 drug molecule per 1 000 000 DNA nucleotides) it can be said that, again, 
the limit of measurement for this analytical approach could be found between 100 000 
and 500 000 DNA nucleotides per drug molecule for both cisplatin and oxaliplatin.  
As mentioned in Section 4.4.2 the limit of detection capability of ICP-MS is less than 
1 ng l-1.  Again the background concentrations are relatively high for Pt so it could be 
confidently said that there was a source of contamination present within the system or 
samples affecting the analysis.  Leaching from the peristaltic pump tubing or 
centrifuge tubes could be a source of such contamination. 
 
There are two points to be made considering this limit for both drugs.  Firstly, in the 
case of cisplatin, this work has shown to be repeatable on comparison with the data of 
study 2.  Secondly, however, the data for study 3 has shown very similar limits for 
both cisplatin and oxaliplatin.  Although this work was carried out in vitro, it 
contradicts with previous research that has shown that there is a significant difference 
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in the degree of binding between cisplatin and oxaliplatin in vivo.176  So, either the 
interaction between drug and target in vitro is very different to that in vivo or there 
one or more aspects of the analytical method that is establishing contradictory data. 
 
Finally, as can be seen in the bar charts of Figures 61 and 62, and similar to the bar 
chart constructed for study 2 (see Figure 57) there were large quantities of 31P present 
in a majority of the final sample solutions analysed.  Such quantities in most of these 
samples suggests that 31P based fragments of DNA (of <100 000 molecular weight) 
were passing through the centrifuge filter during the separation procedure, most likely 
due to an over-harsh NH3 treatment for separation of drug and target. 
 
In general a linear response was observed between drug exposure concentration and 
Pt signal response, the R2 value of the graphs comparing these two parameters (see 
Figures 58 and 59) are dictated by the most concentrated sample.  The reason for this 
is that the exposure concentrations described in the sample list increase in an almost 
exponential way.  For this reason a fourth study into these interactions was undertaken 
with a revised sample list to confirm the linearity between drug exposure and binding 
(i.e. ICP-MS signal) without relying on such a concentrated sample.  The sample list 
was also expanded at the lower end to provide more accurate data for the method limit 
of measurement. 
 
 
Study 4 
 
The reasons behind carrying out a fourth study into these cisplatin/DNA and 
oxaliplatin/DNA interactions were two-fold.  Firstly the analysis of the oxaliplatin 
drug interactions required repeating to ensure consistency with the data of study 3.  
Secondly, and more importantly, a revised sample list was needed to study linearity 
between exposure concentration and binding (i.e. ICP-MS signal). 
 
As with study 3 the first issue for discussion, with regard to the study 4 data, is that in 
each cisplatin and oxaliplatin exposed DNA sample analysed there were significant 
quantities of the Pt isotopes present.  As can be seen in the graphs of Figures 63 and 
64 there was a clear linear response between the number of cisplatin and oxaliplatin 
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molecules per DNA nucleotide and the m/z = 194 and 195 signals.  Although such 
trends have always been expected it has not been until this fourth study that they have 
been confirmed during this work.  The data of this fourth study has, again, shown 
reproducibility of this analytical method and that the failure seen during study 1 was 
the result of incompatibility of instrumental conditions. 
 
The second issue is that the ion counts accrued during the analysis of samples during 
study 4 show that a limit for the measurement of cisplatin exposed DNA lies in the 
region of 1 drug molecule per 250 000 DNA nucleotides whilst that for the oxaliplatin 
exposed samples leans more towards 1 drug molecule per 500 000 DNA nucleotides.  
Again, these limits are in the desired range for therapeutic activity and show the 
potential of ICP-MS for this type of work.  The Pt concentration of each sample 
analysed was established via the external calibration equations of the graphs in 
Figures 65 and 66.  The calculated Pt concentrations can be seen in Tables 36 to 39. 
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Table 36.  194Pt Isotope Content of the DNA/Cisplatin Samples Analysed During Study 4. 
N° of DNA 
Nucleotides Per 
Cisplatin 
N° of Cisplatins 
Per DNA 
Nucleotide 
194Pt Stds 
Curve 
Equation 
m/z = 194 
Sample 
Signal (cps) 
194Pt Concn 
(μg l-1) 
Blank 2 Blank 2 y = 5753.8x + 352.44 594.554 0.04 
Control 2 Control 2 y = 5753.8x + 352.44 966.139 0.11 
100 0.01 y = 5753.8x + 352.44 2426296 421.62 
150 A 0.00667 y = 5753.8x + 352.44 1503598 261.26 
150 B 0.00667 y = 5753.8x + 352.44 1405440 244.20 
300 A 0.00333 y = 5753.8x + 352.44 628084 109.10 
300 B 0.00333 y = 5753.8x + 352.44 664254 115.38 
500 0.002 y = 5753.8x + 352.44 289479 50.25 
1 000 0.001 y = 5753.8x + 352.44 220257 38.22 
5 000 0.0002 y = 5753.8x + 352.44 34650.2 5.96 
10 000 0.0001 y = 5753.8x + 352.44 23200.5 3.97 
50 000 0.00002 y = 5753.8x + 352.44 6722.20 1.11 
100 000 0.00001 y = 5753.8x + 352.44 4796.61 0.77 
250 000 A 0.000004 y = 5753.8x + 352.44 1352.15 0.17 
250 000 B 0.000004 y = 5753.8x + 352.44 1433.90 0.19 
250 000 C 0.000004 y = 5753.8x + 352.44 1318.33 0.17 
500 000 0.000002 y = 5753.8x + 352.44 3080.78 0.47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 210
Table 37.  195Pt Isotope Content of the DNA/Cisplatin Samples Analysed During Study 4. 
N° of DNA 
Nucleotides Per 
Cisplatin 
N° of Cisplatins 
Per DNA 
Nucleotide 
195Pt Stds 
Curve 
Equation 
m/z = 195 
Sample 
Signal (cps) 
195Pt Concn 
(μg l-1) 
Blank 2 Blank 2 y = 5925.1x + 221.44 612.659 0.07 
Control 2 Control 2 y = 5925.1x + 221.44 1001.29 0.13 
100 0.01 y = 5925.1x + 221.44 2495780 421.18 
150 A 0.00667 y = 5925.1x + 221.44 1551885 261.88 
150 B 0.00667 y = 5925.1x + 221.44 1450669 244.80 
300 A 0.00333 y = 5925.1x + 221.44 647716 109.28 
300 B 0.00333 y = 5925.1x + 221.44 685725 115.69 
500 0.002 y = 5925.1x + 221.44 298307 50.31 
1 000 0.001 y = 5925.1x + 221.44 226771 38.24 
5 000 0.0002 y = 5925.1x + 221.44 35828.5 6.01 
10 000 0.0001 y = 5925.1x + 221.44 24159.3 4.04 
50 000 0.00002 y = 5925.1x + 221.44 6931.36 1.13 
100 000 0.00001 y = 5925.1x + 221.44 4896.41 0.79 
250 000 A 0.000004 y = 5925.1x + 221.44 1382.56 0.20 
250 000 B 0.000004 y = 5925.1x + 221.44 1459.02 0.21 
250 000 C 0.000004 y = 5925.1x + 221.44 1382.55 0.20 
500 000 0.000002 y = 5925.1x + 221.44 3126.73 0.49 
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Table 38.  194Pt Isotope Content of the DNA/Oxaliplatin Samples Analysed During Study 4. 
N° of DNA 
Nucleotides Per 
Oxaliplatin 
N° of Oxaliplatins 
Per DNA 
Nucleotide 
194Pt Stds 
Curve 
Equation 
m/z = 194 
Sample 
Signal (cps) 
194Pt Concn 
(μg l-1) 
Blank 2 Blank 2 y = 4431x + 1811 2413.36 0.14 
Control 2 Control 2 y = 4431x + 1811 1333.38 <0.14 
100 0.01 y = 4431x + 1811 1480804 333.78 
150 A 0.00667 y = 4431x + 1811 1308963 295.00 
150 B 0.00667 y = 4431x + 1811 2360702 547.18 
300 A 0.00333 y = 4431x + 1811 649510 146.17 
300 B 0.00333 y = 4431x + 1811 619977 139.51 
500 0.002 y = 4431x + 1811 293269 65.78 
1 000 0.001 y = 4431x + 1811 147249 32.82 
5 000 0.0002 y = 4431x + 1811 39277.4 8.46 
10 000 0.0001 y = 4431x + 1811 21993.0 4.55 
50 000 0.00002 y = 4431x + 1811 7105.54 1.19 
100 000 0.00001 y = 4431x + 1811 8433.38 1.49 
250 000 A 0.000004 y = 4431x + 1811 2855.42 0.24 
250 000 B 0.000004 y = 4431x + 1811 3325.83 0.34 
250 000 C 0.000004 y = 4431x + 1811 4256.99 0.55 
500 000 0.000002 y = 4431x + 1811 1966.78 0.04 
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Table 39.  195Pt Isotope Content of the DNA/Oxaliplatin Samples Analysed During Study 4. 
N° of DNA 
Nucleotides Per 
Oxaliplatin 
N° of Oxaliplatins 
Per DNA 
Nucleotide 
195Pt Stds 
Curve 
Equation 
m/z = 195 
Sample 
Signal (cps) 
195Pt Concn 
(μg l-1) 
Blank 2 Blank 2 y = 4601.4 + 1772.2 2433.32 0.14 
Control 2 Control 2 y = 4601.4 + 1772.2 1335.33 <0.14 
100 0.01 y = 4601.4 + 1772.2 1533310 332.84 
150 A 0.00667 y = 4601.4 + 1772.2 1363158 295.86 
150 B 0.00667 y = 4601.4 + 1772.2 2453064 532.73 
300 A 0.00333 y = 4601.4 + 1772.2 671724 145.60 
300 B 0.00333 y = 4601.4 + 1772.2 640683 138.85 
500 0.002 y = 4601.4 + 1772.2 304659 65.82 
1 000 0.001 y = 4601.4 + 1772.2 152257 32.70 
5 000 0.0002 y = 4601.4 + 1772.2 40829.2 8.49 
10 000 0.0001 y = 4601.4 + 1772.2 22713.1 4.55 
50 000 0.00002 y = 4601.4 + 1772.2 7275.23 1.20 
100 000 0.00001 y = 4601.4 + 1772.2 8690.51 1.50 
250 000 A 0.000004 y = 4601.4 + 1772.2 2967.49 0.26 
250 000 B 0.000004 y = 4601.4 + 1772.2 3422.16 0.36 
250 000 C 0.000004 y = 4601.4 + 1772.2 4356.50 0.56 
500 000 0.000002 y = 4601.4 + 1772.2 1969.50 0.04 
 
 
Similar to the data of study 3, Tables 36 to 39 show the background concentration of 
Pt for both cisplatin and oxaliplatin exposures were of the order of 0.10 to 0.20 μg l-1 
which translates to an equivalent of 1 drug molecule per 250 000 DNA nucleotides.  
Slightly elevated background counts at m/z = 194 and 195 suggest the presence of a 
small degree of Pt contamination. 
 
Again the analysis of study 4 has shown repeatability with previous work, this 
includes the contradiction described previously in this section regarding the similar 
degree of binding between cisplatin and oxaliplatin drugs and their target.  The bar 
charts of Figures 67 and 68 again show that the fragmentation of the DNA target (and 
passage through the centrifuge filters) was significant during the species separation 
process.  This is most likely due to the NH3 treatment being overly aggressive.  The 
data for this fourth study has shown that the relationship between drug exposure 
 213
concentration and ICP-MS signal is in fact a linear one, with R2 values in the order of 
0.99 for cisplatin and 0.97 for oxaliplatin.  With the limit of measurement, via this 
method, being in the region of 1 drug molecule per 250 000 DNA nucleotides, ICP-
MS appears to have a lot of potential for this kind of biological analysis. 
 
Following the success of the third and fourth studies, and similar to the second study, 
work was commenced on establishing binding constant data that could be used as the 
basis of a clinical test for the determination of drug efficacy of cisplatin and 
oxaliplatin in individual patients, see section 4.5. 
 
 
At this stage during the work on these drugs, to cover as many unknowns as possible, 
it was decided to carry out further analysis on the centrifuge filters used during one of 
the studies (in this case it was study 4) to establish whether any Pt based species were 
being retained.  It was also decided to carry out one final study, on another sample 
series for each drug, without separating drug and target to establish the degree of any 
loss of Pt species during the preparation and treatment procedures and to determine 
the degree of any matrix effects from the quantity of DNA present. 
 
 
4.4.4.  The Analysis of Study 4 Centrifuge Filters 
 
To establish the efficiency of the drug and target separation method employed during 
this work, the centrifuge filters used in the final stages were leached to remove any 
material retained on the filter.  The study of such leachate solutions would establish 
whether any Pt based species were being kept behind and determine whether this 
separation of species is the best approach to ICP-MS study of these samples. 
 
 
Experimental Details 
 
Following the analysis of study 4 samples the 100 000 molecular weight centrifuge 
tubes, that were used during the separation process, were broken to remove the filter 
 214
at the base of the inner tube.  These filters were then leached, in deionised water, to 
remove any material on them to provide solutions that could be analysed by ICP-MS. 
 
The filter and surrounding material, removed from the bottom section of the inner 
tube of each centrifuge tube was accurately weighed and suspended in approximately 
2 ml of deionised water (again accurately weighed) in sealed tubes that were then 
incubated in a water bath at 75 °C for 24 hours.  Following incubation the leachate 
solution was then analysed by ICP-MS.  The details of sample preparation can be seen 
in Tables 125 and 126.  From the measurements taken for these leachate solutions 
correction factors can be calculated and applied when establishing concentration data 
from the ICP-MS analysis and external calibration (see the results and discussion 
section). 
 
The instrument used in analysis of the samples was as described previously.  Leachate 
solutions and Pt standards were analysed under standard mode for the presence of 
190,192,194,195,196,198Pt and 31P isotopes.  The optimised operating conditions employed 
during this work are in Table 127.  Results of the sample analysis can be seen in the 
next section. 
 
 
Results and Discussion 
 
The data generated following the ICP-MS study of these centrifuge filter leachate 
solutions and Pt external standards can be seen in Tables 128, 129 and 130 (Appendix 
4).  From this data six bar charts were constructed, four describing the Pt data (see 
Figures 69 to 72) and a further two for the 31P data (see Figures 73 and 74).  An 
external calibration graph for the 194,195Pt isotopes can be seen in Figure 75.  The 
reason that bar charts have been drawn up to qualitatively compare the Pt present in 
each leachate solution rather than calculating concentration by the external calibration 
is that the signals measured were far out of the calibration range that was expected. 
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Figure 69.  A Bar Chart Comparing m/z = 194 Signals (cps) Between Centrifuge Filter Leachate 
Solutions of the DNA/Cisplatin Samples Studied for Study 4. 
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Figure 70.  A Bar Chart Comparing m/z = 195 Signals (cps) Between Centrifuge Filter Leachate 
Solutions of the DNA/Cisplatin Samples Studied for Study 4. 
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Figure 71.  A Bar Chart Comparing m/z = 194 Signals (cps) Between Centrifuge Filter Leachate 
Solutions of the DNA/Oxaliplatin Samples Studied for Study 4. 
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Figure 72.  A Bar Chart Comparing m/z = 195 Signals (cps) Between Centrifuge Filter Leachate 
Solutions of the DNA/Oxaliplatin Samples Studied for Study 4. 
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Figure 73.  A Bar Chart Comparing m/z = 31 Signals (cps) Between Centrifuge Filter Leachate 
Solutions of the DNA/Cisplatin Samples Studied for Study 4. 
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Figure 74.  A Bar Chart Comparing m/z = 31 Signals (cps) Between Centrifuge Filter Leachate 
Solutions of the DNA/Oxaliplatin Samples Studied for Study 4. 
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Figure 75.  An External Calibration Graph Comparing Pt Standard Concentration (μg l-1) with 
m/z = 194 and 195 Signal (cps) for the Centrifuge Filter Leachate Solutions of the DNA/Cisplatin 
and DNA/Oxaliplatin Samples Studied for Study 4. 
 
 
The data accrued during the study of these centrifuge filter leachate solutions has 
proved to be very interesting and has provided some contradicting information 
compared to that of the previous studies (studies 2 to 4).  Two major issues have been 
raised as a result of study of the data produced.  It should be noted that in the data 
tables and bar charts, a signal of 0 ion counts per second represents a signal of such 
great intensity that it exceeded the capability of the electron multiplier detector.  
Although an external calibration was carried out during the analysis of the leachate 
solutions, the calibration range was not compatible with the Pt signals obtained from 
the samples (most such signals exceeded that of the top standard of 15 μg l-1 so can be 
described as being in excess of this particular concentration).  For this reason the work 
cannot be discussed in terms of quantification.  Instead, analytical signals are 
compared in a qualitative fashion. 
 
On comparison of the Pt signals between sample solutions it can be seen that there is 
very little Pt present in either the deionised water blank, DNA control or centrifuge 
tube blank solutions (for both the cisplatin and oxaliplatin sample series) compared to 
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the drug exposed sample tube leachates.  So, from this information, the first issue for 
discussion is that each centrifuge filter leachate solution contains large quantities of 
Pt.  In most cases those quantities of Pt seem to exceed those measured in previous 
solutions, obtained following separation of the drug and DNA target species, and are 
assumed to be in the μg l-1 (ppb) to mg l-1 (ppm) range.  One conclusion that could be 
drawn from this data is that in previous sample solutions (obtained following the 
separation), during the sample treatment there was one or more problematic 
procedural stages that resulted in such quantities of Pt being left behind.  Such stages 
could either have been associated with the separation of species (i.e. the NH3 
treatment did not efficiently remove drug species or caused fragmentation of the DNA 
strands such that fragments containing the Pt were in excess of 10 000 molecular 
weight so were not allowed through the filter) or the filtering process (i.e. the filters 
were not particularly efficient).  Another conclusion, however, far less likely is that 
there could be a contamination issue associated with these centrifuge filter tubes that 
results in erroneous data.  On comparison of the data accrued from the cisplatin and 
oxaliplatin filter leachate solutions there appears to be a significant difference.  For 
the oxaliplatin leachates several of the more concentrated sample signals are very high 
(in the region of 3 million to 4 million cps) but none exceed the capability of the 
detector unlike many of the cisplatin leachates.  This comparison could highlight a 
difference between these two drugs with regard to the interaction between drug and 
target species. 
 
The second issue to consider is that of the 31P measurements.  The study of the 31P bar 
charts for both cisplatin and oxaliplatin samples series studied has shown that very 
large quantities of DNA molecules and fragments are retained on the filter during the 
separation process.  Comparing the 31P signals obtained from these leachates with 
those from the separated samples analysed during studies 2 to 4 shows that far more 
31P containing components are retained on the centrifuge filters than are allowed 
through.  This suggests that the NH3 treatment caused some fragmentation of the 
DNA target molecule during the separation processes but that breakdown was not 
complete. 
 
At this stage it could be argued that the centrifuge filter leachate data suggests that the 
previous studies, involving the separation of drug and target, were not carried out as 
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efficiently as they could have been and that the unwanted retention of Pt species has a 
significant effect on the limit of measurement and possibly the calculated binding 
constant (see Section 4.5).  However, it appears that there may be a complication to 
this idea and this is the third issue for consideration.  There is contradictory 
information from the previous studies (particularly study 4) in the form of the linear 
relationship between drug exposure concentration and ICP-MS signal (m/z = 194 and 
195) seen following analysis of the separated solutions.  This linear relationship on its 
own would suggest an efficient separation and analysis of a majority of the Pt species, 
however, from the leachate data, it is known that this is not the case.  This conflicting 
information leads to the idea that the Pt species measured in the separated solutions 
and the leachate solutions could differ in terms of the type of binding interaction with 
the DNA target.  As described in Section 4.2.3 there are two major types of binding 
interaction between the cisplatin and oxaliplatin drugs and DNA (inter- and intra-
strand covalent binding) as well as far less significant non-covalent groove binding 
interactions.156, 162, 173, 175, 180  Armed with this information, conclusions can be drawn 
from the qualitative comparison of data between the studies carried out and the 
investigation of centrifuge tube filters.  From the data that has been accrued during the 
first studies (studies 2 to 4) as well as the investigation into the centrifuge tube filters 
of study 4 it can be said that there are two significant sources of Pt being measured; 
the Pt being removed from the DNA via NH3 treatment and the Pt being left behind 
on the filters.  A qualitative comparison of the order of signal derived from these two 
Pt sources suggests that the larger quantity of Pt, that being left behind on the filters, 
was in the form of covalently bound interstrand DNA adducts (that could not be 
removed under the NH3 treatment due to the steric conditions) whilst the smaller Pt 
quantity, measured following the separation process, was in the form of covalently 
bound intrastrand DNA adducts. 
 
This qualitative comparison suggests differences in binding strength, between the two 
types, on exposure to the NH3 treatment.  To confirm these conclusions other 
analytical techniques would be required to establish the number of types of adduct 
species present and their structure.  HPLC-MS and NMR would provide invaluable, 
additional, information in this case. 
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The data generated during the investigation of the centrifuge tube filters, employed 
during study 4, has provided information that allows better understanding of the data 
provided by the studies that preceded it.  Although structural information would be 
required to confirm this the experiments carried out for this investigation have 
suggested that the cisplatin and oxaliplatin drugs are forming adducts with the DNA 
target via both covalent inter- and intra-strand forms of binding.  It would appear that 
following an NH3 treatment the majority of covalently bound interstrand Pt based 
adducts were not removed and were retained on the filter whilst the majority of 
covalently bound intrastrand DNA adducts were removed and allowed through during 
the centrifugation process. 
 
As a final experiment it was decided that an analysis of drug exposed DNA samples, 
without incorporating the separation process, was required in order to measure the 
total quantity of Pt based drug associated with the DNA target (and hence produce 
more realistic Kf and adduct ratio data).  Although this was originally believed to be 
problematic, with regard to the introduction of such large quantities of DNA into the 
plasma, it was decided to attempt to analyse exposed samples with little, or no, pre-
treatment. 
 
 
4.4.5.  Study 5 
 
Although it was originally believed to be problematic, it was decided to analyse a 
series of DNA samples exposed to each drug without any further treatment by ICP-
MS.  If such a study was successful it was hoped that the data would provide an 
improved limit of measurement as well as comparable, if not better, binding constant 
data (compared to those established during studies 2 to 4). 
 
 
Experimental Details 
 
For this final study DNA samples were prepared and exposed to both drugs (cisplatin 
and oxaliplatin) by the same method as that described for the previous studies (see 
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Tables 28 and 29 in section 4.4.3).  Following preparation, aliquots of each sample 
were diluted approximately forty fold and analysed by UV spectroscopy to establish 
the final DNA concentration, see Tables 131 and 132.  Samples were studied for Pt 
and P isotope content under optimum conditions (see Table 133, Appendix 4).  Due to 
limitations of the prepared Pt standard range several of the more concentrated sample 
solutions, between both cisplatin and oxaliplatin drugs, were diluted prior to analysis 
to allow quantification.  Results of the sample analysis described can be seen in the 
next section. 
 
 
Results and Discussion 
 
The data generated following the ICP-QMS study of these drug exposed whole DNA 
solutions and DNA based Pt external standards can be seen in Tables 134, 135 and 
136.  From the data accrued from the standard solutions a calibration curve was 
generated to allow the calculation of Pt concentration of each sample solution to be 
established (see Figure 76).  As some sample dilutions were undertaken during 
analysis, graphs to show linearity between drug exposure and ICP-QMS signal can be 
seen in Figures 77 and 78 following the establishment of sample concentration. 
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Figure 76.  An External Calibration Graph Comparing DNA Based Pt Standard Concentration 
(ng l-1) with m/z = 194 and 195 Signal (cps) for the Untreated DNA/Cisplatin and 
DNA/Oxaliplatin Samples Solutions Studied During Study 5. 
 
 
Following interpretation of the data accrued during this study several issues came to 
light, some of which have implications with regard to the conclusions drawn from 
previous studies.  The first obvious issue for discussion is that of the overall 
successful ICP-MS analysis of both untreated DNA/drug sample series.  Originally it 
was believed that a DNA solution of a concentration of 1 mg ml-1 would yield 
significant matrix effects to an analysis (if indeed it could be analysed without 
extinguishing the ICP).  It is clear from the mean raw data of this study (see Tables 
135 and 136) that the significant quantities of Pt present in each sample solution could 
be measured reliably based on matrix matched standard solutions indicating that the 
separation of drug and target species need not be necessary when considering such 
samples. 
 
Secondly, the ion intensity for Pt shows a limit of measurement of both drugs to be 
below the region of 1 drug molecule per 500 000 DNA nucleotides, i.e. the m/z = 194 
and 195 signals for that lowest exposure concentration was significantly elevated 
above that of the blank and control solutions.  Such LOD’s are far superior to those 
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calculated in previous studies and show that ICP-MS is capable of measurement of 
these Pt based drugs below the desired therapeutic range.  During studies 2 to 4 there 
seemed to be very little difference in ICP-MS signal and LOD between the two drugs, 
however, in this fifth study this does not appear to be the case.  The m/z = 194 and 
195 signal measured for each cisplatin exposed sample appears to be of a greater 
intensity than that of the equivalent oxaliplatin exposed sample.  The concentration of 
each sample analysed was established via the external calibration equations of Figure 
76.  The calculated concentration values can be seen in Tables 40 to 43 (which 
include dilution factors and corrections made during this analysis). 
 
To highlight the linearity between drug exposure concentration and ICP-MS signal (in 
this case the measured and calculated Pt concentration), two graphs were constructed 
to compare these two parameters, see Figures 77 and 78. 
 
 
Table 40.  194Pt Isotope Content of the Untreated DNA/Cisplatin Sample Solutions Analysed 
During Study 5. 
N° of DNA 
Nucleotides 
Per Cisplatin 
N° of Cisplatins 
Per DNA 
Nucleotide 
194Pt Stds 
Curve 
Equation 
m/z = 194 
Sample 
Signal (cps) 
194Pt Concn 
(ng l-1) 
DI Water Blank DI Water Blank y = 61.354x – 48372 141.001 790.7 
Control Control y = 61.354x – 48372 295.67 793.2 
100 (Diln x 25) 0.01 y = 61.354x – 48372 2685407 44557 (1113925) 
500 (Diln x 20) 0.002 y = 61.354x – 48372 543279 9643 (192860) 
1 000 (Diln x 5) 0.001 y = 61.354x – 48372 1058457 18040 (90200) 
5 000 0.0002 y = 61.354x – 48372 864789 14883 
10 000 0.0001 y = 61.354x – 48372 488285 8747 
50 000 0.00002 y = 61.354x – 48372 91931.4 2287 
100 000 0.00001 y = 61.354x – 48372 44915.8 1520 
250 000 0.000004 y = 61.354x – 48372 17035.8 1066 
500 000 0.000002 y = 61.354x - 48372 10975.2 967.3 
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Table 41.  194Pt Isotope Content of the Untreated DNA/Oxaliplatin Sample Solutions Analysed 
During Study 5. 
N° of DNA 
Nucleotides Per 
Oxaliplatin 
N° of 
Oxaliplatins Per 
DNA Nucleotide 
194Pt Stds 
Curve 
Equation 
m/z = 194 
Sample 
Signal (cps) 
194Pt Concn 
(ng l-1) 
DI Water Blank DI Water Blank y = 61.354x – 48372 141.001 790.7 
Control Control y = 61.354x – 48372 270.003 792.8 
100 (Diln x 25) 0.01 y = 61.354x – 48372 244942 4781 (119525) 
500 0.002 y = 61.354x – 48372 1655373 27769 
1 000 0.001 y = 61.354x – 48372 427880 7762 
5 000 0.0002 y = 61.354x – 48372 122725 2789 
10 000 0.0001 y = 61.354x – 48372 68308.6 1902 
50 000 0.00002 y = 61.354x – 48372 16262.9 1053 
100 000 0.00001 y = 61.354x – 48372 7834.82 916.1 
250 000 0.000004 y = 61.354x – 48372 4335.33 859.1 
500 000 0.000002 y = 61.354x – 48372 2083.15 822.4 
 
 
Table 42.  195Pt Isotope Content of the Untreated DNA/Cisplatin Sample Solutions Analysed 
During Study 5. 
N° of DNA 
Nucleotides 
Per Cisplatin 
N° of Cisplatins 
Per DNA 
Nucleotide 
195Pt Stds 
Curve 
Equation 
m/z = 195 
Sample 
Signal (cps) 
195Pt Concn (ng 
l-1) 
DI Water Blank DI Water Blank y = 63.275x – 49344 157.001 782.3 
Control Control y = 63.275x – 49344 297.67 784.5 
100 (Diln x 25) 0.01 y = 63.275x – 49344 2788651 44852 (1121300) 
500 (Diln x 20) 0.002 y = 63.275x – 49344 564077 9695 (193900) 
1 000 (Diln x 5) 0.001 y = 63.275x – 49344 1097030 18117 (90585) 
5 000 0.0002 y = 63.275x – 49344 905806 15095 
10 000 0.0001 y = 63.275x – 49344 506702 8788 
50 000 0.00002 y = 63.275x – 49344 95442.2 2288 
100 000 0.00001 y = 63.275x – 49344 46091.9 1508 
250 000 0.000004 y = 63.275x – 49344 17787.4 1061 
500 000 0.000002 y = 63.275x – 49344 11304.8 958.5 
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Table 43.  195Pt Isotope Content of the Untreated DNA/Oxaliplatin Sample Solutions Analysed 
During Study 5. 
N° of DNA 
Nucleotides Per 
Oxaliplatin 
N° of 
Oxaliplatins Per 
DNA Nucleotide 
195Pt Stds 
Curve 
Equation 
m/z = 195 
Sample 
Signal (cps) 
195Pt Concn 
(ng l-1) 
DI Water Blank DI Water Blank y = 63.275x – 49344 157.001 782.3 
Control Control y = 63.275x – 49344 290.336 784.4 
100 (Diln x 25) 0.01 y = 63.275x – 49344 254474 4802 (120050) 
500 0.002 y = 63.275x – 49344 1708544 27782 
1 000 0.001 y = 63.275x – 49344 442770 7777 
5 000 0.0002 y = 63.275x – 49344 127394 2793 
10 000 0.0001 y = 63.275x – 49344 70903.2 1900 
50 000 0.00002 y = 63.275x – 49344 16965.7 1048 
100 000 0.00001 y = 63.275x – 49344 8213.03 909.6 
250 000 0.000004 y = 63.275x – 49344 4575.73 852.1 
500 000 0.000002 y = 63.275x – 49344 2160.83 814.0 
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Figure 77. A Graph Comparing Number of Drug Molecules Per Nucleotide with the ICP-MS 
Measured Pt Concentration for the Study of Cisplatin Exposed DNA Samples (Study 5). 
 
 
 227
y = 1E+07x + 520.04
R2 = 0.9973
y = 1E+07x + 501.74
R2 = 0.9973
0
20000
40000
60000
80000
100000
120000
140000
0 0.002 0.004 0.006 0.008 0.01 0.012
Number of Oxaliplatin Molecules Per DNA Nucleotide
IC
P-
M
S 
M
ea
su
re
d 
Pt
 C
on
ce
nt
ra
tio
n 
(n
g/
l)
m/z = 194
m/z = 195
Linear (m/z = 194)
Linear (m/z = 195)
 
Figure 78.  A Graph Comparing Number of Drug Molecules Per Nucleotide with the ICP-MS 
Measured Pt Concentration for the Study of Oxaliplatin Exposed DNA Samples (Study 5). 
 
 
Figures 77 and 78 show that there is very good linearity between drug exposure 
(number of drug molecules per DNA nucleotide) and the measured Pt concentration 
for both cisplatin and oxaliplatin.  Such linearity is far superior to that of the previous 
studies involving the separation of drug and target. 
 
As can be seen in Tables 135 and 136, for a majority of the drug sample solutions 
studied the m/z = 31 signals were in excess of the detector capability.  For some of the 
samples exhibiting higher drug exposure concentrations the measurement of the 31P+ 
ion appears to be reduced such that data of the order of 1 to 3 million cps is observed.  
There are two potential reasons for this, the first being the presence of a lower 
quantity of DNA in these samples and the second being that the increased presence of 
Pt (which has slightly lower ionisation potential, 9 eV compared to 10.5 eV of P) was 
preferentially forming ions over 31P. 
 
This study was carried out with the aim of establishing the necessity for the separation 
of the drug and target species by gauging the degree of potential matrix effects that 
could originate from the high concentration of DNA.  Not only did this fifth study 
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show that the separation was not required but it also revealed that direct analysis of 
the sample solutions allows the measurement of Pt at concentrations below that of the 
therapeutic region of these drugs.  This work, as well as conclusions drawn from the 
previous studies, has also highlighted a possible difference in the degree of interaction 
strength between the two types of covalent binding that is possible between the drug 
and target molecules (inter- and intra-strand binding).  Direct comparison between the 
data associated with cisplatin and that of oxaliplatin has shown that there were 
significant differences in the degree of binding.  Such differences were not observed 
following the separation of drug and target during studies 2 to 4. 
 
Following the success of this fifth study (and the provision of some information that 
contradicts that of studies 2 to 4), similar to studies 2 to 4, work was commenced on 
establishing binding constant data for use as the basis of a clinical test for the 
determination of drug efficacy of cisplatin and oxaliplatin in individual patients, see 
section 4.5. 
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4.5.  The Calculation of DNA and Pt Based Drug Formation 
Constants (K f) and Adduct Ratios 
 
Using the data accrued during studies 2 to 5, the calculation of a formation constant 
(Kf) for the cisplatin-nucleotide and oxaliplatin-nucleotide species can be attempted as 
well as that of the number of drug-target adducts actually being formed per DNA 
nucleotide.  Such Kf and adduct data would provide information considering the 
efficiency of binding between these Pt based drug molecules and the nucleotides of a 
DNA strand. 
 
 
4.5.1.  Formation Constant (Kf) Theory 
 
To determine a Kf value in the case of the species involved in these studies the 
exposure reaction between reactant (the Pt drug and nucleotide) molecules must be 
considered, see the equation in Figure 79. 
 
 
 
][][][ ABBA ↔+  Or ][][][ NPtPtN ↔+  
 
Where: 
[A]:  Molar Concentration of Species A 
[B]:  Molar Concentration of Species B 
[AB]:  Molar Concentration of Product Species 
 
[N]:  Molar Concentration of DNA Nucleotides 
[Pt]:  Molar Concentration of Pt Based Drug 
[NPt]:  Molar Concentration of Drug Bound DNA Nucleotide 
Figure 79.  The Equilibrium Reaction between DNA Nucleotides and Pt Based Drug Molecules. 
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As can be seen in Figure 79 the interaction between reactant species, in this case the 
DNA nucleotide and Pt based drug molecules, is described in terms of an equilibrium 
process involving the formation of a product, ‘adduct’, species.  Normally, when 
considering such a reaction the equation in Figure 80 would be appropriate for the 
calculation of a formation constant (Kf). 
 
 
 
][][
][
BA
ABK f =   Or    ][][
][
PtN
NPtK f =  
 
Where: 
Kf:  Formation Constant 
 
[A]:  Molar Concentration of Species A 
[B]:  Molar Concentration of Species B 
[AB]:  Molar Concentration of Product Species 
 
[N]:  Molar Concentration of DNA Nucleotides 
[Pt]:  Molar Concentration of Pt Based Drug 
[NPt]:  Molar Concentration of Drug Bound DNA Nucleotide 
Figure 80.  The Equation Required for the Determination of a Formation Constant (Kf). 
 
 
When normally describing such an equilibrium the reactant and product species are 
considered in terms of molar concentrations.  However, in this case such 
concentrations are not available as DNA does not have a standard molecular weight 
due to variation between individuals.  Therefore, to successfully calculate a Kf value 
the equation in Figure 80 must be altered, this is to be carried out for two reasons.  
Firstly, in this case, the Kf will be calculated in terms of ‘numbers of species’ (i.e. 
number of atoms or molecules) present during the interaction and secondly the 
equation in Figure 80 does not represent an equilibrium with regard to such numbers.  
To balance the equation in Figure 80 for equilibrium, the number concentration of the 
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drug bound nucleotide must be subtracted from the number concentrations of the 
DNA nucleotides and the Pt based drug molecules, respectively.  The result of this is 
the equation seen in Figure 81. 
 
 
 
])[]([])[]([
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f −−=  
 
Or 
 
])[]([])[]([
][
NPtPtNPtN
NPtK
ii
f −−=  
 
Where: 
Kf:  Formation Constant 
 
[Ai]:  Initial Number Concentration of Species A 
[Bi]:  Initial Number Concentration of Species B 
[AB]:  Number Concentration of Product Species 
 
[Ni]:  Initial Number Concentration of DNA Nucleotides 
[Pti]:  Initial Number Concentration of Pt Based Drug 
[NPt]:  Number Concentration of Drug Bound DNA Nucleotide 
Figure 81.  The Altered Equation Required for the Determination of a Formation Constant (Kf). 
 
 
In order to establish Kf and adduct information for the samples analysed during 
studies 2 to 4 the data obtained must be converted into forms compatible with the 
components of the altered equation in Figure 81.  To convert this data the following 
equations were utilised and all parameters were converted to standard international 
(SI) units (see Figure 82). 
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d) 
LitrePersNucleotideofN
LitrePerFormedAdductsetTDrugofNNucleotideDNAPerFormedAdductsofN °
−°=° arg  
 
Where: 
[DNA]: Concentration of DNA 
RMM:  Relative Molecular Mass 
RAM:  Relative Atomic Mass 
Figure 82.  Additional Equations Used During the Conversion of Study Data to Components Required for the Calculation of Kf and Number of Adducts Formed.  
a) An Equation for the Calculation of the Number of Nucleotides Per Litre.  b) An Equation for the Calculation of the Number of Pt Atoms Exposed Per Litre.  c) 
An Equation for the Calculation of the Number of Drug-Target Adducts Formed Per Litre.  d) An Equation for the Calculation of the Number of Adducts formed 
Per DNA Nucleotide. 
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4.5.2.  Formation Constant (Kf) and Adduct Ratios: Calculations 
 
Formation constants and ratios were calculated for each drug exposed DNA sample 
analysed between studies 2 and 5.  The data used for these calculations and the 
resultant values themselves can be seen in Tables 44 to 50. 
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 Table 44.  Further Data Generated During the Calculation of Kf and the Ratio of Number of Adducts Per DNA Nucleotide for the Cisplatin Exposed DNA Samples 
Analysed During Study 2. 
Sample Identity  Final Data 
(Number of 
DNA 
Nucleotides 
Per Cisplatin 
Molecule) 
(Number of 
Cisplatin 
Molecules Per 
DNA 
Nucleotide) 
DNA Concn 
(mg ml-1) 
Number of 
DNA 
Nucleotides Per 
Litre 
Number of Pt 
Atoms 
Exposed Per 
Litre 
Concn of 195Pt 
(mg l-1): 
Established 
by ICP-QMS 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
Litre 
Kf 
(Per Number 
Litre) 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
DNA 
Nucleotide 
Blank 0 0 0 - 0.00044 1.36 x 1015 - - 
Control 0 1 1.96 x 1021 - 0.00036 1.11 x 1015 - - 
10 000 0.0001 1 1.96 x 1021 1.96 x 1017 0.00562 1.74 x 1016 4.97 x 10-23 8.86 x 10-06 
50 000 0.00002 1 1.96 x 1021 3.92 x 1016 0.00136 4.20 x 1015 6.14 x 10-23 2.14 x 10-06 
100 000 0.00001 1 1.96 x 1021 1.96 x 1016 0.00069 2.13 x 1015 6.24 x 10-23 1.09 x 10-06 
500 000 0.000002 1 1.96 x 1021 3.92 x 1015 0.00048 1.48 x 1015 3.11 x 10-22 7.57 x 10-07 
1 000 000 0.000001 1 1.96 x 1021 1.96 x 1015 0.00044 1.36 x 1015 1.16 x 10-21 6.94 x 10-07 
5 000 000 0.0000002 1 1.96 x 1021 3.92 x 1014 0.00046 1.42 x 1015 -7.05 x 10-22 7.25 x 10-07 
10 000 000 0.0000001 1 1.96 x 1021 1.96 x 1014 0.0005 1.54 x 1015 -5.85 x 10-22 7.88 x 10-07 
50 000 000 0.00000002 1 1.96 x 1021 3.92 x 1013 0.00045 1.39 x 1015 -5.26 x 10-22 7.10 x 10-07 
100 000 000 0.00000001 1 1.96 x 1021 1.96 x 1013 0.00042 1.30 x 1015 -5.19 x 10-22 6.62 x 10-07 
500 000 000 0.000000002 1 1.96 x 1021 3.92 x 1012 0.00041 1.27 x 1015 -5.12 x 10-22 6.47 x 10-07 
1 000 000 000 0.000000001 1 1.96 x 1021 1.96 x 1012 0.00041 1.27 x 1015 -5.12 x 10-22 6.47 x 10-07 
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Table 45.  Further Data Generated During the Calculation of Kf and the Ratio of Number of Adducts Per DNA Nucleotide for the Cisplatin Exposed DNA Samples 
Analysed During Study 3. 
Sample Identity  Final Data 
(Number of 
DNA 
Nucleotides 
Per Cisplatin 
Molecule) 
(Number of 
Cisplatin 
Molecules Per 
DNA 
Nucleotide) 
DNA Concn 
(mg ml-1) 
Number of 
DNA 
Nucleotides Per 
Litre 
Number of Pt 
Atoms 
Exposed Per 
Litre 
Concn of 195Pt 
(mg l-1): 
Established 
by ICP-QMS 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
Litre 
Kf 
(Per Number 
Litre) 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
DNA 
Nucleotide 
Blank 0 0 0 - - - - - 
Control 0 1 1.96 x 1021 - 0.00017 5.25 x 1014 - 2.68 x 10-07 
50 0.02 1 1.96 x 1021 3.92 x 1019 - - - - 
100 0.01 1 1.96 x 1021 1.96 x 1019 0.11616 3.59 x 1017 9.53 x 10-24 1.83 x 10-04 
500 0.002 1 1.96 x 1021 3.92 x 1018 0.02251 6.95 x 1016 9.23 x 10-24 3.55 x 10-05 
1 000 0.001 1 1.96 x 1021 1.96 x 1018 0.0255 7.87 x 1016 2.14 x 10-23 4.02 x 10-05 
5 000 0.0002 1 1.96 x 1021 3.92 x 1017 0.00429 1.32 x 1016 1.79 x 10-23 6.77 x 10-06 
10 000 0.0001 1 1.96 x 1021 1.96 x 1017 0.00435 1.34 x 1016 3.76 x 10-23 6.86 x 10-06 
50 000 0.00002 1 1.96 x 1021 3.92 x 1016 0.00085 2.62 x 1015 3.67 x 10-23 1.34 x 10-06 
100 000 0.00001 1 1.96 x 1021 1.96 x 1016 0.00025 7.72 x 1014 2.10 x 10-23 3.94 x 10-07 
500 000 0.000002 1 1.96 x 1021 3.92 x 1015 0.00019 5.87 x 1014 9.00 x 10-23 3.00 x 10-07 
1 000 000 0.000001 1 1.96 x 1021 1.96 x 1015 0.00114 3.52 x 1015 -1.15 x 10-21 1.80 x 10-06 
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Table 46.  Further Data Generated During the Calculation of Kf and the Ratio of Number of Adducts Per DNA Nucleotide for the Oxaliplatin Exposed DNA 
Samples Analysed During Study 3. 
Sample Identity  Final Data 
(Number of 
DNA 
Nucleotides 
Per Cisplatin 
Molecule) 
(Number of 
Cisplatin 
Molecules Per 
DNA 
Nucleotide) 
DNA Concn 
(mg ml-1) 
Number of 
DNA 
Nucleotides Per 
Litre 
Number of Pt 
Atoms 
Exposed Per 
Litre 
Concn of 195Pt 
(mg l-1): 
Established 
by ICP-QMS 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
Litre 
Kf 
(Per Number 
Litre) 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
DNA 
Nucleotide 
Blank 0 0 0 - < 0.0003 - - - 
Control 0 1 1.96 x 1021 - 0.0003 9.26 x 1014 - 4.73 x 10-07 
50 0.02 1 1.96 x 1021 3.92 x 1019 > 0.14187 - - - 
100 0.01 1 1.96 x 1021 1.96 x 1019 0.14187 4.38 x 1017 1.17 x 10-23 2.24 x 10-04 
500 0.002 1 1.96 x 1021 3.92 x 1018 0.04021 1.24 x 1017 1.67 x 10-23 6.34 x 10-05 
1 000 0.001 1 1.96 x 1021 1.96 x 1018 0.02295 7.08 x 1016 1.92 x 10-23 3.62 x 10-05 
5 000 0.0002 1 1.96 x 1021 3.92 x 1017 0.00523 1.61 x 1016 2.20 x 10-23 8.25 x 10-06 
10 000 0.0001 1 1.96 x 1021 1.96 x 1017 0.0036 1.11 x 1016 3.07 x 10-23 5.68 x 10-06 
50 000 0.00002 1 1.96 x 1021 3.92 x 1016 0.00218 6.73 x 1015 1.06 x 10-22 3.44 x 10-06 
100 000 0.00001 1 1.96 x 1021 1.96 x 1016 0.00056 1.73 x 1015 4.95 x 10-23 8.83 x 10-07 
500 000 0.000002 1 1.96 x 1021 3.92 x 1015 0.00043 1.33 x 1015 2.62 x 10-22 6.78 x 10-07 
1 000 000 0.000001 1 1.96 x 1021 1.96 x 1015 0.00039 1.20 x 1015 8.16 x 10-22 6.15 x 10-07 
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Table 47.  Further Data Generated During the Calculation of Kf and the Ratio of Number of Adducts Per DNA Nucleotide for the Cisplatin Exposed DNA Samples 
Analysed During Study 4. 
Sample Identity  Final Data 
(Number of 
DNA 
Nucleotides 
Per Cisplatin 
Molecule) 
(Number of 
Cisplatin 
Molecules Per 
DNA 
Nucleotide) 
DNA Concn 
(mg ml-1) 
Number of 
DNA 
Nucleotides Per 
Litre 
Number of Pt 
Atoms 
Exposed Per 
Litre 
Concn of 195Pt 
(mg l-1): 
Established 
by ICP-QMS 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
Litre 
Kf 
(Per Number 
Litre) 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
DNA 
Nucleotide 
Blank 2 0 0 0 - 0.00007 2.16 x 1014 - - 
Control 2 0 1 1.96 x 1021 - 0.00013 4.01 x 1014 - 2.05 x 10-07 
100 0.01 1 1.96 x 1021 1.96 x 1019 0.42118 1.3 x 1018 3.64 x 10-23 6.64 x 10-04 
150 A 0.006666667 1 1.96 x 1021 1.31 x 1019 0.26188 8.08 x 1017 3.37 x 10-23 4.13 x 10-04 
150 B 0.006666667 1 1.96 x 1021 1.31 x 1019 0.2448 7.56 x 1017 3.14 x 10-23 3.86 x 10-04 
300 A 0.003333333 1 1.96 x 1021 6.53 x 1018 0.10928 3.37 x 1017 2.79 x 10-23 1.72 x 10-04 
300 B 0.003333333 1 1.96 x 1021 6.53 x 1018 0.11569 3.57 x 1017 2.96 x 10-23 1.82 x 10-04 
500 0.002 1 1.96 x 1021 3.92 x 1018 0.05031 1.55 x 1017 2.11 x 10-23 7.93 x 10-05 
1 000 0.001 1 1.96 x 1021 1.96 x 1018 0.03824 1.18 x 1017 3.28 x 10-23 6.03 x 10-05 
5 000 0.0002 1 1.96 x 1021 3.92 x 1017 0.00601 1.86 x 1016 2.54 x 10-23 9.48 x 10-06 
10 000 0.0001 1 1.96 x 1021 1.96 x 1017 0.00404 1.25 x 1016 3.48 x 10-23 6.37 x 10-06 
50 000 0.00002 1 1.96 x 1021 3.92 x 1016 0.00113 3.49 x 1015 5.00 x 10-23 1.78 x 10-06 
100 000 0.00001 1 1.96 x 1021 1.96 x 1016 0.00079 2.44 x 1015 7.27 x 10-23 1.25 x 10-06 
250 000 A 0.000004 1 1.96 x 1021 7.83 x 1015 0.0002 6.17 x 1014 4.37 x 10-23 3.15 x 10-07 
250 000 B 0.000004 1 1.96 x 1021 7.83 x 1015 0.00021 6.48 x 1014 4.61 x 10-23 3.31 x 10-07 
250 000 C 0.000004 1 1.96 x 1021 7.83 x 1015 0.0002 6.17 x 1014 4.37 x 10-23 3.15 x 10-07 
500 000 0.000002 1 1.96 x 1021 3.92 x 1015 0.00049 1.51 x 1015 3.22 x 10-22 7.73 x 10-07 
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Table 48.  Further Data Generated During the Calculation of Kf and the Ratio of Number of Adducts Per DNA Nucleotide for the Oxaliplatin Exposed DNA 
Samples Analysed During Study 4. 
Sample Identity  Final Data 
(Number of 
DNA 
Nucleotides 
Per 
Oxaliplatin 
Molecule) 
(Number of 
Oxaliplatin 
Molecules Per 
DNA 
Nucleotide) 
DNA Concn 
(mg ml-1) 
Number of 
DNA 
Nucleotides Per 
Litre 
Number of Pt 
Atoms 
Exposed Per 
Litre 
Concn of 195Pt 
(mg l-1): 
Established 
by ICP-QMS 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
Litre 
Kf 
(Per Number 
Litre) 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
DNA 
Nucleotide 
Blank 2 0 0 0 - 0.00014 4.32 x 1014 - - 
Control 2 0 1 1.96 x 1021 - - - - - 
100 0.01 1 1.96 x 1021 1.96 x 1019 0.33284 1.03 x 1018 2.83 x 10-23 5.25 x 10-04 
150 A 0.006666667 1 1.96 x 1021 1.31 x 1019 0.29586 9.13 x 1017 3.85 x 10-23 4.67 x 10-04 
150 B 0.006666667 1 1.96 x 1021 1.31 x 1019 0.53273 1.64 x 1018 7.37 x 10-23 8.40 x 10-04 
300 A 0.003333333 1 1.96 x 1021 6.53 x 1018 0.1456 4.49 x 1017 3.78 x 10-23 2.30 x 10-04 
300 B 0.003333333 1 1.96 x 1021 6.53 x 1018 0.13885 4.29 x 1017 3.59 x 10-23 2.19 x 10-04 
500 0.002 1 1.96 x 1021 3.92 x 1018 0.06582 2.03 x 1017 2.80 x 10-23 1.04 x 10-04 
1 000 0.001 1 1.96 x 1021 1.96 x 1018 0.0327 1.01 x 1017 2.78 x 10-23 5.16 x 10-05 
5 000 0.0002 1 1.96 x 1021 3.92 x 1017 0.00849 2.62 x 1016 3.66 x 10-23 1.34 x 10-05 
10 000 0.0001 1 1.96 x 1021 1.96 x 1017 0.00455 1.40 x 1016 3.95 x 10-23 7.17 x 10-06 
50 000 0.00002 1 1.96 x 1021 3.92 x 1016 0.0012 3.70 x 1015 5.34 x 10-23 1.89 x 10-06 
100 000 0.00001 1 1.96 x 1021 1.96 x 1016 0.0015 4.63 x 1015 1.58 x 10-22 2.37 x 10-06 
250 000 A 0.000004 1 1.96 x 1021 7.83 x 1015 0.00026 8.03 x 1014 5.83 x 10-23 4.10 x 10-07 
250 000 B 0.000004 1 1.96 x 1021 7.83 x 1015 0.00036 1.11 x 1015 8.45 x 10-23 5.68 x 10-07 
250 000 C 0.000004 1 1.96 x 1021 7.83 x 1015 0.00056 1.73 x 1015 1.45 x 10-22 8.83 x 10-07 
500 000 0.000002 1 1.96 x 1021 3.92 x 1015 0.00004 1.23 x 1014 1.66 x 10-23 6.31 x 10-08 
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Table 49.  Further Data Generated During the Calculation of Kf and the Ratio of Number of Adducts Per DNA Nucleotide for the Cisplatin Exposed DNA Samples 
Analysed During Study 5. 
Sample Identity  Final Data 
(Number of 
DNA 
Nucleotides 
Per Cisplatin 
Molecule) 
DNA Concn 
(mg ml-1) 
Number of 
DNA 
Nucleotides Per 
Litre 
Number of Pt 
Atoms 
Exposed Per 
Litre 
Concn of 195Pt 
(mg l-1): 
Established 
by ICP-QMS 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
Litre 
Kf 
(Per Number 
Litre) 
(Number of 
Cisplatin 
Molecules Per 
DNA 
Nucleotide) 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
DNA 
Nucleotide 
2.42 x 1015 Blank 0 0 0 - 0.0007823 - - 
Control 0 1 1.96 x 1021 - 0.0007845 2.42 x 1015 - 1.23 x 10-06 
100 0.01 1.96 x 1021 1.96 x 1019 1.1213 3.46 x 1018 1.10 x 10-22 1.77 x 10-03 1 
0.002 1 1.96 x 1021 3.92 x 1018 0.1939 5.99 x 1017 9.22 x 10-23 3.06 x 10-04 500 
1 000 0.001 1 1.96 x 1021 1.96 x 1018 0.090585 2.80 x 1017 8.51 x 10-23 1.43 x 10-04 
5 000 0.0002 1 1.96 x 1021 3.92 x 1017 0.015095 4.66 x 1016 6.90 x 10-23 2.38 x 10-05 
10 000 0.0001 1 1.96 x 1021 1.96 x 1017 0.008788 2.71 x 1016 8.22 x 10-23 1.39 x 10-05 
0.00002 1 1.96 x 1021 3.92 x 1016 0.002288 7.06 x 1015 1.12 x 10-22 3.61 x 10-06 50 000 
100 000 0.00001 1 1.96 x 1021 1.96 x 1016 0.001508 4.66 x 1015 1.59 x 10-22 2.38 x 10-06 
250 000 0.000004 1 1.96 x 1021 7.83 x 1015 0.001061 3.28 x 1015 3.67 x 10-22 1.67 x 10-06 
500 000 0.000002 1 1.96 x 1021 3.92 x 1015 0.0009585 2.96 x 1015 1.58 x 10-21 1.51 x 10-06 
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Table 50.  Further Data Generated During the Calculation of Kf and the Ratio of Number of Adducts Per DNA Nucleotide for the Oxaliplatin Exposed DNA 
Samples Analysed During Study 5. 
Sample Identity  Final Data 
(Number of 
DNA 
Nucleotides 
Per 
Oxaliplatin 
Molecule) 
(Number of 
Oxaliplatin 
Molecules Per 
DNA 
Nucleotide) 
DNA Concn 
(mg ml-1) 
Number of 
DNA 
Nucleotides Per 
Litre 
Number of Pt 
Atoms 
Exposed Per 
Litre 
Concn of 195Pt 
(mg l-1): 
Established 
by ICP-QMS 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
Litre 
Kf 
(Per Number 
Litre) 
Number of 
Drug-
Nucleotide 
Adducts 
Formed Per 
DNA 
Nucleotide 
Blank 0 0 0 - 0.0007823 2.41 x 1015 - - 
Control 0 1 1.96 x 1021 - 0.0007844 2.42 x 1015 - 1.24 x 10-06 
100 0.01 1 1.96 x 1021 1.96 x 1019 0.12005 3.71 x 1017 9.86 x 10-24 1.89 x 10-04 
500 0.002 1 1.96 x 1021 3.92 x 1018 0.027782 8.58 x 1016 1.14 x 10-23 4.38 x 10-05 
1 000 0.001 1 1.96 x 1021 1.96 x 1018 0.007777 2.40 x 1016 6.34 x 10-24 1.23 x 10-05 
5 000 0.0002 1 1.96 x 1021 3.92 x 1017 0.002793 8.62 x 1015 1.15 x 10-23 4.40 x 10-06 
10 000 0.0001 1 1.96 x 1021 1.96 x 1017 0.0019 5.87 x 1015 1.58 x 10-23 3.00 x 10-06 
50 000 0.00002 1 1.96 x 1021 3.92 x 1016 0.001048 3.24 x 1015 4.60 x 10-23 1.65 x 10-06 
100 000 0.00001 1 1.96 x 1021 1.96 x 1016 0.0009096 2.81 x 1015 8.55 x 10-23 1.43 x 10-06 
250 000 0.000004 1 1.96 x 1021 7.83 x 1015 0.0008521 2.63 x 1015 2.58 x 10-22 1.34 x 10-06 
500 000 0.000002 1 1.96 x 1021 3.92 x 1015 0.000814 2.51 x 1015 9.15 x 10-22 1.28 x 10-06 
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4.5.3.  Formation Constant (Kf) and Adduct Ratios: Discussion and 
Conclusions 
 
Following analysis of the numerous Pt based drug exposed DNA samples during 
studies 2 to 5, Kf data and the number of adducts formed per DNA nucleotide were 
successfully calculated.  Table 51 compares the parameter value ranges obtained 
between the four successful studies. 
 
 
Table 51.  A General Comparison of Kf Values and Numbers of Drug-Nucleotide Adducts 
Formed Per DNA Nucleotide Between Studies 2 to 5. 
Study 
Number 
Pt Based Drug 
Identity 
Kf 
(Per Number Litre) 
Number of Drug-Nucleotide 
Adducts Formed Per DNA 
Nucleotide 
2 Cisplatin 10-21 to 10-23 10-06 to 10-07 
Cisplatin 10-21 to 10-24 10-04 to 10-07 3 
Oxaliplatin 10-22 to 10-23 10-04 to 10-07 
Cisplatin 10-22 to 10-23 10-04 to 10-07 4 
Oxaliplatin 10-22 to 10-23 10-04 to 10-07 
Cisplatin 10-21 to 10-23 10-03 to 10-06 5 
Oxaliplatin 10-22 to 10-24 10-04 to 10-06 
 
 
Between studies 2 to 5 the values calculated, for both of the final parameters, 
appeared to fall within the same ranges.  For the Kf parameter all of the calculated 
values for both cisplatin and oxaliplatin drugs were in the range of 10-21 to 10-24, such 
values were very low.  For the number of adducts formed per DNA nucleotide 
parameter all of the calculated values for both drugs were of the order of 10-03 to 10-07, 
such values would appear to be the equivalent of the numbers of drug molecules per 
DNA molecule stated by Akaboshi et al and Jamieson et al.162, 186 
 
This information gives rise to three issues that require discussion.  Firstly the 
calculated data backs up previous research suggesting that the binding between these 
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drugs and their DNA target is particularly inefficient.162, 186  As mentioned previously 
the binding of drug to DNA target was different between cisplatin and oxaliplatin in 
vivo,177, 178, 188 however, this work has shown similarities between the degree of 
binding that took place (via the calculation of Kf and the number of adducts formed 
parameters) during in vitro experiments.  The reason for this was that a huge 
environmental difference exists between in vivo and in vitro experiments.  If this 
difference is simplified slightly to compare the condition in which DNA exists within 
a cell to naked DNA in the in vitro experiment then a gulf can be seen in terms of the 
target exposure area, chemical conditions and the presence of alternate binding sites.  
Therefore, with the two drugs being structurally different, a difference in the degree of 
binding in vivo would be expected.  For the interaction between naked DNA and these 
drugs, in vitro, these environmental differences would be minimised and binding 
would be similar. 
 
Secondly, there appears to be no significant difference in the Kf and number of 
adducts per nucleotide parameters between the initial studies (2 to 4) and the final 
study (5).  The data, however, is not the best approach to comparing the studies with 
regard to how these two drugs respond as the degree of difference is rather small.  If 
the components of the equations used to calculate the two final parameters are 
considered then it can be seen that the final Pt concentrations of the samples are 
incorporated.  Therefore, if there is no significant difference in the two parameters 
between the initial and final studies then the concentration component must be being 
masked, to a certain degree, by the other components.  The best approach to a 
comparison is, therefore, to consider the Pt isotope instrument signals, at m/z = 194 
and 195, and concentrations of each sample between drugs. 
 
Finally, to describe the Kf data a range of values to cover the samples studied has been 
quoted rather than a single figure.  This shows that the calculated Kf values are 
varying according to the drug exposure concentration which implies that the 
calculated data cannot be truly described as a constant.  Although the data discussed 
in this section are adequate for describing the drug-target interaction, the original 
calculation needs to be revisited to develop an equation that can better describe a 
binding constant parameter.  With regard to using data as the basis of an efficacy test 
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the number of drug-nucleotide adducts formed data is probably more meaningful at 
this stage. 
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4.6.  Conclusions and Further Work 
 
The overall result of the work described in this chapter is that it appears that a low 
resolution quadrupole based ICP-MS instrument is more than capable of measuring Pt 
isotopes at the desired concentrations when analysing highly concentrated, drug 
exposed, DNA samples.  Therefore, such an instrument would be a viable option in 
the development of a clinical test for drug efficacy determination for blood samples 
from individual patients.  However, the overall aim of such a test is to establish the 
quantity of DNA bound drug molecules within the cell so the analyst must be able to 
appreciate the different types of drug-DNA interactions and the final distribution of 
drug molecules within a cell. 
 
A greater amount of work is required on the development of Kf equations that can 
better describe the interactions between drug and target.  Improved equations would 
lead to an easier interpretation of data generated following the analysis of patient 
DNA during an efficacy test. 
 
Further work must be carried out in this area prior to the establishment of a final test.  
Following the work that was carried out it became apparent that the separation of drug 
and target molecules to avoid potential matrix effects was not necessary.  However, 
such work has provided some very interesting data with regard to appreciating inter- 
and intra strand DNA binding and, potentially, the difference in ‘binding strength’ 
according to steric conditions.  This work has also shown that the analysis of a 1 mg 
ml-1 DNA solution (what would be considered a highly concentrated solution) via the 
usual nebuliser and spray chamber arrangement is not problematic with regard to the 
presence of non-spectroscopic interferences.  The direct introduction of such a 
sample, without further treatment, maintains a simple ICP-MS analysis.  The next step 
for this work is the study of blood samples taken from patients and untreated 
volunteers to establish the limitations of this approach in vivo.  With regard to the 
observed differences between inter- and intra-strand drug binding, it would be 
interesting to continue this work and quantitatively determine a ratio between the two 
types.  It may then be possible to relate the type of covalent binding with drug 
efficacy. 
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Chapter 5 
 
The Development of ICP-MS Interface 
Structures 
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5.1.  The ICP-MS Interface 
 
Without doubt the most important, and in many ways problematic, region of an ICP-
MS instrument is the interface between the atmospheric pressure plasma ion source 
and the mass analyser operating at vacuum conditions.  Although the design of this 
interface has been very successful, it has changed very little in the twenty years of 
commercially available instruments.  The main reason for this lack of design 
development is that the smallest change made can have a dramatic detrimental affect 
on instrument sensitivity, even the same design built with the same materials but from 
different manufacturers can produce vastly different analytical performances.189 
 
Although little has changed with regard to the interface design, research into the 
processes that take place within the region has been ongoing.  A significant degree of 
research has been carried out to establish the fate of plasma species as they pass into 
the vacuum interface region.  Over the past ten years measurements have been carried 
out to determine the temperature and pressure environments of the interface region 
and to establish the velocity and trajectory of ions passing through.  The overall 
conclusions of such measurements have been that the physical behaviour is as would 
be expected of a gaseous flow through an orifice and into a low-pressure region.  
However, there are some departures from what would be expected and currently the 
expressions used to describe the region are too simple.  The ICP-MS interface region 
remains to be an area of very interesting research that is not yet fully understood.  A 
complete knowledge of the processes that take place in this region is required before 
any significant changes in its construction can be carried out for the improved 
sampling of ions from the ICP ion source.101, 190-193 
 
ICP-MS can be described as a “flow into” technique whereby the ions generated are 
transported from the ICP, through the interface region and the mass analyser and into 
the detector.  This is the opposite of what can be described as a “flow by” technique, 
such as ICP-OES, where the ions generated in the plasma are detected by their photon 
emission without passage into any instrumental regions.  Due to this instrument 
configuration the ICP-MS technique exhibits some significant analytical problems, 
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not observed in ICP-OES, originating within the current interface design region.  
These problems are described as follows. 
 
 
5.1.1.  Deposition problems within the ICP-MS Interface 
 
As the ions generated are transported between extreme pressure and temperature 
environments and through the cone orifices the deposition of ions, particularly matrix 
ions, on and within the sample and skimmer cones can lead to blockage which results 
in a degradation, and sometimes complete loss, of analyte sensitivity.  This problem is 
a limiting factor in the analysis of samples containing a high concentration of matrix, 
during the analysis of some of which the cones have been known to block completely 
within a short period of time (see section 1.2.2). 
 
 
5.1.2.  Ion Kinetic Energy Spread Associated with the ICP-MS 
Interface 
 
The current standard ICP-MS interface design carries ions through a step-down in 
pressure from atmospheric conditions at the ICP ion source (≈ 1 Bar) to a low 
pressure in an expansion chamber (≈ 2 mBar) and then to vacuum conditions in the 
mass analyser (≈ 1.33 x 10-9 Bar).  As previously described in section 1.3, ions 
passing through the interface, from the ICP ion source to the mass analyser, are 
subject to a number of influential factors that can cause a wide ion kinetic energy 
spread for an individual ion species.  Such a wide ion energy spread leads to some 
ions of the same element having a greater or lesser stable trajectory in the mass 
analyser, or the multipole of a collision/reaction cell, hence such a spread has an 
effect on overall sensitivity.4 
 
Any development of the ICP-MS interface region that can result in the restriction of 
ion kinetic energy spread would be a welcome evolution of the technique.  One such 
approach to achieving this restriction could lie in the transport of ions between the 
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different ICP ion source and the mass analyser environments whilst limiting ions to 
sub-sonic velocities. 
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5.2.  Previous Approaches to Tackling ICP-MS Interface 
Problems 
 
Various approaches have been made to the improvement of ion transport through the 
ICP-MS interface.  Skimmer cone geometry, sample/skimmer cone separation and a 
greater number of pressure reduction steps have all been studied as potential avenues 
for transport improvement.  Such approaches to the development of the ICP-MS 
interface design are described as follows.  When considering such variations in 
interface design it should be appreciated that even changes that may be considered 
insignificant can have drastic effects on instrument sensitivity.189  The smallest of 
variations in the construction of an ICP-MS have led to significant differences in 
sensitivity capability between instruments. 
 
 
5.2.1.  Skimmer Cone Geometry 
 
The geometry, i.e. size and shape, of the skimmer cone is an important parameter in 
the ICP-MS interface region.  As the skimmer cone samples ions for analysis from the 
barrel shock region of the expansion chamber its shape is important with regard to the 
temperature that it reaches, the quantity of ions that it allows through and the point at 
which it skims from the zone of silence. 
 
Various designs of skimmer cone are commercially available with differing 
dimensions of the tip and base of the cone as well as a variable orifice diameter.  
Jarvis et al.194 compared three commercially available skimmers (mini, micro and 
polyskim skimmers) in ICP-MS analysis with the aim of reducing interferences.  This 
work showed that the magnitude of polyatomic ions, oxide ions and doubly charged 
ions entering the mass analyser was dependent, to a certain degree, on the type of 
skimmer in use.  Therefore, skimmer geometry is critical in the reduction of some 
interferences originating from such ions. 
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5.2.2.  Sample and Skimmer Cone Separation 
 
Similar to certain aspects of the skimmer cone geometry, the separation distance 
between sample and skimmer cones is a significant parameter with regard to the 
extraction of ions.  Typically the sample and skimmer cones in the interface are 
separated by approximately 5 mm, this yields the maximum ion beam intensity on the 
opposite side of the skimmer cone which samples ions from the zone of silence. 
 
Lam and Horlick studied the effects of the separation distance between the sample and 
skimmer cones during the analysis of Cu in a HNO3 matrix employing both an Ar 
based ICP and a N2/Ar mixed gas ICP.195  By adjusting the separation distance 
between the two cones and the nebuliser flow, for both types of plasma, some 
common polyatomic Ar based ions could be attenuated with respect to the Cu analyte 
signal.  For example, in the Ar only ICP at a cone separation of 2.3 mm the 
40Ar16O1H+ (m/z = 57) and 40Ar21H+ (m/z = 81) polyatomic ions were observed to be 
attenuated whilst in the N2/Ar mixed gas ICP at the same cone separation the 
40Ar16O1H+ (m/z = 57) and 40Ar14N+ (m/z = 54) polyatomic ions were attenuated. 
 
Lam and Horlick also observed the effects of sample cone-skimmer separation on 
signal suppression associated with matrix effects.195  Lam and Horlick studied the Mn 
signal (m/z = 55) of a 0.2 μg ml-1 Mn solution and observed a maximum signal at a 
sone separation of 6 mm.  The m/z = 55 signal was then seen to be suppressed linearly 
to 20 % of its original value when the separation was increased to 12 mm.  By spiking 
another 0.2 μg ml-1 Mn solution with 1000 μg ml-1 U and then another with a similar 
level of Na further experiments were carried out.  At a cone separation of 6 mm the 
Mn (m/z = 55) signal of the U spiked solution was suppressed to approximately 10 % 
whilst for the Na spiked solution a suppression to 40 % was observed.  As the cone 
separation distance was increased a change in the degree of Mn suppression for both 
spiked solutions was observed.  At a separation of 12 mm the Mn signal suppression 
was improved to 50 % and 60 % for the U and Na spiked solutions, respectively. 
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5.2.3.  Three Cone Interface 
 
Tanner et al.72 studied the effects of a more gradual reduction in pressure environment 
between the ICP ion source and the mass analyser in an ICP-MS instrument.  An extra 
pressure reduction region was incorporated into the typical interface design in the 
form of a third cone situated between the skimmer cone and the extraction lens.  In 
this case a reduction in pressure was observed from 1 Bar (at the plasma ion source) 
to approximately 4 mBar (between the sampler and skimmer cones) then to 0.4 mBar 
(in the new region between the skimmer cone and the third cone) and finally to 1.33 x 
10-5 mBar (at the extraction lens). 
 
Analytical sensitivity employing the instrument containing this three cone interface 
was comparable to a typical commercial instrument.  There was significant benefit 
observed, using such an interface, in the form of a reduction in signal suppression 
previously seen due to the presence of high mass matrix elements.  It was thought that 
the acceleration of electrons due to supersonic expansion, in this interface, would be 
reduced hence charge separation and space charge effects may have occurred to a 
lesser degree. 
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5.3.  The Development of an Adapted ICP-MS Interface for 
the Reduction of Ion Deposition 
 
An adaptation to the current Thermo Electron PQ ExCell ICP-MS interface region 
was considered with the aim of improving the extraction of ions into the mass 
analyser for the analysis of samples composed of a highly concentrated matrix.  As 
mentioned previously in this chapter one of the major problems of analysing such 
samples by ICP-MS is the issue of ion deposition on the skimmer cone. 
 
The idea behind such an adaptation is the manipulation of the interaction between the 
shockwave generated within the expansion chamber and the skimmer cone.  Such an 
interaction can be compared to that between a shockwave and a conical surface as a 
skimmer cone tip is essentially conical in shape.  On the meeting between a 
shockwave and a conical surface a curved shape deflected shock emanates from the 
tip of the cone, the degree of this deflection being dependent on the angle of the 
conical tip at the point of meeting.196  Within the ICP-MS interface as this shock 
deflection takes place a small quantity of ions are skimmed to form the ion beam, in 
the state ready for detection, behind the skimmer cone whilst the bulk of ions in the 
shock are carried down the sides of the cone.  During the analysis of a sample based 
on a highly concentrated matrix, this deflected bulk flow of ions typically results in 
deposition at and around the skimmer orifice which has a detrimental effect on 
instrument sensitivity.  On the meeting of the adiabatic shock and the tip of the 
skimmer cone, the larger the angle of the tip then the further the shock is deflected 
around the tip itself and, in theory, less deposition should occur, see Figures 83 and 
84.196 
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Figure 83.  The Deflected Shock at a Small Tip Angle Skimmer Cone. 
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Figure 84.  The Deflected Shock at a Large Tip Angle Skimmer Cone. 
 
 
Based on the idea that a skimmer cone exhibiting a large tip angle deflects the bulk 
ion flow further away from the orifice a structure was proposed to fit into the ICP-MS 
interface that could deflect the bulk flow even further whilst allowing a limited, 
‘clean’, ion flow through the skimmer orifice.  By incorporating a plate with an orifice 
at the centre 1 mm ahead of the skimmer tip this enhanced deflection could be 
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achieved and then the majority of ion deposition could take place elsewhere in the 
expansion chamber.  The proposed structure can be seen in Figure 85. 
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Figure 85.  The Suggested Deflected Shock Arising from Supersonic Flow Against an Additional 
Plate and Orifice. 
 
 
Prior to the manufacture and implementation of such a structure the environment of 
the ICP-MS interface region must first be fully appreciated.  Due to the massive 
reduction in pressure in the expansion chamber, compared to the atmospheric pressure 
ICP ion source, the local volume of the ion flow is drastically increased to 
compensate according to the ideal gas equation (PV = nRT).  This increase in volume 
is described as the adiabatic expansion.  As can be seen in the equation of Figure 87, 
the temperature of the expansion region is related to both the temperature of the ICP 
source and the velocity of the ion flow (i.e. the Mach number).  So, as the velocity of 
the flow increases the temperature within the expansion region decreases due to the 
conversion of energy (see section 5.3.1).  An exception to this, however, is when the 
ion flow comes into contact with a surface and is brought to a halt.  When this occurs 
the local temperature elevates.  To accommodate such elevated temperatures at 
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surfaces within the region cooling is required, hence the cooling of sample and 
skimmer cones by a water flow system seen in all ICP-MS instruments. 
 
It is for this reason that any additional structures, that were to be placed within the 
ICP-MS interface, had to be manufactured from a material exhibiting a very high 
melting point as they would be standing independently of the chamber cooling 
system.  Before selection of a material that could be used for this work the 
temperatures of the expansion chamber were evaluated, see section 5.3.1. 
 
 
5.3.1.  The Temperature Environment of an ICP-MS Interface 
Expansion Chamber 
 
Due to the nature and design of an ICP-MS instrument there are a number of factors 
that affect the temperature environment of the interface expansion chamber.  The 
conditions at the ICP ion source, the pressure of the expansion chamber and the ion 
velocity through it all contribute to the local temperature.  A series of equations have 
been published that describe the temperature, pressure and ion velocity conditions of 
the interface expansion chamber, many of which are employed in this chapter to 
justify certain work.4  For this section, two such equations were used to establish the 
temperature conditions of the expansion chamber and hence provide the information 
required in the selection of a material for production of an additional structure, see 
Figures 86 and 87. 
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Where: 
Po:  Pressure Within the Ion Source 
Pi:  Pressure Within the Isentropic Core of the Expansion 
γ: Ratio of Heat Capacity at Constant Pressure to Heat Capacity at 
Constant Volume 
M:  Mach Number 
Figure 86.  An Equation Comparing Pre/Post Sampler Orifice Pressures with Mach Number. 
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Where: 
To:  Temperature Within the Ion Source 
Ti:  Temperature Within the Isentropic Core of the Expansion 
γ: Ratio of Heat Capacity at Constant Pressure to Heat Capacity at 
Constant Volume 
M:  Mach Number 
Figure 87.  An Equation Comparing Pre/Post Sampler Orifice Temperatures with Mach 
Number. 
 
 
Using the equations of Figures 86 and 87 the temperature within the expansion 
chamber was calculated based on certain information and assumptions.  This 
temperature was based on ICP ion source pressures and temperatures of 1 Bar and 8 
000 K respectively and an expansion chamber pressure of 2 mBar.  One further 
assumption made prior to calculation was that the ratio of heat capacity at constant 
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pressure to heat capacity at constant volume (γ) was 5/3, i.e. it was a parameter based 
on the assumption that the only gaseous species entering the expansion chamber was 
Ar. 
 
So using this information and assumption the equation of Figure 86 was used to 
calculate the mach number of the ion flow in the chamber.  This mach number data 
was then used to calculate a temperature of the expansion chamber, using the equation 
of Figure 87, of 667 K.  Therefore a material had to be selected to withstand 667 K.  
Tantalum metal was therefore selected for manufacture of this interface structure due 
to its high melting point (3269 K).135 
 
 
5.3.2.  Manufacture and Testing of an Adapted ICP-MS Interface for 
the Reduction of Ion Deposition 
 
Two attempts were made at the construction and testing of an ICP-MS interface 
adaptation intended for the reduction of ion deposition on the skimmer cone.  The 
work carried out on such an adaptation is described as follows. 
 
 
Construction and Testing: First Attempt 
 
A first attempt at the construction of a tantalum interface adaptation was carried out 
such that a flat plate of 4.8 mm diameter and 0.25 mm thickness was positioned 1 mm 
ahead of the tip of an Xi skimmer cone.  This plate was held in position by tantalum 
rods (1.5 mm thick, rod angles of 56 degrees) attached to a base ring (17.95 mm wide 
and 1 mm thick) that was held in place over the skimmer cone using two screws, see 
Figure 135 for a schematic of the similar four rod design.  Each component of this 
structure was welded together using a Nd:YAG laser (Starworld Performance, SWP 
5002, λ = 1.06 μm) at the Loughborough University School of Art and Design 
(LUSAD). 
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The first attempt at construction of this adaptation involved the top plate being held in 
place by two parallel rods.  Following welding, initial experimentation was carried out 
to determine whether or not this structure could withstand the expansion chamber 
environment.  The structure was held in place, over the skimmer cone, in the 
expansion chamber and the ICP ion source was established.  The plasma was operated 
for a 10 minute period whilst introducing deionised water only via the standard 
Micromist 100 μl min-1 nebuliser and impact bead spray chamber arrangement. 
 
Following this initial experimentation it was determined that the expansion chamber 
temperature was not a problem for the tantalum metal with regard to mechanical 
stability of the structure.  However, two problems were revealed which denied the 
opportunity to study the effects of the presence of this adaptation on the mass 
spectrum. 
 
Firstly, it appeared that within this expansion region the tantalum metal was subject to 
reactions due to the environment to which it was exposed.  On removal of the 
structure from the expansion chamber, sections of the top plate and supporting rods 
appeared to have lost a top layer of the metal revealing a ‘grainy’ surface to the metal.  
It was also noticed that a white substance had formed on the plate which has, so far, 
remained unidentified as its colour did not correspond to the common tantalum 
reaction products. 
 
The structure was also removed from the expansion chamber carrying a certain 
amount of damage.  The plate had bent slightly against the rods at the points at which 
they were welded and a crack had appeared on one side of the plate at the origin of 
one of these bends.  This bending may have taken place due to a ‘drag’ effect where 
the adiabatic shock within the expansion chamber met the plate. 
 
 
Construction and Testing: Second Attempt 
 
A second attempt at construction of this interface adaptation was carried out.  Again 
tantalum was used in its construction and the individual sections were welded together 
with the Nd:YAG laser at LUSAD.  This time the design was changed slightly with 
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the plate being held in place by two pairs of parallel rods rather than just one, the aim 
being to enhance the mechanical strength of the structure and provide greater 
resistance to the potential ‘drag’ effect against the plate.  A diagram of this second 
interface adaptation design can be seen in Figure 88.  Prior to testing in the ICP-MS 
interface, the second tantalum structure was heated in a furnace to 450 °C in order to 
form an oxidised surface.  It was hoped that such action would render the structure 
surface less chemically reactive in the expansion chamber. 
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 Figure 88.  A Schematic of the Second (Four Rod) ICP-MS Interface Structure. 
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Similar to the first design, initial experimentation was carried out on this second 
structure to establish its stability within the expansion chamber.  This time there was 
no damage to the structure and the degree of metal layer removal and deposition of 
the unknown substance was far less than with the first design.  So, following this 
successful work, further experimentation was undertaken to establish the effect of the 
presence of this structure on the mass spectrum.  Prior to positioning the structure in 
the interface the ICP-MS instrument was tuned, stabilised and tested to ensure that it 
was producing desirable signals.  With the structure in place the mass spectrum was 
monitored when introducing deionised water and 1 μg l-1 In, Pb, U and Li solutions.  
Unfortunately, with the structure in place, the signals observed at nearly all m/z’s were 
next to nothing and the only difference that manipulation of the instrument parameters 
made to this was a slight enhancement of the 40Ar+ (m/z = 40) and 40Ar2+ (m/z = 80) 
signals. 
 
It is believed that this limitation of the instrument signal was due to the orifice of the 
plate being far too small.  It is thought that the shock being created at the plate is 
scattering the sample ions and not allowing transport through the orifice and into the 
skimmer cone.  Therefore, a plate with a larger orifice at the centre is required. 
 
 
5.3.3.  The Development of an Adapted ICP-MS Interface for the 
Reduction of Ion Deposition: Conclusion 
 
Although, through incorporation of both structure designs in the ICP-MS interface, 
there was no beneficial effect achieved there is great potential in this work to develop 
the interface region for the reduction of ion deposition.  As mentioned in section 5.3.2 
the plate of this structure may require changing with the orifice size possibly being the 
key to generating a beneficial shock deflection whilst allowing ions through the 
skimmer orifice.  Such change to the structure design would be the first area of future 
work for this idea as well as the study of the distance between the plate and skimmer 
tip and the material used in production. 
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5.4.  The Development of an ICP-MS Interface with a 
Gradual Pressure Reduction 
 
As mentioned in sections 1.3 and 5.1.2 one of the significant problems associated with 
the ICP-MS instrument is that of the ion kinetic energy spread that occurs due to the 
rollercoaster to which ions are exposed.  One of the greatest contributors to this ion 
kinetic energy spread is the acceleration of ions in the expansion chamber during the 
transition from atmospheric pressure (≈ 1 Bar) to low pressure (≈ 2 mBar).  It is 
thought that the energy spread could be reduced by transporting ions from the ICP to 
the mass analyser whilst limiting them to subsonic velocities.  This section of Chapter 
5 assesses the feasibility of such an approach. 
 
 
5.4.1.  The Transitions Required for a Gradual Interface Pressure 
Reduction 
 
Using the equation of Figure 86 the pressures required during a step-down from 1 Bar 
at the ICP ion source to vacuum conditions at the mass analyser (≈ 1.33 x 10-9 Bar) 
were calculated assuming that the ion velocity doesn’t exceed  a mach number of 1.  
For these calculations mach number was assumed to be 0.95.  The calculated 
transition pressures and the number of transition ‘chambers’ required to achieve a 
subsonic reduction can be seen in Table 52. 
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Table 52.  Calculated Transition Pressures and Numbers of Transition ‘Chambers’ for a 
Gradual Pressure Reduction in the ICP-MS Interface. 
Transition 
Number 
Transition ‘Chamber’ 
Description 
Initial Pressure 
(mBar) 
Final Pressure 
(mBar) 
1 Atmospheric Pressure → Chamber 1 1000 630 
2 Chamber 1 → Chamber 2 630 396 
3 Chamber 2 → Chamber 3 396 250 
4 Chamber 3 → Chamber 4 250 157 
5 Chamber 4 → Chamber 5 157 98.9 
6 Chamber 5 → Chamber 6 98.9 62.3 
7 Chamber 6 → Chamber 7 62.3 39.2 
8 Chamber 7 → Chamber 8 39.2 24.7 
9 Chamber 8 → Chamber 9 24.7 15.5 
10 Chamber 9 → Chamber 10 15.5 9.78 
11 Chamber 10 → Chamber 11 9.78 6.16 
12 Chamber 11 → Chamber 12 6.16 3.88 
13 Chamber 12 → Chamber 13 3.88 2.44 
14 Chamber 13 → Chamber 14 2.44 1.54 
15 Chamber 14 → Chamber 15 1.54 0.97 
16 Chamber 15 → Chamber 16 0.97 0.61 
17 Chamber 16 → Chamber 17 0.61 0.38 
18 Chamber 17 → Chamber 18 0.38 0.24 
19 Chamber 18 → Chamber 19 0.24 0.15 
20 Chamber 19 → Chamber 20 0.15 9.56 x 10-2 
21 Chamber 20 → Chamber 21 9.56 x 10-2 6.02 x 10-2 
22 Chamber 21 → Chamber 22 6.02 x 10-2 3.79 x 10-2 
23 Chamber 22 → Chamber 23 3.79 x 10-2 2.39 x 10-2 
24 Chamber 23 → Chamber 24 2.39 x 10-2 1.50 x 10-2 
25 Chamber 24 → Chamber 25 1.50 x 10-2 9.46 x 10-3 
26 Chamber 25 → Chamber 26 9.46 x 10-3 5.96 x 10-3 
27 Chamber 26 → Chamber 27 5.96 x 10-3 3.75 x 10-3 
28 Chamber 27 → Chamber 28 3.75 x 10-3 2.36 x 10-3 
29 Chamber 28 → Chamber 29 2.36 x 10-3 1.49 x 10-3 
30 Chamber 29 → Chamber 30 1.49 x 10-3 9.36 x 10-4 
31 Chamber 30 → Chamber 31 9.36 x 10-4 5.89 x 10-4 
32 Chamber 31 → Chamber 32 5.89 x 10-4 3.71 x 10-4 
33 Chamber 32 → Chamber 33 3.71 x 10-4 2.33 x 10-4 
34 Chamber 33 → Chamber 34 2.33 x 10-4 1.47 x 10-4 
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Table 52 Continued.  Calculated Transition Pressures and Numbers of Transition ‘Chambers’ 
for a Gradual Pressure Reduction in the ICP-MS Interface. 
Transition 
Number 
Transition ‘Chamber’ 
Description 
Initial Pressure 
(mBar) 
Final Pressure 
(mBar) 
35 Chamber 34 → Chamber 35 1.47 x 10-4 9.25 x 10-5 
36 Chamber 35 → Chamber 36 9.25 x 10-5 5.82 x 10-5 
37 Chamber 36 → Chamber 37 5.82 x 10-5 3.67 x 10-5 
38 Chamber 37 → Chamber 38 3.67 x 10-5 2.31 x 10-5 
39 Chamber 38 → Chamber 39 2.31 x 10-5 1.45 x 10-5 
40 Chamber 39 → Chamber 40 1.45 x 10-5 9.15 x 10-6 
41 Chamber 40 → Chamber 41 9.15 x 10-6 5.76 x 10-6 
42 Chamber 41 → Chamber 42 5.76 x 10-6 3.63 x 10-6 
43 Chamber 42 → Chamber 43 3.63 x 10-6 2.28 x 10-6 
44 Chamber 43 → Chamber 44 2.28 x 10-6 1.44 x 10-6 
45 Chamber 44 → Chamber 45 1.44 x 10-6 9.05 x 10-7 
46 Chamber 45 → Chamber 46 9.05 x 10-7 5.70 x 10-7 
 
 
As can be seen from Table 52, to successfully transport ions between the ICP and the 
mass analyser without them exceeding a mach number of 0.95 they would have to 
pass through forty-six transitions.  The construction of an ICP-MS interface consisting 
of forty-six separately pressurised chambers would be impractical unless close to 100 
% ion transmission could be guaranteed between the sample cone and the mass 
analyser.  As previously described, see section 5.2.3, it has been shown that analytical 
benefit can be obtained by incorporating further pressurised chambers into the 
interface region but this work has certainly not gone to the lengths of incorporating 
forty-six of them. 
 
 
5.4.2.  A Potential Approach to a Gradual Interface Pressure 
Reduction 
 
An approach to an ICP-MS interface adaptation that could allow a gradual pressure 
reduction is still in the concept and design stages.  It may be possible to construct a 
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small interface adaptation to sit between the sample and skimmer cones to restrict 
transport of ions at supersonic velocities.  Initial ideas include the use of an open plate 
stack design, with orifices through the centre of each for the transmission of ions, 
fitted horizontally.  Taking advantage of the pressure in the expansion chamber, it 
may be possible to create localised pressures at different points in this region.  A 
structure composed of a series of plates held in place by parallel rods, fixed at a base 
plate, may allow the creation of progressively lower localised pressures between the 
two cones.  Whilst maintaining regular pumping in the expansion chamber it is 
believed that varying the distance between the plates of such a structure could create 
the desired effect.  A diagram of the potential structure described in this section can 
be seen in Figure 89. 
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 Figure 89.  A Diagram Showing a Potential Plate Stack Interface Structure Design for the Gradual Reduction of Pressure in the Expansion Chamber. 
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5.4.3.  The Development of an ICP-MS Interface with a Gradual 
Pressure Reduction: Conclusion 
 
Although the transport of ions through the ICP-MS interface at subsonic velocities 
would require forty-six pressure transitions, a well conceived and designed interface 
region may be able to accomplish this.  The addition of a structure between the 
sample cone and mass analyser may be the way forward for this kind of work but 
what is more likely is that the interface region may have to be completely redesigned 
to achieve this aim.  The addition of a series of plates with an orifice at the centre of 
each may provide a benefit with regard to limiting ion velocity but such an 
arrangement would incorporate a further problem in the form a greater surface area 
for ion deposition and degradation of ion transmission. 
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5.5.  Conclusions 
 
This chapter has highlighted certain problems associated with the current ICP-MS 
interface region.  Although the ion deposition problem can be overcome by cautious 
sample preparation and analysis it is the ion kinetic energy problem that, if overcome, 
could define the next generation of ICP-MS instrumentation. 
 
What the work of this chapter has shown is that the positioning of additional 
structures within the ICP-MS interface can be a feasible approach to changing 
interface conditions.  With good design the addition of such structures will allow 
research to be carried out on this region with relatively low cost and without 
significant change to the instrument.  Within this chapter further work has been 
highlighted for continuation of what has been carried out so far. 
 
Following presentation of this interface work to representatives of the Thermo 
Electron Corporation at the Winsford factory on 9th December 2005, interest has been 
shown by the sponsors of this research in furthering this work by their research and 
development group. 
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Chapter 6 
 
General Conclusions and Future Work 
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6.1.  The Development of Methods for the Determination of 
31P and 32S Isotopes by ICP-MS 
 
Collision cell technology and the ‘cold/cool plasma’ approach are two techniques 
used within ICP-MS that can be employed to overcome certain spectroscopic 
interferences.  Four final methods, of six originally conceived, were successfully 
developed for the determination of 31P and 32S isotopes by quadrupole based ICP-MS.  
Of these four methods two were based on the use of a hexapole collision cell with He 
or O2 collision/reaction gases whilst two were based on the use of a ‘cold/cool 
plasma’ with and without a supplementary O2 flow through the central channel of the 
ICP.  Each of these four methods was calibrated and limits of detection were 
established that were comparable to those previously published.  With access to a 
‘clean-room’ and ultra pure reagents the limits of detection for these methods may be 
superior to those previously published. 
 
 
6.1.1.  Hexapole Collision Cell Methods 
 
Two collision cell methods were developed to determine 31P and 32S isotopes whilst 
overcoming the spectroscopic interferences at m/z = 31 and 32, respectively.  One of 
these methods employed an O2 reaction gas leading to the formation of the oxide 
species 31P16O+ and 32S16O+ that can be measured at m/z = 47 and 48, respectively 
therefore avoiding native spectroscopic interferences at m/z = 31 and 32.  The 47,48Ti 
isotopes do not hinder measurement of these oxide species as they are also oxidised 
and moved to m/z = 63 and 64 in the mass spectrum.  The ion kinetic energy effect 
(IKEE), see section 1.3.3 in Chapter 1, was used to maximise the formation of these 
oxide species.  The limits of detection obtained by this method were 0.69 μg l-1 to 
9.50 μg l-1 for 31P measurement and 1.43 μg l-1 to 6.50 μg l-1 for 32S measurement.  
The LOD’s obtained via this method are comparable to those published by Bandura et 
al showing that the measurement of 31P and 32S isotopes by this approach is very 
similar between the use of a collision cell and a dynamic reaction cell.90 
 
 271
The second successfully developed collision cell method employed a He collision gas 
used in conjunction with kinetic energy discrimination (KED), see section 1.3.3 of 
Chapter 1, to allow the transmission of 31P+ ions through the hexapole whilst 
restricting the passage of cell formed polyatomic ions that could interfere with the m/z 
= 31 signal.  The limit of detection obtained by this method for the measurement of 
31P was 1.48 μg l-1 to 7.78 μg l-1.  Such an LOD for the measurement of 31P is similar 
to that obtained employing the O2 collision cell method. 
 
 
6.1.2.  ‘Cold/Cool Plasma’ Methods 
 
Two ‘cold/cool plasma’ methods were developed to determine 31P and 32S isotopes 
whilst overcoming the spectroscopic interferences at m/z = 31 and 32.  These methods 
are very similar with the second being a development of the first. 
 
The first ‘cold/cool plasma’ method employed an ICP with a forward power of 800 
W.  Such an ICP operates at a lower temperature which leads to the significant 
formation of metal oxides.  Similar to the first collision cell method, the oxide species 
31P16O+ and 32S16O+ are readily formed at this forward power and can be measured at 
m/z = 47 and 48 therefore avoiding native spectroscopic interferences at m/z = 31 and 
32, respectively.  The limits of detection obtained by this method were 0.89 μg l-1 to 
6.56 μg l-1 for 31P measurement and 6.84 μg l-1 to 25 μg l-1 for 32S measurement.  The 
second successful ‘cold/cool plasma’ method was a development of the first whereby 
the same 800 W ICP was employed with an additional O2 nebuliser gas flow to 
maximise the formation of the 31P16O+ and 32S16O+ species (m/z = 47 and 48 
measurement respectively).  The limits of detection obtained by this method were 
0.74 μg l-1 to 14 μg l-1 for 31P measurement and 1.23 μg l-1 to 80 μg l-1 for 32S 
measurement.  It should be noted that the LOD’s obtained employing these two 
‘cold/cool plasma’ methods are similar to those obtained by the collision cell 
methods.  Therefore, for the determination of 31P and 32S isotopes in samples that are 
not too complex, the use of one of these ‘cold/cool plasma’ methods is recommended 
for laboratories that do not have access to collision cell or DRC technology. 
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6.2.  The Application of Methods Developed for the 
Determination of 31P and 32S Isotopes by ICP-MS 
 
The four successfully developed ICP-MS methods were evaluated for the analysis of 
DNA and DNA components via the measurement of the 31P isotope.  These methods 
were used in the quantification of DNA, the study of DNA components within an 
agarose gel, the study of polymerase chain reaction (PCR) and the study of single 
nucleotide polymorphisms. 
 
Each of the four methods were evaluated for their ability to quantify DNA via the 
measurement of 31P content.  Each method produced reliable data when DNA 
solutions were analysed.  However, the limits of detection of these methods were 
significantly inferior to those exhibited by fluorescence or UV methods.  For this 
reason ICP-MS will not replace fluorescence in such applications but will be 
important in areas such as metallo-drug or protein-drug efficacy testing as illustrated 
in the work on Pt based anti-cancer drugs in Chapter 4. 
 
The collision cell method employing an O2 reaction gas was used in the analysis of 
digested agarose gels containing separated DNA.  The data generated from this 
analysis showed that this approach can provide quantitative information but again it 
can’t compete with the well established fluorescence or UV methods. 
 
The progression of a PCR process was studied employing the collision cell method 
using an O2 reaction gas.  Unfortunately this method was not sensitive enough to 
measure the changes in 31P concentration as the replication took place.  Again, this 
method cannot compete with the well established fluorescence and UV methods. 
 
The O2 collision cell and first ‘cold/cool plasma’ methods were employed in the study 
of nucleotide sequences differing in structure by one base molecule.  The aim of this 
work was to establish whether ICP-MS could be used to study single nucleotide 
polymorphisms.  Online HPLC was used to separate these nucleotides before 
measurement via UV spectrophotometry and the 31P isotope by ICP-MS.  Of the two 
ICP-MS methods employed the collision cell approach was successful whilst the 
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‘cold/cool plasma’ wasn’t.  The reason for this was that the standard ICP used with 
the collision cell was robust enough to handle the mobile phase eluting from the 
HPLC column whilst the reduced forward power plasma was not.  The work carried 
out during the study of these nucleotides has shown that ICP-MS has potential for the 
analysis of single nucleotide polymorphisms. 
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6.3.  The Analysis of Platinum Based Anti-Cancer Drugs and 
DNA by ICP-MS 
 
Cisplatin and oxaliplatin are two platinum based complexes that are used in the 
treatment of a range of cancers.  These two drugs bind with DNA within the cell 
nucleus and inhibit replication processes leading to apoptosis.  Treatment with both of 
these drugs is relatively harsh so efficacy is a major issue.  Currently there is not a fast 
and inexpensive test to establish efficacy of these drugs for individual patients.  ICP-
MS was used to study the interaction of these drugs with their DNA target and 
establish binding constant and adduct data that could be used as the basis of an 
efficacy test. 
 
Five studies were undertaken to observe the interaction between these drugs and their 
biological target.  Although the first of these studies was unsuccessful due to 
complications regarding the method employed the subsequent studies revealed several 
issues.  Firstly ICP-QMS was capable of the measurement of Pt in these samples 
down to the lowest concentrations studied, i.e. in the region of 1 drug molecule to 500 
000 DNA nucleotides for both drug complexes, which is beyond the suggested 
therapeutic region of 1 drug molecule to 400 000 DNA nucleotides.  The second to 
fifth studies carried out showed that there is a significant difference in binding 
strength between inter- and intra-strand covalent binding in vitro.  Further work in this 
area may be able to relate the type of covalent binding with drug efficacy.  Finally the 
binding data calculated, in the form of ‘Kf data’ and the number of adducts formed, 
has shown that the binding between drug and target is particularly inefficient and that 
there is agreement with Akaboshi et al and Jamieson et al who have published data 
describing the number of Pt atoms that bind per DNA molecule when exposing DNA 
to these drugs.162, 186 
 
Further work is required in this area prior to the development of an efficacy test, 
however, significant advances were made through the work described here to guide 
the remaining work which would hopefully be straight forward. 
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6.4.  The Development of ICP-MS Interface Structures 
 
The work described in Chapter 5 has highlighted certain problems regarding the 
design of the current ICP-MS interface region.  Although, as previously described, the 
problem of ion and material deposition can be limited through cautious sample 
preparation, the solution of the ion kinetic energy problem could be the defining 
quality of the next generation of ICP-MS instrumentation. 
 
The work of Chapter 5 showed that the placing of additional structures within the 
ICP-MS interface can be a feasible approach to varying the interface conditions.  
Good design of such structures would allow further research to be carried out on this 
region at reasonable cost and without significant alteration of the instrument.  As 
described in Chapter 5, further work has been highlighted for continuation of what has 
been carried out so far.  It should be noted, however, that the work described in this 
chapter is, to a certain degree, specific for a PQ ExCell ICP-QMS instrument as the 
interface region is easily accessible.  This is not the case for certain other types of 
ICP-QMS instrument, such as the Perkin Elmer Elan 6100, which are either more 
enclosed or exhibit less space to carry out this type of work. 
 
As mentioned previously, following presentation of this interface work to 
representatives of the Thermo Electron Corporation at the Winsford factory on 9th 
December 2005, interest has been shown by the sponsors in furthering this work by 
their research and development group. 
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